PU.1	B-protein
(	O
Spi-1	B-protein
)	O
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Growth	B-protein
factor	I-protein
receptors	I-protein
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B-protein
factors	I-protein
activating	O
the	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
directs	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

The	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B-DNA
constructs	I-DNA
.	O

We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B-DNA
site	I-DNA
located	O
upstream	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
.	O

C/EBP	B-protein
alpha	I-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	O
C/EBP	B-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B-protein
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	B-protein
)	O
when	O
binding	O
the	O
GM-CSF	B-protein
receptor	I-protein
alpha	I-protein
promoter	O
PU.1	B-DNA
site	I-DNA
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B-protein
on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	I-DNA
.	O

The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	B-DNA
cell	I-DNA
enhancer	I-DNA
sites	I-DNA
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	B-protein
to	O
extracts	O
from	O
certain	O
nonmyeloid	B-cell_type
cell	I-cell_type
types	I-cell_type
which	O
do	O
not	O
express	O
PU.1	B-protein
,	O
including	O
T	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
from	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU-SF	B-protein
complex	I-protein
binds	O
to	O
PU.1	B-protein
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	B-DNA
promoters	I-DNA
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	B-DNA
site	I-DNA
adjacent	O
to	O
a	O
single-stranded	O
region	O
.	O

Expression	O
of	O
PU.1	B-protein
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
can	O
activate	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Deletion	O
of	O
the	O
amino-terminal	B-protein
region	I-protein
of	O
PU.1	B-protein
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU-SF	B-protein
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU-SF	B-protein
complex	I-protein
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
can	O
also	O
active	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGy	NULL
,	NULL
October	NULL
.	NULL

1995	NULL
,	NULL
p.	NULL
5830-5845	NULL
0270-7306/95/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

15	NULL
,	NULL
No	NULL
.	NULL

10	NULL
PU.1	NULL
(	NULL
Spi-1	NULL
)	NULL
and	NULL
C/EBPa	NULL
Regulate	NULL
Expression	NULL
of	NULL
the	NULL
Granulocyte	NULL
Macrophage	NULL
Colony-Stimulating	NULL
Factor	NULL
Receptor	NULL
«	NULL
Gene	NULL
STEFAN	NULL
HOHAUS	NULL
,	NULL
MARTHA	NULL
S.	NULL
PETROVICK	NULL
,	NULL
MARIA	NULL
TERESA	NULL
VOSO	NULL
,	NULL
ZIJIE	NULL
SUN	NULL
,	NULL
DONG-ER	NULL
ZHANG	NULL
,	NULL
anp	NULL
DANIEL	NULL
G.	NULL
TENEN®*	NULL
Division	NULL
of	NULL
Hematology/Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
and	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Received	NULL
31	NULL
January	NULL
1995/Returned	NULL
for	NULL
modification	NULL
29	NULL
April	NULL
1995/Accepted	NULL
12	NULL
July	NULL
1995	NULL
Growth	NULL
factor	NULL
receptors	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
hematopoiesis	NULL
.	NULL

In	NULL
order	NULL
to	NULL
further	NULL
understand	NULL
the	NULL
mechanisms	NULL
directing	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
key	NULL
regulators	NULL
of	NULL
hematopoiesis	NULL
,	NULL
we	NULL
initiated	NULL
a	NULL
study	NULL
investigating	NULL
the	NULL
transcription	NULL
factors	NULL
activating	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
receptor	NULL
«	NULL
gene	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
human	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
directs	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
a	NULL
tissue-specific	NULL
fashion	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
,	NULL
which	NULL
correlates	NULL
with	NULL
its	NULL
expression	NULL
pattern	NULL
as	NULL
analyzed	NULL
by	NULL
reverse	NULL
transcription	NULL
PCR	NULL
.	NULL

The	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
contains	NULL
an	NULL
important	NULL
functional	NULL
site	NULL
between	NULL
positions	NULL
-53	NULL
and	NULL
-41	NULL
as	NULL
identified	NULL
by	NULL
deletion	NULL
analysis	NULL
of	NULL
reporter	NULL
constructs	NULL
.	NULL

We	NULL
show	NULL
that	NULL
the	NULL
myeloid	NULL
and	NULL
B	NULL
cell	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
specifically	NULL
to	NULL
this	NULL
site	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
a	NULL
CCAAT	NULL
site	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
between	NULL
positions	NULL
-70	NULL
and	NULL
-54	NULL
is	NULL
involved	NULL
in	NULL
positive-negative	NULL
regulation	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
activity	NULL
.	NULL

C/EBPa	NULL
is	NULL
the	NULL
major	NULL
CCAAT/	NULL
enhancer-binding	NULL
protein	NULL
(	NULL
C/EBP	NULL
)	NULL
form	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

Point	NULL
mutations	NULL
of	NULL
either	NULL
the	NULL
PU.1	NULL
site	NULL
or	NULL
the	NULL
C/EBP	NULL
site	NULL
that	NULL
abolish	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
respective	NULL
factors	NULL
result	NULL
in	NULL
a	NULL
significant	NULL
decrease	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
activity	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
only	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
in	NULL
myeloid	NULL
and	NULL
B	NULL
cell	NULL
extracts	NULL
,	NULL
PU.1	NULL
forms	NULL
a	NULL
novel	NULL
,	NULL
specific	NULL
,	NULL
more	NULL
slowly	NULL
migrating	NULL
complex	NULL
(	NULL
PU-SF	NULL
)	NULL
when	NULL
binding	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
PU.1	NULL
site	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
demonstration	NULL
of	NULL
a	NULL
specific	NULL
interaction	NULL
with	NULL
PU.1	NULL
on	NULL
a	NULL
myeloid	NULL
PU.1	NULL
binding	NULL
site	NULL
.	NULL

The	NULL
novel	NULL
complex	NULL
is	NULL
distinct	NULL
from	NULL
that	NULL
described	NULL
previously	NULL
as	NULL
binding	NULL
to	NULL
B	NULL
cell	NULL
enhancer	NULL
sites	NULL
and	NULL
can	NULL
be	NULL
formed	NULL
by	NULL
addition	NULL
of	NULL
PU.1	NULL
to	NULL
extracts	NULL
from	NULL
certain	NULL
nonmyeloid	NULL
cell	NULL
types	NULL
which	NULL
do	NULL
not	NULL
express	NULL
PU.1	NULL
,	NULL
including	NULL
T	NULL
cells	NULL
and	NULL
epithelial	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
from	NULL
erythroid	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
PU-SF	NULL
complex	NULL
binds	NULL
to	NULL
PU.1	NULL
sites	NULL
found	NULL
on	NULL
a	NULL
number	NULL
of	NULL
myeloid	NULL
promoters	NULL
,	NULL
and	NULL
its	NULL
formation	NULL
requires	NULL
an	NULL
intact	NULL
PU.1	NULL
site	NULL
adjacent	NULL
to	NULL
a	NULL
single-stranded	NULL
region	NULL
.	NULL

Expression	NULL
of	NULL
PU.1	NULL
in	NULL
nonmyeloid	NULL
cells	NULL
can	NULL
activate	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
amino-terminal	NULL
region	NULL
of	NULL
PU.1	NULL
results	NULL
in	NULL
a	NULL
failure	NULL
to	NULL
form	NULL
the	NULL
PU-SF	NULL
complex	NULL
and	NULL
in	NULL
a	NULL
concomitant	NULL
loss	NULL
of	NULL
transactivation	NULL
,	NULL
suggesting	NULL
that	NULL
formation	NULL
of	NULL
the	NULL
PU-SF	NULL
complex	NULL
is	NULL
of	NULL
functional	NULL
importance	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
C/EBPa	NULL
can	NULL
also	NULL
activate	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
in	NULL
nonmyeloid	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
PU.1	NULL
and	NULL
C/EBPa	NULL
direct	NULL
the	NULL
cell-type-specific	NULL
expression	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
,	NULL
further	NULL
establish	NULL
the	NULL
role	NULL
of	NULL
PU.1	NULL
as	NULL
a	NULL
key	NULL
regulator	NULL
of	NULL
hematopoiesis	NULL
,	NULL
and	NULL
point	NULL
to	NULL
C/EBPa	NULL
as	NULL
an	NULL
additional	NULL
important	NULL
factor	NULL
in	NULL
this	NULL
process	NULL
.	NULL

Hematopoietic	NULL
growth	NULL
factors	NULL
and	NULL
their	NULL
receptors	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
survival	NULL
of	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Among	NULL
these	NULL
factors	NULL
,	NULL
functional	NULL
and	NULL
binding	NULL
analyses	NULL
suggest	NULL
that	NULL
the	NULL
receptor	NULL
for	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
is	NULL
expressed	NULL
specifically	NULL
on	NULL
myeloid	NULL
cells	NULL
and	NULL
their	NULL
precursors	NULL
(	NULL
8	NULL
,	NULL
42	NULL
,	NULL
43	NULL
,	NULL
68	NULL
)	NULL
.	NULL

In	NULL
myeloid	NULL
cells	NULL
,	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
is	NULL
expressed	NULL
on	NULL
early	NULL
myeloid	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
on	NULL
mature	NULL
phagocytic	NULL
cells	NULL
,	NULL
reflecting	NULL
the	NULL
ability	NULL
of	NULL
GM-CSF	NULL
to	NULL
modulate	NULL
the	NULL
development	NULL
and	NULL
activity	NULL
of	NULL
myeloid	NULL
cells	NULL
throughout	NULL
differentiation	NULL
(	NULL
21	NULL
,	NULL
50	NULL
,	NULL
68	NULL
)	NULL
.	NULL

The	NULL
heterodimeric	NULL
GM-CSF	NULL
receptor	NULL
consists	NULL
of	NULL
at	NULL
least	NULL
two	NULL
subunits	NULL
,	NULL
an	NULL
«	NULL
chain	NULL
,	NULL
which	NULL
binds	NULL
GM-CSF	NULL
with	NULL
low	NULL
affinity	NULL
when	NULL
expressed	NULL
alone	NULL
,	NULL
and	NULL
a	NULL
nonbinding	NULL
B	NULL
chain	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
high-affinity	NULL
receptors	NULL
and	NULL
signal	NULL
transduction	NULL
and	NULL
is	NULL
shared	NULL
by	NULL
two	NULL
other	NULL
cytokine	NULL
receptors	NULL
,	NULL
the	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
and	NULL
IL-5	NULL
receptors	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Functional	NULL
GM-CSF	NULL
receptors	NULL
have	NULL
been	NULL
identified	NULL
on	NULL
primary	NULL
and	NULL
cultured	NULL
myeloblasts	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
and	NULL
on	NULL
neutro-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
Research	NULL
East	NULL
,	NULL
Room	NULL
219	NULL
,	NULL
41	NULL
Avenue	NULL
Louis	NULL
Pasteur	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
667-5561	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
667-3299	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
tenen	NULL
@	NULL
mbcrr.harvard.edu	NULL
.	NULL

5830	NULL
phils	NULL
and	NULL
basophils	NULL
from	NULL
patients	NULL
with	NULL
juvenile	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
(	NULL
12	NULL
,	NULL
43	NULL
)	NULL
.	NULL

An	NULL
increased	NULL
responsiveness	NULL
to	NULL
GM-CSF	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
juvenile	NULL
chronic	NULL
myelomonocytic	NULL
leukemia	NULL
(	NULL
12	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
differential	NULL
expression	NULL
of	NULL
the	NULL
«	NULL
and	NULL
B	NULL
subunits	NULL
,	NULL
their	NULL
tissue	NULL
specificity	NULL
,	NULL
and	NULL
their	NULL
developmental	NULL
regulation	NULL
on	NULL
both	NULL
hematopoietic	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
remain	NULL
poorly	NULL
understood	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
gene	NULL
for	NULL
the	NULL
«	NULL
subunit	NULL
of	NULL
the	NULL
human	NULL
GM-CSF	NULL
receptor	NULL
has	NULL
been	NULL
cloned	NULL
,	NULL
and	NULL
its	NULL
genomic	NULL
structure	NULL
,	NULL
including	NULL
the	NULL
putative	NULL
promoter	NULL
region	NULL
,	NULL
has	NULL
been	NULL
described	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
major	NULL
transcription	NULL
initiation	NULL
site	NULL
in	NULL
hematopoietic	NULL
cells	NULL
was	NULL
determined	NULL
to	NULL
be	NULL
195	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
translation	NULL
initiation	NULL
site	NULL
(	NULL
35	NULL
)	NULL
.	NULL

As	NULL
with	NULL
many	NULL
other	NULL
genes	NULL
which	NULL
are	NULL
regulated	NULL
during	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
does	NULL
not	NULL
contain	NULL
an	NULL
obvious	NULL
TATA	NULL
motif	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
several	NULL
purine-rich	NULL
stretches	NULL
,	NULL
resembling	NULL
PU.1	NULL
binding	NULL
sites	NULL
,	NULL
were	NULL
identified	NULL
in	NULL
the	NULL
proximal	NULL
5	NULL
'	NULL
upstream	NULL
region	NULL
.	NULL

PU.1	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
is	NULL
specifically	NULL
expressed	NULL
in	NULL
myeloid	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
24	NULL
)	NULL
.	NULL

PU.1	NULL
was	NULL
first	NULL
identified	NULL
as	NULL
the	NULL
product	NULL
of	NULL
the	NULL
Spi-1	NULL
oncogene	NULL
in	NULL
Friend	NULL
virus-induced	NULL
erythroleukemia	NULL
(	NULL
16	NULL
,	NULL
33	NULL
,	NULL
44	NULL
)	NULL
,	NULL
and	NULL
over-expression	NULL
of	NULL
PU.1	NULL
in	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
can	NULL
block	NULL
erythroblast	NULL
differentiation	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
many	NULL
target	NULL
genes	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5831	NULL
-393	NULL
-393	NULL
TGCAGCAAAGTGGGGATGTGTGAGTGTGCAGCTCTGTGTGTGC	NULL
-350	NULL
_	NULL
AGATGTGTGTGCAGACATGTATGTGTGTGCAGCTGTGTGTGCAGCGTGTGT	NULL
-2	NULL
'I7	NULL
8	NULL
-300	NULL
_	NULL
GTGCAAACATGCACACGCGTGCAAGCATGTGTGCAGCGAGTGTGTGTGecac	NULL
-250	NULL
-	NULL
GTGTGTGCGGeCoTreTreceAaATGoTreTreceTreTrecaceTcrerererecac	NULL
-200	NULL
_	NULL
ATGTGTGTGCAGACATACATGTGTCTGCAGGTGTGTGTGTGTAGATGTGT	NULL
-	NULL
14I	NULL
6	NULL
-150	NULL
_	NULL
GTGGGACTCACACTTGAGCTGTTCCACCGGCCAGTCTTTGCAGACGAGGT	NULL
-	NULL
7I0	NULL
-	NULL
SI	NULL
3	NULL
-100	NULL
_	NULL
CAGGAGCCAATGAACTCACGGAGCAATTACAGGTTTCCCAATCCTATGAA	NULL
-41	NULL
-10	NULL
*__*	NULL
*	NULL
1	NULL
I	NULL
-50	NULL
_	NULL
ATGAGGAAGCAGGGCGCAGGGAGCGGCAGGGAGTGTATGATCACACAGACGCA	NULL
]	NULL
+49	NULL
I	NULL
+1	NULL
TCTGAAGGGACGCTACTCACAAGCGGCGAGTCTCCGAGAGAAGCAAAAGCG	NULL
+73	NULL
I	NULL
INTRON	NULL
1	NULL
--	NULL
>	NULL
+51	NULL
GTTGGAAGGAGAGAAAGCGTACCCCGTGGGGgtaagctaagttctttect	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
,	NULL
PU.1	NULL
and	NULL
C/EBP	NULL
«	NULL
binding	NULL
sites	NULL
,	NULL
and	NULL
deletion	NULL
mutants	NULL
.	NULL

The	NULL
DNA	NULL
sequence	NULL
is	NULL
taken	NULL
from	NULL
reference	NULL
35	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
is	NULL
numbered	NULL
+1	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
purine-rich	NULL
region	NULL
(	NULL
bp	NULL
-39	NULL
to	NULL
-27	NULL
)	NULL
common	NULL
to	NULL
several	NULL
myeloid	NULL
promoters	NULL
is	NULL
circled	NULL
(	NULL
35	NULL
)	NULL
.	NULL

A	NULL
GA-rich	NULL
sequence	NULL
(	NULL
bp	NULL
-5	NULL
to	NULL
+1	NULL
)	NULL
,	NULL
which	NULL
does	NULL
not	NULL
bind	NULL
PU.1	NULL
,	NULL
and	NULL
the	NULL
actual	NULL
PU.1	NULL
binding	NULL
site	NULL
identified	NULL
by	NULL
gel	NULL
shift	NULL
assay	NULL
(	NULL
bp	NULL
-48	NULL
to	NULL
-43	NULL
)	NULL
are	NULL
boxed	NULL
.	NULL

The	NULL
guanosine	NULL
residues	NULL
at	NULL
bp	NULL
-48	NULL
,	NULL
-46	NULL
,	NULL
and	NULL
-45	NULL
which	NULL
contact	NULL
PU.1	NULL
as	NULL
identified	NULL
by	NULL
methylation	NULL
interference	NULL
are	NULL
indicated	NULL
by	NULL
asterisks	NULL
.	NULL

The	NULL
CCAAT	NULL
box	NULL
at	NULL
bp	NULL
-63	NULL
to	NULL
-59	NULL
is	NULL
overlined	NULL
.	NULL

The	NULL
construct	NULL
-393GM-CSFr-luc	NULL
contains	NULL
the	NULL
sequence	NULL
from	NULL
residue	NULL
-393	NULL
to	NULL
+49	NULL
cloned	NULL
into	NULL
the	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
pXP2	NULL
.	NULL

The	NULL
5	NULL
'	NULL
positions	NULL
of	NULL
the	NULL
deletion	NULL
constructs	NULL
are	NULL
indicated	NULL
by	NULL
numbers	NULL
above	NULL
the	NULL
sequence	NULL
.	NULL

The	NULL
first	NULL
intron	NULL
,	NULL
which	NULL
starts	NULL
after	NULL
bp	NULL
+81	NULL
,	NULL
is	NULL
indicated	NULL
by	NULL
lowercase	NULL
letters	NULL
.	NULL

for	NULL
the	NULL
transcriptional	NULL
regulation	NULL
by	NULL
PU.1	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
10	NULL
,	NULL
13	NULL
,	NULL
25	NULL
,	NULL
29	NULL
,	NULL
34	NULL
,	NULL
41	NULL
,	NULL
45	NULL
,	NULL
52	NULL
,	NULL
62	NULL
,	NULL
70	NULL
)	NULL
.	NULL

Among	NULL
these	NULL
is	NULL
the	NULL
receptor	NULL
for	NULL
M-CSF	NULL
(	NULL
70	NULL
)	NULL
,	NULL
which	NULL
has	NULL
a	NULL
PU.1	NULL
site	NULL
at	NULL
nearly	NULL
the	NULL
identical	NULL
position	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
as	NULL
a	NULL
putative	NULL
PU.1	NULL
site	NULL
in	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
.	NULL

PU.1	NULL
has	NULL
a	NULL
crucial	NULL
role	NULL
for	NULL
hematopoietic	NULL
devel-opment	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
inhibition	NULL
of	NULL
colony	NULL
formation	NULL
of	NULL
human	NULL
CD34¢*	NULL
cells	NULL
by	NULL
PU.1	NULL
binding	NULL
double-stranded	NULL
oligonucleotides	NULL
(	NULL
66	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
gene	NULL
targeting	NULL
of	NULL
PU.1	NULL
in	NULL
mice	NULL
results	NULL
in	NULL
a	NULL
complete	NULL
abrogation	NULL
of	NULL
fetal	NULL
development	NULL
of	NULL
myeloid	NULL
cells	NULL
and	NULL
lymphocytes	NULL
(	NULL
56	NULL
)	NULL
.	NULL

The	NULL
PU.1	NULL
protein	NULL
consists	NULL
of	NULL
272	NULL
amino	NULL
acids	NULL
,	NULL
with	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
located	NULL
in	NULL
the	NULL
carboxyl-terminal	NULL
part	NULL
of	NULL
the	NULL
protein	NULL
,	NULL
while	NULL
the	NULL
amino	NULL
terminus	NULL
contains	NULL
an	NULL
activation	NULL
do-main	NULL
,	NULL
which	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
interactions	NULL
with	NULL
other	NULL
regulatory	NULL
proteins	NULL
(	NULL
19	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
B	NULL
cells	NULL
,	NULL
PU.1	NULL
recruits	NULL
a	NULL
second	NULL
,	NULL
B	NULL
cell-specific	NULL
DNA	NULL
binding	NULL
factor	NULL
,	NULL
NF-EMS5	NULL
,	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
k	NULL
3	NULL
'	NULL
enhancer	NULL
function	NULL
(	NULL
11	NULL
,	NULL
46	NULL
,	NULL
47	NULL
)	NULL
.	NULL

For	NULL
this	NULL
interaction	NULL
,	NULL
phosphorylation	NULL
of	NULL
a	NULL
serine	NULL
residue	NULL
at	NULL
position	NULL
148	NULL
is	NULL
necessary	NULL
(	NULL
47	NULL
)	NULL
.	NULL

However	NULL
,	NULL
such	NULL
interactions	NULL
have	NULL
not	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
functional	NULL
role	NULL
in	NULL
previously	NULL
described	NULL
myeloid	NULL
targets	NULL
of	NULL
PU.1	NULL
,	NULL
such	NULL
as	NULL
CD11b	NULL
and	NULL
the	NULL
M-CSF	NULL
receptor	NULL
(	NULL
41	NULL
,	NULL
70	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
experiments	NULL
also	NULL
demonstrated	NULL
an	NULL
interaction	NULL
of	NULL
the	NULL
amino-terminal	NULL
region	NULL
of	NULL
PU.1	NULL
with	NULL
a	NULL
conserved	NULL
region	NULL
in	NULL
both	NULL
the	NULL
basal	NULL
transcription	NULL
factor	NULL
TATA-binding	NULL
protein	NULL
(	NULL
TBP	NULL
)	NULL
and	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
protein	NULL
(	NULL
19	NULL
)	NULL
,	NULL
and	NULL
in	NULL
these	NULL
TATA	NULL
box-lacking	NULL
,	NULL
myeloid	NULL
promoters	NULL
,	NULL
the	NULL
PU.1	NULL
site	NULL
could	NULL
function	NULL
like	NULL
a	NULL
TATA	NULL
box	NULL
to	NULL
recruit	NULL
the	NULL
basal	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
promoters	NULL
(	NULL
10	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Upstream	NULL
of	NULL
the	NULL
potential	NULL
PU.1	NULL
sites	NULL
in	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
are	NULL
sequences	NULL
representing	NULL
potential	NULL
binding	NULL
sites	NULL
for	NULL
CCAAT-binding	NULL
proteins	NULL
.	NULL

Members	NULL
of	NULL
the	NULL
CCAAT/enhancer-binding	NULL
protein	NULL
(	NULL
C/EBP	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
the	NULL
terminal	NULL
differentiation	NULL
of	NULL
adipocytes	NULL
and	NULL
hepatocytes	NULL
(	NULL
5	NULL
,	NULL
28	NULL
)	NULL
.	NULL

In	NULL
the	NULL
hematopoietic	NULL
system	NULL
,	NULL
C/EBPa	NULL
,	NULL
C/EBPRB	NULL
,	NULL
and	NULL
C/EBP3	NULL
are	NULL
specifically	NULL
expressed	NULL
in	NULL
myeloid	NULL
,	NULL
but	NULL
not	NULL
in	NULL
erythroid	NULL
or	NULL
lymphoid	NULL
cells	NULL
and	NULL
are	NULL
differentially	NULL
expressed	NULL
during	NULL
myelomonocytic	NULL
differentiation	NULL
(	NULL
18	NULL
,	NULL
22	NULL
,	NULL
36	NULL
,	NULL
57	NULL
,	NULL
64	NULL
)	NULL
.	NULL

High	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
C/EBPa	NULL
in	NULL
proliferating	NULL
myeloid	NULL
cells	NULL
(	NULL
36	NULL
,	NULL
57	NULL
)	NULL
suggest	NULL
that	NULL
C/EBPa	NULL
may	NULL
activate	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Currently	NULL
,	NULL
few	NULL
target	NULL
genes	NULL
for	NULL
the	NULL
regulatory	NULL
function	NULL
of	NULL
C/EBP	NULL
have	NULL
been	NULL
definitely	NULL
identified	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

In	NULL
chicken	NULL
cells	NULL
,	NULL
the	NULL
C/EBP	NULL
factor	NULL
NF-M	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
mim-1	NULL
gene	NULL
(	NULL
4	NULL
,	NULL
37	NULL
)	NULL
and	NULL
of	NULL
chicken	NULL
myelomonocytic	NULL
growth	NULL
factor	NULL
,	NULL
a	NULL
homolog	NULL
of	NULL
human	NULL
G-CSF	NULL
(	NULL
18	NULL
,	NULL
22	NULL
,	NULL
64	NULL
)	NULL
.	NULL

The	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
neutrophil	NULL
elastase	NULL
gene	NULL
contains	NULL
a	NULL
functional	NULL
site	NULL
which	NULL
resembles	NULL
a	NULL
C/EBP	NULL
site	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
the	NULL
genes	NULL
for	NULL
several	NULL
cytokines	NULL
which	NULL
are	NULL
expressed	NULL
in	NULL
macrophages	NULL
,	NULL
including	NULL
human	NULL
G-CSF	NULL
,	NULL
IL-6	NULL
,	NULL
IL-1a	NULL
,	NULL
IL-1B	NULL
,	NULL
IL-8	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
and	NULL
monocyte	NULL
chemoattractant	NULL
protein	NULL
1	NULL
,	NULL
contain	NULL
known	NULL
or	NULL
predicted	NULL
C/EBP	NULL
binding	NULL
sites	NULL
(	NULL
3	NULL
,	NULL
36	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Potential	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
of	NULL
an	NULL
impor-	NULL
5832	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

tant	NULL
myeloid	NULL
growth	NULL
factor	NULL
receptor	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
,	NULL
prompted	NULL
us	NULL
to	NULL
investigate	NULL
whether	NULL
PU.1	NULL
and/or	NULL
C/EBP	NULL
play	NULL
important	NULL
roles	NULL
in	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
this	NULL
key	NULL
regulator	NULL
of	NULL
hematopoietic	NULL
development	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
both	NULL
PU.1	NULL
and	NULL
C/EBP	NULL
bind	NULL
to	NULL
sites	NULL
critical	NULL
for	NULL
myeloid	NULL
cell-specific	NULL
expression	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
.	NULL

Moreover	NULL
,	NULL
PU.1	NULL
forms	NULL
a	NULL
larger	NULL
complex	NULL
with	NULL
another	NULL
protein	NULL
which	NULL
may	NULL
be	NULL
important	NULL
for	NULL
functional	NULL
activ-	NULL
ity	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

Human	NULL
myelomonocytic	NULL
U937	NULL
cells	NULL
(	NULL
ATCC	NULL
CRL	NULL
1593	NULL
;	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

,	NULL
B-lymphoblastic	NULL
Raji	NULL
and	NULL
BJAB	NULL
cells	NULL
,	NULL
and	NULL
T-lymphoblastic	NULL
REX	NULL
cells	NULL
(	NULL
provided	NULL
by	NULL
James	NULL
Griffin	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
)	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
HyClone	NULL
,	NULL
Logan	NULL
,	NULL
Utah	NULL
)	NULL
and	NULL
2	NULL
mM	NULL
r-glutamine	NULL
(	NULL
Gibco	NULL
)	NULL
.	NULL

Human	NULL
cervical	NULL
carcinoma	NULL
HeLa	NULL
cells	NULL
(	NULL
ATCC	NULL
CCL	NULL
2	NULL
)	NULL
and	NULL
monkey	NULL
kidney	NULL
Cos	NULL
?	NULL

cells	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
Gibco	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Gibco	NULL
)	NULL
and	NULL
2	NULL
mM	NULL
1-glutamine	NULL
(	NULL
Gibco	NULL
)	NULL
.	NULL

The	NULL
human	NULL
hepatoma	NULL
cell	NULL
line	NULL
HepG2	NULL
(	NULL
provided	NULL
by	NULL
J.	NULL
Papaconstantinou	NULL
)	NULL
was	NULL
maintained	NULL
in	NULL
a	NULL
1:1	NULL
mixture	NULL
of	NULL
F12	NULL
medium	NULL
(	NULL
GIBCO	NULL
)	NULL
and	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
and	NULL
10	NULL
g	NULL
of	NULL
bovine	NULL
insulin	NULL
per	NULL
ml	NULL
.	NULL

CV-1	NULL
cells	NULL
,	NULL
an	NULL
African	NULL
green	NULL
monkey	NULL
kidney	NULL
cell	NULL
line	NULL
(	NULL
ATCC	NULL
CCL	NULL
70	NULL
)	NULL
,	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
calf	NULL
serum	NULL
(	NULL
Gibco	NULL
)	NULL
and	NULL
2	NULL
mM	NULL
1-glutamine	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
gene	NULL
expression	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
cell	NULL
lines	NULL
by	NULL
the	NULL
guanidium	NULL
isothiocyanate-CsCl	NULL
method	NULL
(	NULL
53	NULL
)	NULL
.	NULL

First-strand	NULL
cDNA	NULL
was	NULL
synthesized	NULL
from	NULL
30	NULL
ng	NULL
of	NULL
total	NULL
RNA	NULL
,	NULL
using	NULL
200	NULL
U	NULL
of	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
in	NULL
a	NULL
20-pl	NULL
reaction	NULL
mixture	NULL
containing	NULL
1	NULL
mM	NULL
deoxynucleoside	NULL
triphosphates	NULL
(	NULL
dNTPs	NULL
)	NULL
,	NULL
1	NULL
U	NULL
of	NULL
RNasin	NULL
per	NULL
pl	NULL
,	NULL
100	NULL
pmol	NULL
of	NULL
random	NULL
hexamers	NULL
(	NULL
Pharmacia	NULL
)	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
dithiothreitol	NULL
in	NULL
1	NULL
%	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris	NULL
HCl	NULL
[	NULL
pH	NULL
8.3	NULL
]	NULL
,	NULL
75	NULL
mM	NULL
KCl	NULL
,	NULL
6	NULL
mM	NULL
MgCl	NULL
;	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
23°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
42°C	NULL
for	NULL
60	NULL
min	NULL
,	NULL
and	NULL
94°C	NULL
for	NULL
5	NULL
min	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
reaction	NULL
volume	NULL
containing	NULL
2	NULL
pl	NULL
of	NULL
the	NULL
reverse	NULL
transcription	NULL
(	NULL
RT	NULL
)	NULL
product	NULL
,	NULL
40	NULL
pmol	NULL
of	NULL
each	NULL
primer	NULL
,	NULL
200	NULL
M	NULL
dNTPs	NULL
,	NULL
and	NULL
2	NULL
U	NULL
of	NULL
Taq	NULL
polymerase	NULL
in	NULL
1	NULL
%	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
HCl	NULL
[	NULL
pH	NULL
8.3	NULL
]	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
)	NULL
,	NULL
0.001	NULL
%	NULL
gelatin	NULL
)	NULL
.	NULL

Each	NULL
cycle	NULL
of	NULL
PCR	NULL
included	NULL
1	NULL
min	NULL
of	NULL
denaturation	NULL
at	NULL
94°C	NULL
,	NULL
1	NULL
min	NULL
of	NULL
annealing	NULL
at	NULL
60°C	NULL
for	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
primers	NULL
(	NULL
5'-C	NULL
TTCTCTCTGACCAGCA-3	NULL
'	NULL
and	NULL
5	NULL
``	NULL
-ACATGGGTTCCTGAGTC-3	NULL
'	NULL
)	NULL
(	NULL
15	NULL
)	NULL
or	NULL
at	NULL
50°C	NULL
for	NULL
the	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
primers	NULL
(	NULL
5'-CCATGGAGAAGGCTGGGG-3	NULL
'	NULL
and	NULL
5°CAAAGTTGTCATGGATGACC-3	NULL
'	NULL
)	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
90	NULL
s	NULL
of	NULL
extension	NULL
at	NULL
72°C	NULL
.	NULL

A	NULL
control	NULL
for	NULL
DNA	NULL
contamination	NULL
,	NULL
containing	NULL
water	NULL
instead	NULL
of	NULL
cDNA	NULL
,	NULL
was	NULL
used	NULL
in	NULL
each	NULL
RT-PCR	NULL
.	NULL

To	NULL
ensure	NULL
that	NULL
the	NULL
RT-PCR	NULL
signal	NULL
was	NULL
linear	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
RNA	NULL
input	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
kinctic	NULL
analysis	NULL
by	NULL
varying	NULL
the	NULL
number	NULL
of	NULL
cycles	NULL
of	NULL
amplification	NULL
for	NULL
each	NULL
primer	NULL
set	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
RNA	NULL
input	NULL
(	NULL
66	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
this	NULL
analysis	NULL
,	NULL
we	NULL
used	NULL
20	NULL
cycles	NULL
for	NULL
the	NULL
GAPDH	NULL
primers	NULL
and	NULL
27	NULL
cycles	NULL
for	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
primers	NULL
.	NULL

RT-PCR	NULL
products	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
1.5	NULL
%	NULL
agarose	NULL
gel	NULL
and	NULL
blotted	NULL
on	NULL
a	NULL
Biotrans+	NULL
membrane	NULL
(	NULL
ICN	NULL
)	NULL
in	NULL
0.4	NULL
M	NULL
NaOH	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
dried	NULL
,	NULL
prehybridized	NULL
,	NULL
and	NULL
hybridized	NULL
in	NULL
0.5	NULL
M	NULL
NaPO	NULL
,	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
-7	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
at	NULL
65°C	NULL
with	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
cDNA	NULL
and	NULL
GAPDH	NULL
cDNA	NULL
as	NULL
probes	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
washed	NULL
in	NULL
2	NULL
SSC	NULL
(	NULL
2	NULL
%	NULL
SSC	NULL
is	NULL
0.15	NULL
NaCl	NULL
plus	NULL
0.015	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
-0.1	NULL
%	NULL
SDS	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
in	NULL
0.2	NULL
SSC-0.1	NULL
%	NULL
SDS	NULL
at	NULL
65°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Exposures	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
at	NULL
-80°C	NULL
with	NULL
an	NULL
intensifying	NULL
screen	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
human	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
,	NULL
The	NULL
sequence	NULL
5	NULL
'	NULL
of	NULL
exon	NULL
1	NULL
of	NULL
the	NULL
human	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
gene	NULL
was	NULL
amplified	NULL
and	NULL
cloned	NULL
from	NULL
Beilll-digested	NULL
human	NULL
genomic	NULL
DNA	NULL
(	NULL
peripheral	NULL
blood	NULL
of	NULL
a	NULL
normal	NULL
donor	NULL
)	NULL
by	NULL
PCR	NULL
based	NULL
on	NULL
the	NULL
published	NULL
sequence	NULL
(	NULL
35	NULL
)	NULL
with	NULL
primer	NULL
A	NULL
(	NULL
5-GTGGGATCCTG	NULL
CAGGAAAGTGGGGAT-3	NULL
'	NULL
)	NULL
and	NULL
primer	NULL
B	NULL
(	NULL
5	NULL
%	NULL
-GTGGATCCGGTACGCTIT	NULL
CTCTCCT-3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
synthesized	NULL
fragment	NULL
was	NULL
466	NULL
bp	NULL
long	NULL
,	NULL
extending	NULL
from	NULL
bp	NULL
-393	NULL
to	NULL
+73	NULL
with	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
designated	NULL
+1	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
35	NULL
)	NULL
.	NULL

A	NULL
second	NULL
PCR	NULL
fragment	NULL
from	NULL
bp	NULL
-	NULL
393	NULL
to	NULL
+49	NULL
was	NULL
generated	NULL
by	NULL
using	NULL
primer	NULL
A	NULL
and	NULL
primer	NULL
C	NULL
(	NULL
5-/GTGGTACCGCITTITTCTTCTCTCGGA-3	NULL
'	NULL
)	NULL
and	NULL
the	NULL
466-bp-con-taining	NULL
plasmid	NULL
as	NULL
a	NULL
template	NULL
.	NULL

This	NULL
PCR	NULL
fragment	NULL
was	NULL
digested	NULL
with	NULL
BemHI	NULL
and	NULL
KpnI	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
promoterless	NULL
luciferase	NULL
vector	NULL
pXP2	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
this	NULL
fragment	NULL
matched	NULL
the	NULL
published	NULL
genomic	NULL
sequence	NULL
.	NULL

This	NULL
construct	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
-393GM-CSFr-luc	NULL
.	NULL

Transient	NULL
transfections	NULL
.	NULL

U937	NULL
,	NULL
Raji	NULL
,	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
in	NULL
IMDM	NULL
medium	NULL
(	NULL
GIBCO	NULL
)	NULL
at	NULL
960	NULL
F	NULL
and	NULL
300	NULL
V	NULL
,	NULL
and	NULL
Rex	NULL
cells	NULL
were	NULL
transfected	NULL
at	NULL
280	NULL
V	NULL
,	NULL
with	NULL
a	NULL
Bio-Rad	NULL
Genepulser	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
7	NULL
h	NULL
posttransfection	NULL
into	NULL
0.25	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
,	NULL
and	NULL
0.1	NULL
ml	NULL
of	NULL
this	NULL
lysate	NULL
was	NULL
added	NULL
to	NULL
0.3	NULL
ml	NULL
of	NULL
assay	NULL
buffer	NULL
for	NULL
luciferase	NULL
assays	NULL
.	NULL

The	NULL
details	NULL
of	NULL
the	NULL
transfection	NULL
and	NULL
luciferase	NULL
assay	NULL
procedures	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
growth	NULL
hormone	NULL
produced	NULL
by	NULL
2	NULL
ug	NULL
of	NULL
cotransfected	NULL
plasmid	NULL
containing	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
directing	NULL
human	NULL
growth	NULL
hormone	NULL
gene	NULL
expression	NULL
(	NULL
CMV-hGH	NULL
)	NULL
.	NULL

Growth	NULL
hormone	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
a	NULL
y	NULL
$	NULL
4	NULL
Eo	NULL
&	NULL
``	NULL
Z	NULL
T	NULL
o	NULL
s	NULL
S	NULL
asiﬂfx==	NULL
?	NULL

``	NULL
'	NULL
;	NULL
;	NULL
o	NULL
%	NULL
8	NULL
§	NULL
%	NULL
$	NULL
2	NULL
a	NULL
@	NULL
a	NULL
2	NULL
1	NULL
&	NULL
4	NULL
%	NULL
Z	NULL
Z	NULL
=	NULL
z	NULL
3	NULL
<	NULL
»	NULL
@	NULL
»	NULL
n	NULL
GM-CSF	NULL
receptor	NULL
--	NULL
-	NULL
ain	NULL
we	NULL
e	NULL
C	NULL
;	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
B	NULL
U937	NULL
Raji	NULL
Jurkat	NULL
REX	NULL
1007	NULL
2007	NULL
3007	NULL
400	NULL
~	NULL
Promoter	NULL
activity	NULL
(	NULL
Fold	NULL
above	NULL
pxP2	NULL
)	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Expression	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
.	NULL

RNA	NULL
from	NULL
the	NULL
following	NULL
sources	NULL
was	NULL
reverse	NULL
transcribed	NULL
,	NULL
amplified	NULL
by	NULL
PCR	NULL
with	NULL
primers	NULL
for	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
or	NULL
GAPDH	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
the	NULL
respective	NULL
cDNA	NULL
probe	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
no-RT	NULL
control	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
HeLa	NULL
cells	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
Raji	NULL
B	NULL
cells	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
Rex	NULL
T	NULL
cells	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
Monomac	NULL
(	NULL
monocytic	NULL
)	NULL
cells	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
monocytes	NULL
isolated	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
HL-60	NULL
(	NULL
promyelocytic	NULL
)	NULL
cells	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
NB4	NULL
(	NULL
promyelocytic	NULL
)	NULL
cells	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
U937	NULL
(	NULL
myelomonocytic	NULL
)	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Tissue	NULL
specificity	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
in	NULL
transient	NULL
transfections	NULL
.	NULL

-393GM-CSFr-luc	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
promoterless	NULL
vector	NULL
pXP2	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
-expressing	NULL
cell	NULL
line	NULL
U937	NULL
and	NULL
into	NULL
the	NULL
GM-CSF	NULL
receptor-negative	NULL
cell	NULL
lines	NULL
Raji	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
Rex	NULL
.	NULL

The	NULL
transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
by	NULL
cotransfecting	NULL
CMV-hGH	NULL
.	NULL

Data	NULL
are	NULL
shown	NULL
as	NULL
fold	NULL
induction	NULL
over	NULL
the	NULL
level	NULL
with	NULL
plasmid	NULL
pXP2	NULL
and	NULL
represent	NULL
the	NULL
means	NULL
of	NULL
three	NULL
to	NULL
six	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

Results	NULL
similar	NULL
to	NULL
those	NULL
for	NULL
Raji	NULL
B	NULL
cells	NULL
were	NULL
also	NULL
obtained	NULL
with	NULL
the	NULL
BJAB	NULL
cell	NULL
line	NULL
,	NULL
but	NULL
they	NULL
are	NULL
not	NULL
presented	NULL
because	NULL
the	NULL
experiment	NULL
was	NULL
performed	NULL
only	NULL
once	NULL
.	NULL

concentrations	NULL
were	NULL
measured	NULL
by	NULL
radioimmunoassay	NULL
(	NULL
Nichol	NULL
's	NULL
Institute	NULL
,	NULL
San	NULL
Juan	NULL
Capistrano	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
fold	NULL
induction	NULL
over	NULL
that	NULL
with	NULL
the	NULL
plasmid	NULL
pXP2	NULL
.	NULL

Nuclear	NULL
extracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
U937	NULL
,	NULL
Raji	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
Rex	NULL
cells	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
7	NULL
)	NULL
,	NULL
modified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
41	NULL
)	NULL
,	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
mM	NULL
diisopropylfluorophosphate	NULL
(	NULL
Sigma	NULL
)	NULL
to	NULL
buffers	NULL
A	NULL
and	NULL
C.	NULL
Extracts	NULL
of	NULL
Cos	NULL
?	NULL

and	NULL
HepG2	NULL
cells	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
following	NULL
method	NULL
.	NULL

Adherent	NULL
cells	NULL
(	NULL
10°	NULL
to	NULL
10	NULL
``	NULL
cells	NULL
per	NULL
100-mm-diameter	NULL
tissue	NULL
culture	NULL
plate	NULL
)	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
scraped	NULL
from	NULL
the	NULL
plate	NULL
,	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
200	NULL
x	NULL
g	NULL
,	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
PBS	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
microcentrifuge	NULL
tubes	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
pelleted	NULL
again	NULL
and	NULL
resuspended	NULL
in	NULL
400	NULL
pl	NULL
of	NULL
cold	NULL
hypotonic	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
[	NULL
N-2-hydroxyeth-ylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
]	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
KC	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.2	NULL
mM	NULL
phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
)	NULL
,	NULL
and	NULL
allowed	NULL
to	NULL
swell	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
lysed	NULL
by	NULL
being	NULL
vortexed	NULL
for	NULL
10	NULL
s	NULL
,	NULL
and	NULL
the	NULL
nuclei	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
12,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
s	NULL
in	NULL
a	NULL
microcentrifuge	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
40	NULL
pl	NULL
of	NULL
cold	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
,	NULL
with	NULL
flicking	NULL
of	NULL
the	NULL
tube	NULL
several	NULL
times	NULL
.	NULL

The	NULL
nuclei	NULL
were	NULL
pelleted	NULL
at	NULL
4°C	NULL
and	NULL
12,000	NULL
x	NULL
g	NULL
for	NULL
3	NULL
min	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Analysis	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
)	NULL
showed	NULL
that	NULL
the	NULL
extracts	NULL
contained	NULL
2	NULL
to	NULL
3	NULL
mg	NULL
of	NULL
protein	NULL
per	NULL
ml	NULL
.	NULL

EMSA	NULL
.	NULL

P-labeled	NULL
double-stranded	NULL
oligonucleotides	NULL
for	NULL
electrophoretic	NULL
mo	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
-393	NULL
+49	NULL
Lue	NULL
PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5833	NULL
U	NULL
T	NULL
<	NULL
I	NULL
&	NULL
D	NULL
u	NULL
u	NULL
t	NULL
250	NULL
1000	NULL
Promoter	NULL
activity	NULL
(	NULL
Fold	NULL
above	NULL
pxP2	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Identification	NULL
of	NULL
critical	NULL
cis	NULL
elements	NULL
in	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
.	NULL

A	NULL
series	NULL
of	NULL
5	NULL
'	NULL
deletion	NULL
constructs	NULL
was	NULL
generated	NULL
and	NULL
transiently	NULL
transfected	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL

Four	NULL
to	NULL
eight	NULL
independent	NULL
experiments	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
the	NULL
average	NULL
fold	NULL
luciferase	NULL
activity	NULL
over	NULL
the	NULL
level	NULL
with	NULL
pXP2	NULL
and	NULL
standard	NULL
errors	NULL
were	NULL
calculated	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
normalized	NULL
to	NULL
growth	NULL
hormone	NULL
produced	NULL
by	NULL
a	NULL
cotransfected	NULL
CMV-hGH	NULL
plasmid	NULL
.	NULL

bility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
0.5	NULL
ng	NULL
(	NULL
specific	NULL
activity	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cpm/ug	NULL
)	NULL
was	NULL
used	NULL
per	NULL
reaction	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
preincubated	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
20	NULL
al	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-50	NULL
mM	NULL
KCl-5	NULL
mM	NULL
MgCl	NULL
,	NULL
-1	NULL
mM	NULL
dithiothreitol-1	NULL
mM	NULL
EDTA-5	NULL
%	NULL
glycerol	NULL
.	NULL

As	NULL
described	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
,	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
(	NULL
50	NULL
ng	NULL
=	NULL
100-fold	NULL
excess	NULL
)	NULL
were	NULL
included	NULL
in	NULL
this	NULL
30-min	NULL
preincubation	NULL
.	NULL

For	NULL
supershift	NULL
experiments	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
either	NULL
specific	NULL
polyclonal	NULL
antiserum	NULL
or	NULL
normal	NULL
rabbit	NULL
serum	NULL
was	NULL
added	NULL
to	NULL
the	NULL
preincubation	NULL
mixture	NULL
.	NULL

A	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
recognizing	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
PU.1	NULL
(	NULL
amino	NULL
acids	NULL
33	NULL
to	NULL
45	NULL
of	NULL
the	NULL
murine	NULL
protein	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Richard	NULL
Maki	NULL
(	NULL
24	NULL
,	NULL
46	NULL
)	NULL
,	NULL
and	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
full-length	NULL
PU.1	NULL
protein	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
David	NULL
Kabat	NULL
.	NULL

Rabbit	NULL
antisera	NULL
raised	NULL
against	NULL
the	NULL
carboxyl	NULL
four-fifths	NULL
of	NULL
C/EBP	NULL
«	NULL
,	NULL
against	NULL
the	NULL
carboxyl-terminal	NULL
18	NULL
amino	NULL
acids	NULL
of	NULL
C/EBPB	NULL
,	NULL
and	NULL
against	NULL
full-length	NULL
C/EBP3	NULL
were	NULL
provided	NULL
by	NULL
Steven	NULL
McKnight	NULL
.	NULL

An	NULL
Oct-1	NULL
peptide	NULL
antiserum	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
served	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Antiserum	NULL
raised	NULL
against	NULL
the	NULL
full-length	NULL
RB	NULL
protein	NULL
(	NULL
N9	NULL
serum	NULL
)	NULL
and	NULL
preimmune	NULL
serum	NULL
were	NULL
provided	NULL
by	NULL
Bill	NULL
Kaelin	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
of	NULL
PU.1	NULL
,	NULL
PU.1	NULL
deletion	NULL
mutants	NULL
,	NULL
and	NULL
other	NULL
ets	NULL
family	NULL
members	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
rabbit	NULL
reticulocyte	NULL
lysate	NULL
system	NULL
(	NULL
TnT	NULL
system	NULL
;	NULL
Promega	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
66	NULL
)	NULL
,	NULL
and	NULL
1	NULL
pl	NULL
was	NULL
added	NULL
in	NULL
the	NULL
20	NULL
pl	NULL
reaction	NULL
mixture	NULL
instead	NULL
of	NULL
adding	NULL
the	NULL
nuclear	NULL
extract	NULL
.	NULL

Reaction	NULL
mixtures	NULL
were	NULL
then	NULL
electrophoresed	NULL
at	NULL
10	NULL
V/cm	NULL
on	NULL
a	NULL
5.2	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
(	NULL
45	NULL
mM	NULL
Tris-borate	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
at	NULL
4°C	NULL
.	NULL

Methylation	NULL
interference	NULL
analysis	NULL
.	NULL

Twenty-five	NULL
picomoles	NULL
of	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
bp	NULL
-70	NULL
to	NULL
-54	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
75	NULL
w.Ci	NULL
of	NULL
[	NULL
y*	NULL
``	NULL
-PJATP	NULL
by	NULL
T4	NULL
kinase	NULL
(	NULL
10	NULL
U	NULL
)	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
for	NULL
60	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
heat	NULL
inactivation	NULL
at	NULL
65°C	NULL
for	NULL
20	NULL
min	NULL
,	NULL
PCR	NULL
was	NULL
performed	NULL
by	NULL
adding	NULL
25	NULL
pmol	NULL
of	NULL
primer	NULL
C	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
-393GM-CSFr-lue	NULL
as	NULL
the	NULL
template	NULL
,	NULL
and	NULL
KCI	NULL
and	NULL
dNTPs	NULL
to	NULL
final	NULL
concentrations	NULL
of	NULL
50	NULL
mM	NULL
and	NULL
50	NULL
pM	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
100	NULL
fJ	NULL
.	NULL

The	NULL
amplification	NULL
procedure	NULL
included	NULL
denaturation	NULL
at	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
annealing	NULL
at	NULL
55°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
1	NULL
min	NULL
during	NULL
35	NULL
PCR	NULL
cycles	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
then	NULL
isolated	NULL
after	NULL
electrophoresis	NULL
in	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

The	NULL
PCR	NULL
fragment	NULL
was	NULL
partially	NULL
methylated	NULL
by	NULL
treatment	NULL
with	NULL
dimethyl	NULL
sulfate	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
30	NULL
,	NULL
63	NULL
,	NULL
70	NULL
)	NULL
,	NULL
subjected	NULL
to	NULL
a	NULL
binding	NULL
reaction	NULL
which	NULL
was	NULL
scaled	NULL
up	NULL
fivefold	NULL
from	NULL
the	NULL
EMSA	NULL
conditions	NULL
described	NULL
above	NULL
,	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
then	NULL
electrophoresed	NULL
on	NULL
low-ionic-strength	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
complexes	NULL
in	NULL
the	NULL
free	NULL
and	NULL
bound	NULL
fractions	NULL
were	NULL
visualized	NULL
by	NULL
autoradiography	NULL
,	NULL
excised	NULL
from	NULL
the	NULL
gel	NULL
,	NULL
and	NULL
isolated	NULL
by	NULL
electroclution	NULL
.	NULL

Each	NULL
sample	NULL
was	NULL
extracted	NULL
twice	NULL
with	NULL
phenol-chloro-form	NULL
and	NULL
once	NULL
with	NULL
chloroform	NULL
and	NULL
ethanol	NULL
precipitated	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
150	NULL
pl	NULL
of	NULL
1	NULL
M	NULL
piperidine	NULL
and	NULL
incubated	NULL
at	NULL
90°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Piperidine	NULL
was	NULL
removed	NULL
by	NULL
butanol	NULL
precipitation	NULL
and	NULL
drying	NULL
in	NULL
a	NULL
speed	NULL
vacuum	NULL
apparatus	NULL
.	NULL

Samples	NULL
with	NULL
equivalent	NULL
amounts	NULL
of	NULL
radioactivity	NULL
were	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
on	NULL
an	NULL
8	NULL
%	NULL
polyacrylamide-urea	NULL
sequencing	NULL
gel	NULL
and	NULL
visualized	NULL
by	NULL
auto-radiography	NULL
.	NULL

Construction	NULL
of	NULL
plasmids	NULL
with	NULL
deletions	NULL
,	NULL
with	NULL
site-directed	NULL
mutations	NULL
,	NULL
and	NULL
with	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
(	NULL
TK	NULL
)	NULL
promoter	NULL
.	NULL

Deletion	NULL
constructs	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
with	NULL
-393GM-CSFr-luc	NULL
as	NULL
the	NULL
template	NULL
with	NULL
primer	NULL
C	NULL
(	NULL
described	NULL
above	NULL
)	NULL
and	NULL
the	NULL
respective	NULL
5'-3	NULL
'	NULL
primers	NULL
containing	NULL
a	NULL
5	NULL
'	NULL
BemHI	NULL
site	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
digested	NULL
with	NULL
BermHI	NULL
and	NULL
KpnI	NULL
and	NULL
ligated	NULL
into	NULL
BamHI-KpnT-digested	NULL
luciferase	NULL
vector	NULL
pXP2	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Mutated	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
fragments	NULL
were	NULL
also	NULL
generated	NULL
by	NULL
PCR	NULL
(	NULL
26	NULL
)	NULL
.	NULL

For	NULL
generation	NULL
of	NULL
-53GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-luc	NULL
,	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
PU.1	NULL
site	NULL
at	NULL
positions	NULL
-48	NULL
,	NULL
-46	NULL
,	NULL
and	NULL
-45	NULL
,	NULL
the	NULL
plasmid	NULL
-393GM-CSFr-luc	NULL
served	NULL
as	NULL
the	NULL
template	NULL
and	NULL
primer	NULL
C	NULL
and	NULL
were	NULL
used	NULL
as	NULL
primers	NULL
(	NULL
mu-tated	NULL
bases	NULL
are	NULL
shown	NULL
in	NULL
lowercase	NULL
)	NULL
.	NULL

For	NULL
construction	NULL
of	NULL
-70GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-luc	NULL
,	NULL
the	NULL
resulting	NULL
PCR	NULL
fragment	NULL
then	NULL
served	NULL
as	NULL
a	NULL
primer	NULL
for	NULL
the	NULL
second	NULL
PCR	NULL
,	NULL
using	NULL
this	NULL
fragment	NULL
and	NULL
5'-AGGTITCCCAATCCTAT-3	NULL
'	NULL
as	NULL
primers	NULL
and	NULL
-393GM-CSFr-lue	NULL
as	NULL
the	NULL
template	NULL
.	NULL

The	NULL
plasmid	NULL
-70GM-CSFr	NULL
(	NULL
GM-2	NULL
)	NULL
-luc	NULL
,	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
CCAAT	NULL
site	NULL
at	NULL
positions	NULL
-60	NULL
and	NULL
-61	NULL
,	NULL
was	NULL
generated	NULL
by	NULL
PCR	NULL
with	NULL
primer	NULL
C	NULL
and	NULL
5	NULL
``	NULL
-AGGTITTCCCg	NULL
@	NULL
gTCCTAT-3	NULL
'	NULL
with	NULL
-393GM-CSFr-luc	NULL
as	NULL
the	NULL
template	NULL
.	NULL

To	NULL
generate	NULL
the	NULL
double	NULL
PU.1-C/EBP	NULL
mutant	NULL
-70GM-CS-Fr	NULL
(	NULL
GM-1/2	NULL
)	NULL
,	NULL
-70GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-lue	NULL
was	NULL
used	NULL
instead	NULL
as	NULL
the	NULL
template	NULL
.	NULL

The	NULL
final	NULL
PCR	NULL
products	NULL
were	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
KpnI	NULL
and	NULL
ligated	NULL
into	NULL
BamHI-Kpnl-digested	NULL
pXP2	NULL
.	NULL

The	NULL
plasmids	NULL
PU.1-T81-lue	NULL
and	NULL
mutPU.1-T81-lue	NULL
were	NULL
constructed	NULL
from	NULL
oligonucleotides	NULL
with	NULL
wild-type	NULL
and	NULL
GM1	NULL
mutant	NULL
sequences	NULL
,	NULL
respectively	NULL
,	NULL
from	NULL
positions	NULL
-53	NULL
to	NULL
-36	NULL
,	NULL
with	NULL
XhoI	NULL
and	NULL
Sell	NULL
restriction	NULL
sites	NULL
(	NULL
5'-tegagGAAATGAGGAAGCAGGGGg-3	NULL
'	NULL
and	NULL
5'-tegacCCCCTGCTTCCT	NULL
CATITCe-3	NULL
'	NULL
,	NULL
5'-tegagGAAATcAccAAGCAGGGGg-3	NULL
'	NULL
and	NULL
5'-tegacCCCCT	NULL
GCTTegTgATITCce-3	NULL
'	NULL
)	NULL
.	NULL

These	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
Sal	NULL
site	NULL
of	NULL
pBluescript	NULL
KS	NULL
(	NULL
-	NULL
)	NULL
(	NULL
Strategene	NULL
)	NULL
.	NULL

A	NULL
single	NULL
wild-type	NULL
PU.1	NULL
site	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
BarHI-Sall	NULL
site	NULL
of	NULL
pT81-luc	NULL
,	NULL
and	NULL
a	NULL
single	NULL
PU.1	NULL
mutant	NULL
GM1	NULL
sequence	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
HindIIM-SsfI	NULL
site	NULL
of	NULL
pT81-luc	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
all	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
the	NULL
dideoxy	NULL
chain	NULL
termination	NULL
method	NULL
.	NULL

Transactivation	NULL
.	NULL

HepG2	NULL
and	NULL
CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
;	NULL
with	NULL
expression	NULL
vectors	NULL
containing	NULL
full-length	NULL
PU.1	NULL
(	NULL
24	NULL
)	NULL
,	NULL
amino-terminally	NULL
deleted	NULL
forms	NULL
of	NULL
the	NULL
PU.1	NULL
protein	NULL
(	NULL
N133	NULL
PU.1	NULL
or	NULL
N70	NULL
PU.1	NULL
)	NULL
(	NULL
59	NULL
)	NULL
,	NULL
or	NULL
the	NULL
C/EBP	NULL
expression	NULL
vector	NULL
MSV-C/EBPa	NULL
(	NULL
5	NULL
)	NULL
;	NULL
and	NULL
with	NULL
0.25	NULL
ug	NULL
of	NULL
CMV-hGH	NULL
plasmid	NULL
and	NULL
sonicated	NULL
double-stranded	NULL
salmon	NULL
sperm	NULL
DNA	NULL
,	NULL
to	NULL
a	NULL
total	NULL
of	NULL
20	NULL
ug	NULL
of	NULL
DNA	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
40	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Titration	NULL
of	NULL
expression	NULL
vectors	NULL
over	NULL
the	NULL
range	NULL
of	NULL
1	NULL
to	NULL
8	NULL
pg	NULL
did	NULL
not	NULL
produce	NULL
any	NULL
significant	NULL
difference	NULL
in	NULL
results	NULL
.	NULL

RESULTS	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
is	NULL
specifically	NULL
expressed	NULL
in	NULL
myelomonocytic	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
chain	NULL
and	NULL
its	NULL
regulation	NULL
during	NULL
hematopoietic	NULL
differentiation	NULL
have	NULL
not	NULL
been	NULL
extensively	NULL
characterized	NULL
.	NULL

As	NULL
a	NULL
basis	NULL
for	NULL
the	NULL
subsequent	NULL
comparative	NULL
analysis	NULL
of	NULL
the	NULL
cell-type-specific	NULL
activity	NULL
of	NULL
the	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
mRNA	NULL
expression	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
in	NULL
the	NULL
hematopoietic	NULL
system	NULL
.	NULL

We	NULL
analyzed	NULL
several	NULL
myeloid	NULL
and	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
ob	NULL
5834	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

-s3	NULL
-37	NULL
Probe	NULL
:	NULL
gtggatccGAAATGAGGAAGCAGGG	NULL
CTTTACTCCTTCOTCCCecatggty	NULL
Protein	NULL
:	NULL
=	NULL
-	NULL
C	NULL
PU.1	NULL
U937	NULL
Antibody	NULL
:	NULL
|	NULL
=	NULL
co	NULL
c	NULL
o	NULL
>	NULL
=-	NULL
NRS	NULL
PU.L-	NULL
-	NULL
-~	NULL
PUI	NULL
Competitor	NULL
:	NULL
|	NULL
to	NULL
=o	NULL
-	NULL
S	NULL
GML	NULL
-	NULL
-	NULL
-	NULL
$	NULL
GMI	NULL
T	NULL
_	NULL
C	NULL
=	NULL
S	NULL
_	NULL
eom	NULL
-S	NULL
PU-SF	NULL
-	NULL
-	NULL
PU-SF	NULL
PU.1	NULL
-	NULL
Sues	NULL
Wth	NULL
cname	NULL
23	NULL
1	NULL
-	NULL
PUA	NULL
s	NULL
-	NULL
-	NULL
%	NULL
F	NULL
1°	NULL
20	NULL
3	NULL
4	NULL
506	NULL
708	NULL
9	NULL
10	NULL
11	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
PU.1	NULL
binding	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
by	NULL
gel	NULL
shift	NULL
assay	NULL
.	NULL

A	NULL
double-stranded	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
position	NULL
-53	NULL
to	NULL
-37	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
ATP	NULL
and	NULL
incubated	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
protein	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
pl	NULL
of	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
reticulocyte	NULL
lysate	NULL
containing	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
(	NULL
lanes	NULL
3	NULL
through	NULL
7	NULL
)	NULL
,	NULL
or	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
lanes	NULL
8	NULL
through	NULL
11	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
double-stranded	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
over	NULL
the	NULL
probe	NULL
oligonu-cleotide	NULL
:	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
(	NULL
self	NULL
[	NULL
S	NULL
]	NULL
)	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
and	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
mutated	NULL
PU.1	NULL
site	NULL
oligonucleotide	NULL
(	NULL
GM1	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
,	NULL
antiserum	NULL
recognizing	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
PU.1	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
;	NULL
in	NULL
lane	NULL
6	NULL
,	NULL
normal	NULL
rabbit	NULL
serum	NULL
(	NULL
NRS	NULL
)	NULL
was	NULL
added	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Abbreviations	NULL
on	NULL
the	NULL
sides	NULL
of	NULL
the	NULL
gel	NULL
:	NULL
T	NULL
,	NULL
top	NULL
of	NULL
the	NULL
gel	NULL
;	NULL
S	NULL
,	NULL
supershifted	NULL
PU.1-DNA	NULL
complex	NULL
with	NULL
PU.1	NULL
antibody	NULL
;	NULL
PU.1	NULL
,	NULL
gel-shifted	NULL
complex	NULL
formed	NULL
with	NULL
full-length	NULL
PU.1	NULL
;	NULL
F	NULL
,	NULL
unbound	NULL
free	NULL
oligonucleotide	NULL
probe	NULL
;	NULL
PU-SF	NULL
,	NULL
complex	NULL
formed	NULL
by	NULL
PU.1	NULL
with	NULL
another	NULL
protein	NULL
in	NULL
nuclear	NULL
extracts	NULL
;	NULL
*	NULL
,	NULL
complex	NULL
formed	NULL
by	NULL
proteolytic	NULL
product	NULL
of	NULL
PU.1	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
6	NULL
,	NULL
41	NULL
,	NULL
70	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
GM1	NULL
mutated	NULL
PU.1	NULL
site	NULL
oligonucleotide	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9.	NULL
tained	NULL
only	NULL
a	NULL
very	NULL
weak	NULL
signal	NULL
with	NULL
Northern	NULL
(	NULL
RNA	NULL
)	NULL
blot	NULL
analysis	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
applied	NULL
the	NULL
sensitive	NULL
technique	NULL
of	NULL
RT-PCR	NULL
for	NULL
analysis	NULL
of	NULL
expression	NULL
.	NULL

Primers	NULL
were	NULL
chosen	NULL
to	NULL
detect	NULL
mRNA	NULL
independent	NULL
of	NULL
alternative	NULL
splicing	NULL
(	NULL
49	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
relative	NULL
expression	NULL
of	NULL
the	NULL
housekeeping	NULL
GAPDH	NULL
gene	NULL
.	NULL

GM-CSF	NULL
receptor	NULL
a	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
myeloid	NULL
cell	NULL
lines	NULL
U937	NULL
,	NULL
HL-60	NULL
,	NULL
Monomac	NULL
,	NULL
and	NULL
NB4	NULL
and	NULL
also	NULL
in	NULL
monocytes	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
but	NULL
not	NULL
in	NULL
the	NULL
B-lymphoblastic	NULL
cell	NULL
line	NULL
Raji	NULL
or	NULL
the	NULL
T-lymphoblastic	NULL
cell	NULL
lines	NULL
REX	NULL
and	NULL
Jurkat	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
the	NULL
myeloid	NULL
cell-specific	NULL
expression	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
mRNA	NULL
in	NULL
the	NULL
hematopoietic	NULL
system	NULL
.	NULL

The	NULL
promoter	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
exhibits	NULL
cell-type-specific	NULL
activity	NULL
.	NULL

To	NULL
analyze	NULL
whether	NULL
the	NULL
promoter	NULL
exhibits	NULL
myeloid	NULL
cell-specific	NULL
activity	NULL
,	NULL
a	NULL
DNA	NULL
fragment	NULL
spanning	NULL
from	NULL
bp	NULL
-393	NULL
to	NULL
+49	NULL
of	NULL
the	NULL
human	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
luciferase	NULL
reporter	NULL
vector	NULL
pXP2	NULL
to	NULL
form	NULL
-393GM-CSFr-luc	NULL
.	NULL

Promoter	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
luciferase	NULL
assay	NULL
after	NULL
transfection	NULL
into	NULL
the	NULL
human	NULL
myelomonocytic	NULL
cell	NULL
line	NULL
U937	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
transfected	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
the	NULL
B-lymphoblastoid	NULL
Raji	NULL
and	NULL
BJAB	NULL
and	NULL
T-lymphoblastoid	NULL
Rex	NULL
and	NULL
Jurkat	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

All	NULL
luciferase	NULL
values	NULL
were	NULL
corrected	NULL
for	NULL
transfection	NULL
efficiency	NULL
by	NULL
cotransfection	NULL
of	NULL
CMV-hGH	NULL
and	NULL
compared	NULL
with	NULL
those	NULL
for	NULL
the	NULL
promoterless	NULL
vector	NULL
pXP2	NULL
.	NULL

In	NULL
the	NULL
myelomonocytic	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
demonstrated	NULL
very	NULL
strong	NULL
activity	NULL
.	NULL

The	NULL
luciferase	NULL
activity	NULL
of	NULL
-393GM-CSFr-lue	NULL
was	NULL
303-fold	NULL
(	NULL
mean	NULL
)	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

pXP2	NULL
.	NULL

Comparative	NULL
analysis	NULL
revealed	NULL
that	NULL
this	NULL
promoter	NULL
is	NULL
five-to	NULL
eight-fold	NULL
more	NULL
active	NULL
than	NULL
in	NULL
the	NULL
nonmyeloid	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
contains	NULL
cell-type-specific	NULL
activity	NULL
.	NULL

The	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
contains	NULL
an	NULL
important	NULL
functional	NULL
site	NULL
between	NULL
bp	NULL
-53	NULL
and	NULL
-41	NULL
.	NULL

To	NULL
localize	NULL
the	NULL
functionally	NULL
important	NULL
sites	NULL
for	NULL
the	NULL
promoter	NULL
activity	NULL
in	NULL
myeloid	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
deletion	NULL
analysis	NULL
of	NULL
the	NULL
5	NULL
-flanking	NULL
region	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
gene	NULL
.	NULL

We	NULL
created	NULL
a	NULL
series	NULL
of	NULL
deletions	NULL
of	NULL
the	NULL
-flanking	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
and	NULL
the	NULL
activities	NULL
of	NULL
the	NULL
5	NULL
'	NULL
deletion	NULL
series	NULL
with	NULL
endpoints	NULL
at	NULL
bp	NULL
-278	NULL
,	NULL
-146	NULL
,	NULL
-70	NULL
,	NULL
-53	NULL
,	NULL
-41	NULL
,	NULL
and	NULL
-10	NULL
were	NULL
assessed	NULL
in	NULL
U937	NULL
cells	NULL
by	NULL
transient	NULL
transfections	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Deletion	NULL
to	NULL
position	NULL
-70	NULL
was	NULL
of	NULL
no	NULL
significant	NULL
consequence	NULL
.	NULL

Deletion	NULL
to	NULL
position	NULL
-53	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
of	NULL
activity	NULL
(	NULL
mean	NULL
,	NULL
2.3-fold	NULL
)	NULL
.	NULL

Additional	NULL
deletion	NULL
to	NULL
position	NULL
-41	NULL
,	NULL
which	NULL
removed	NULL
a	NULL
potential	NULL
PU.1	NULL
binding	NULL
site	NULL
,	NULL
diminished	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
activity	NULL
from	NULL
668-fold	NULL
above	NULL
that	NULL
for	NULL
pXP2	NULL
to	NULL
88-fold	NULL
,	NULL
an	NULL
87	NULL
%	NULL
drop	NULL
in	NULL
activity	NULL
.	NULL

Further	NULL
deletion	NULL
to	NULL
position	NULL
-10	NULL
did	NULL
not	NULL
change	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

PU.1	NULL
binds	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
region	NULL
.	NULL

The	NULL
functionally	NULL
important	NULL
region	NULL
between	NULL
bp	NULL
-53	NULL
and	NULL
-41	NULL
contains	NULL
a	NULL
purine-rich	NULL
sequence	NULL
resembling	NULL
sites	NULL
known	NULL
to	NULL
bind	NULL
PU.1	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
35	NULL
)	NULL
.	NULL

PU.1	NULL
is	NULL
a	NULL
myeloid	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
which	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
several	NULL
myeloid	NULL
cell-specific	NULL
genes	NULL
,	NULL
including	NULL
another	NULL
receptor	NULL
for	NULL
a	NULL
myeloid	NULL
growth	NULL
factor	NULL
,	NULL
the	NULL
M-CSF	NULL
receptor	NULL
(	NULL
70	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
region	NULL
from	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
was	NULL
prepared	NULL
and	NULL
used	NULL
in	NULL
EMSA	NULL
with	NULL
either	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
or	NULL
nuclear	NULL
extracts	NULL
from	NULL
U937	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
protein	NULL
comigrates	NULL
with	NULL
a	NULL
complex	NULL
(	NULL
labeled	NULL
PU.1	NULL
)	NULL
formed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
U937	NULL
cells	NULL
.	NULL

This	NULL
complex	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
the	NULL
wild-type	NULL
PU.1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
a	NULL
mutant	NULL
PU.1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
;	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
can	NULL
be	NULL
supershifted	NULL
by	NULL
using	NULL
a	NULL
specific	NULL
amino-terminal	NULL
peptide	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
)	NULL
.	NULL

In	NULL
vitro-translated	NULL
Spi-B	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
closely	NULL
related	NULL
to	NULL
PU.1	NULL
(	NULL
51	NULL
)	NULL
,	NULL
can	NULL
also	NULL
bind	NULL
to	NULL
this	NULL
PU.1	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
other	NULL
ets	NULL
family	NULL
mem-bers	NULL
,	NULL
including	NULL
ets-1	NULL
,	NULL
ets-2	NULL
,	NULL
elf-1	NULL
,	NULL
and	NULL
fli-1	NULL
,	NULL
failed	NULL
to	NULL
interact	NULL
with	NULL
this	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
complex	NULL
designated	NULL
PU.1	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
faster-and	NULL
more	NULL
slowly	NULL
migrating	NULL
specific	NULL
complexes	NULL
can	NULL
be	NULL
observed	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

The	NULL
faster-migrating	NULL
band	NULL
,	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
with	NULL
an	NULL
asterisk	NULL
,	NULL
has	NULL
been	NULL
observed	NULL
previously	NULL
in	NULL
EMSA	NULL
with	NULL
probes	NULL
containing	NULL
PU.1	NULL
sites	NULL
in	NULL
the	NULL
CD11b	NULL
and	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoters	NULL
and	NULL
has	NULL
been	NULL
described	NULL
extensively	NULL
(	NULL
6	NULL
,	NULL
41	NULL
,	NULL
70	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
is	NULL
formed	NULL
by	NULL
a	NULL
proteolytic	NULL
product	NULL
of	NULL
PU.1	NULL
which	NULL
retains	NULL
the	NULL
carboxyl-terminal	NULL
DNA	NULL
binding	NULL
domain	NULL
but	NULL
has	NULL
lost	NULL
the	NULL
amino-terminal	NULL
region	NULL
recognized	NULL
by	NULL
the	NULL
peptide	NULL
antiserum	NULL
.	NULL

The	NULL
more	NULL
slowly	NULL
migrating	NULL
complex	NULL
(	NULL
PU-SF	NULL
)	NULL
can	NULL
be	NULL
diminished	NULL
by	NULL
both	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
an	NULL
amino-terminal	NULL
PU.1	NULL
peptide	NULL
(	NULL
24	NULL
,	NULL
46	NULL
)	NULL
and	NULL
an	NULL
antibody	NULL
raised	NULL
against	NULL
the	NULL
full-length	NULL
PU.1	NULL
protein	NULL
(	NULL
54	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
PU.1	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
interaction	NULL
with	NULL
another	NULL
protein	NULL
,	NULL
which	NULL
we	NULL
refer	NULL
to	NULL
as	NULL
PU.1-shifting	NULL
factor	NULL
,	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
,	NULL
PU-SF	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
11	NULL
;	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
unlabeled	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
PU.1	NULL
binding	NULL
sites	NULL
from	NULL
the	NULL
promoters	NULL
of	NULL
the	NULL
CD11b	NULL
and	NULL
the	NULL
M-CSF	NULL
receptor	NULL
genes	NULL
inhibit	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
complex	NULL
,	NULL
PU-SF	NULL
,	NULL
supporting	NULL
the	NULL
notion	NULL
that	NULL
it	NULL
contains	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

While	NULL
these	NULL
functional	NULL
PU.1	NULL
sites	NULL
can	NULL
compete	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
,	NULL
a	NULL
purine-rich	NULL
potential	NULL
PU.1	NULL
site	NULL
(	NULL
35	NULL
)	NULL
from	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
positions	NULL
-10	NULL
to	NULL
+7	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
fails	NULL
to	NULL
compete	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5835	NULL
Raji	NULL
_	NULL
Jurkat	NULL
Protein	NULL
:	NULL
U937	NULL
Antibody	NULL
:	NULL
=-	NULL
=	NULL
0	NULL
e	NULL
0	NULL
&	NULL
0	NULL
&	NULL
&	NULL
=	NULL
&	NULL
.	NULL

-10	NULL
=	NULL
-41	NULL
0-80	NULL
Competitor	NULL
:	NULL
GML	NULL
CD11b	NULL
M1	NULL
fms	NULL
+7	NULL
|	NULL
-25	NULL
49	NULL
=	NULL
#	NULL
@	NULL
#	NULL
up	NULL
w	NULL
w	NULL
``	NULL
T	NULL
-	NULL
~	NULL
Wl	NULL
PU-SF	NULL
-	NULL
We	NULL
PU.1	NULL
NRS	NULL
PUa	NULL
PUb	NULL
Octl	NULL
Spl	NULL
=	NULL
=	NULL
e	NULL
/e	NULL
@	NULL
--	NULL
NS	NULL
®	NULL
-	NULL
PU-SF	NULL
--	NULL
PU.1	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1112	NULL
1314151617	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
PU-SF	NULL
complex	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
oligonucleotide	NULL
from	NULL
position	NULL
-53	NULL
to	NULL
-37	NULL
(	NULL
same	NULL
as	NULL
for	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
and	NULL
incubated	NULL
with	NULL
10	NULL
jg	NULL
of	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
either	NULL
U937	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
12	NULL
)	NULL
,	NULL
Raji	NULL
B	NULL
cells	NULL
(	NULL
lanes	NULL
13	NULL
through	NULL
15	NULL
)	NULL
,	NULL
or	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
lanes	NULL
16	NULL
and	NULL
17	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
double-stranded	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
:	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
(	NULL
self	NULL
)	NULL
(	NULL
lanes	NULL
14	NULL
and	NULL
17	NULL
)	NULL
,	NULL
mutated	NULL
PU.1	NULL
site	NULL
(	NULL
GM1	NULL
)	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
15	NULL
)	NULL
,	NULL
PU.1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
41	NULL
)	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
mutated	NULL
PU.1	NULL
site	NULL
from	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
M1	NULL
mutation	NULL
[	NULL
41	NULL
]	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
M-CSF	NULL
receptor	NULL
(	NULL
c-fins	NULL
)	NULL
promoter	NULL
PU.1	NULL
binding	NULL
site	NULL
(	NULL
70	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-10	NULL
to	NULL
+7	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
bp	NULL
-41	NULL
to	NULL
-25	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
and	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-80	NULL
to	NULL
-49	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

The	NULL
following	NULL
antisera	NULL
were	NULL
added	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
:	NULL
antiserum	NULL
recognizing	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
PU.1	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
antiserum	NULL
against	NULL
the	NULL
full-length	NULL
PU.1	NULL
protein	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
antiserum	NULL
against	NULL
Oct-1	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
antiserum	NULL
raised	NULL
against	NULL
Sp1	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
rabbit	NULL
serum	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Abbreviations	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
;	NULL
in	NULL
addition	NULL
,	NULL
a	NULL
nonspecific	NULL
band	NULL
observed	NULL
near	NULL
the	NULL
top	NULL
of	NULL
the	NULL
gel	NULL
is	NULL
labeled	NULL
NS	NULL
.	NULL

The	NULL
autoradiograph	NULL
was	NULL
extensively	NULL
exposed	NULL
in	NULL
order	NULL
to	NULL
show	NULL
the	NULL
PU-SF	NULL
complex	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

indicating	NULL
that	NULL
it	NULL
does	NULL
not	NULL
bind	NULL
PU.1	NULL
.	NULL

Moreover	NULL
,	NULL
oligonucleotides	NULL
spanning	NULL
the	NULL
regions	NULL
adjacent	NULL
to	NULL
the	NULL
PU.1	NULL
site	NULL
in	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
fail	NULL
to	NULL
compete	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
(	NULL
positions	NULL
-41	NULL
to	NULL
-25	NULL
[	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
6	NULL
]	NULL
;	NULL
positions	NULL
-80	NULL
to	NULL
-49	NULL
[	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
7	NULL
]	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
complex	NULL
is	NULL
not	NULL
formed	NULL
with	NULL
a	NULL
neighboring	NULL
DNA-binding	NULL
protein	NULL
,	NULL
particularly	NULL
not	NULL
with	NULL
C/EBP	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
upstream	NULL
area	NULL
(	NULL
positions	NULL
-80	NULL
to	NULL
-49	NULL
)	NULL
,	NULL
as	NULL
shown	NULL
below	NULL
.	NULL

PU.1	NULL
forms	NULL
a	NULL
novel	NULL
complex	NULL
via	NULL
its	NULL
amino-terminal	NULL
domain	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
which	NULL
protein	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
,	NULL
we	NULL
tested	NULL
nuclear	NULL
extracts	NULL
from	NULL
different	NULL
sources	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
B-lymphoblastoid	NULL
cell	NULL
line	NULL
Raji	NULL
also	NULL
contain	NULL
PU.1	NULL
and	NULL
form	NULL
complexes	NULL
with	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
PU.1	NULL
site	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
U937	NULL
nuclear	NULL
extracts	NULL
,	NULL
except	NULL
that	NULL
relatively	NULL
more	NULL
PU-SF	NULL
(	NULL
compared	NULL
with	NULL
full-length	NULL
PU.1	NULL
)	NULL
is	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
T-lymphoblastoid	NULL
cell	NULL
lines	NULL
Jurkat	NULL
and	NULL
REX	NULL
,	NULL
which	NULL
do	NULL
not	NULL
contain	NULL
PU.1	NULL
,	NULL
fail	NULL
to	NULL
form	NULL
any	NULL
specific	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
16	NULL
;	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
is	NULL
added	NULL
to	NULL
PU.l-negative	NULL
nuclear	NULL
extracts	NULL
from	NULL
REX	NULL
cells	NULL
,	NULL
a	NULL
complex	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
in	NULL
myeloid	NULL
and	NULL
B	NULL
cells	NULL
is	NULL
formed	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
HepG2	NULL
hepatoma	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
cervical	NULL
carcinoma	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
the	NULL
glial	NULL
cell	NULL
line	NULL
U87	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
monkey	NULL
kidney	NULL
Cos	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
are	NULL
capable	NULL
of	NULL
forming	NULL
PU-SF	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
.	NULL

However	NULL
,	NULL
the	NULL
erythroid	NULL
cell	NULL
lines	NULL
MEL	NULL
,	NULL
which	NULL
overexpresses	NULL
PU.1	NULL
,	NULL
and	NULL
CBS5	NULL
,	NULL
which	NULL
does	NULL
not	NULL
express	NULL
PU.1	NULL
(	NULL
58	NULL
)	NULL
,	NULL
fail	NULL
to	NULL
form	NULL
the	NULL
PU-SF	NULL
complex	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
13	NULL
;	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
conclude	NULL
that	NULL
a	NULL
protein	NULL
which	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
the	NULL
cell	NULL
types	NULL
in	NULL
which	NULL
PU.1	NULL
is	NULL
expressed	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
.	NULL

Interestingly	NULL
,	NULL
Spi-B	NULL
is	NULL
also	NULL
capable	NULL
of	NULL
forming	NULL
the	NULL
larger	NULL
PU-SF	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
localize	NULL
the	NULL
domain	NULL
of	NULL
the	NULL
PU.1	NULL
protein	NULL
which	NULL
interacts	NULL
with	NULL
this	NULL
protein	NULL
,	NULL
we	NULL
in	NULL
vitro	NULL
translated	NULL
a	NULL
series	NULL
of	NULL
PU.1	NULL
proteins	NULL
with	NULL
deletions	NULL
in	NULL
the	NULL
amino	NULL
terminus	NULL
.	NULL

These	NULL
truncated	NULL
proteins	NULL
retained	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
located	NULL
in	NULL
the	NULL
carboxyl-terminal	NULL
sequence	NULL
(	NULL
residues	NULL
167	NULL
to	NULL
255	NULL
)	NULL
and	NULL
were	NULL
therefore	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
PU.1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
.	NULL

We	NULL
localized	NULL
the	NULL
region	NULL
in	NULL
the	NULL
PU.1	NULL
protein	NULL
involved	NULL
in	NULL
forming	NULL
PU-SF	NULL
to	NULL
amino	NULL
acids	NULL
32	NULL
to	NULL
70	NULL
in	NULL
the	NULL
transactivation	NULL
domain	NULL
:	NULL
removal	NULL
of	NULL
either	NULL
133	NULL
or	NULL
70	NULL
amino	NULL
acids	NULL
from	NULL
the	NULL
amino	NULL
terminus	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
PU.1	NULL
to	NULL
form	NULL
PU-SF	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

However	NULL
,	NULL
deletion	NULL
of	NULL
amino	NULL
acids	NULL
8	NULL
through	NULL
32	NULL
in	NULL
the	NULL
amino	NULL
terminus	NULL
did	NULL
not	NULL
abolish	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
whether	NULL
PU-SF	NULL
involved	NULL
TBP	NULL
or	NULL
RB	NULL
protein	NULL
,	NULL
ubiquitously	NULL
expressed	NULL
proteins	NULL
which	NULL
have	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
PU.1	NULL
in	NULL
vitro	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
pattern	NULL
of	NULL
PU-SF	NULL
(	NULL
not	NULL
in	NULL
erythroid	NULL
cells	NULL
)	NULL
made	NULL
it	NULL
unlikely	NULL
to	NULL
be	NULL
TBP	NULL
or	NULL
RB	NULL
protein	NULL
,	NULL
and	NULL
an	NULL
anti	NULL
5836	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

-53	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

-37	NULL
Probe	NULL
:	NULL
gtggatccGAAA	NULL
CTTTA	NULL
GAGGAAGCAGGG	NULL
CTCccth	NULL
GTCCCccatygygty	NULL
U937	NULL
Rex	NULL
Nuclear	NULL
extracts	NULL
:	NULL
Protein	NULL
:	NULL
Competitor	NULL
:	NULL
T	NULL
PU	NULL
N133	NULL
N70	NULL
38	NULL
:	NULL
Pest	NULL
<	NULL
s	NULL
¥	NULL
i	NULL
:	NULL
PU.1	NULL
AB/32	NULL
.	NULL

APest	NULL
N7O	NULL
N133	NULL
F	NULL
&	NULL
&	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
6	NULL
7	NULL
Probe	NULL
:	NULL
-53	NULL
gtggatccGAAAT	NULL
CTTTA	NULL
-37	NULL
NGCAGGG	NULL
ICGTecCccecatggty	NULL
Nuclear	NULL
extracts	NULL
:	NULL
CBS	NULL
UST	NULL
HepG2	NULL
COS7	NULL
Protein	NULL
:	NULL
Antibody	NULL
:	NULL
-	NULL
PU	NULL
-	NULL
PU	NULL
PU	NULL
PU	NULL
-	NULL
-	NULL
PU	NULL
-	NULL
PU	NULL
-o	NULL
-	NULL
~	NULL
-	NULL
Pre	NULL
RB	NULL
400800	NULL
}	NULL
o	NULL
T	NULL
wan	NULL
<	NULL
p	NULL
4m	NULL
ain	NULL
ah	NULL
+4	NULL
dont	NULL
tou	NULL
de	NULL
:	NULL
-	NULL
NS	NULL
PU-SF	NULL
-	NULL
--	NULL
PU-SF	NULL
PUL	NULL
-	NULL
|	NULL
-	NULL
PU.1	NULL
R	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
serum	NULL
to	NULL
TBP	NULL
did	NULL
not	NULL
disrupt	NULL
the	NULL
PU-SF	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

An	NULL
antiserum	NULL
raised	NULL
against	NULL
RB	NULL
protein	NULL
also	NULL
did	NULL
not	NULL
alter	NULL
PU-SF	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

We	NULL
also	NULL
think	NULL
it	NULL
unlikely	NULL
that	NULL
PU-SF	NULL
represents	NULL
a	NULL
complex	NULL
formed	NULL
by	NULL
PU.1	NULL
and	NULL
NF-EMS5	NULL
,	NULL
since	NULL
(	NULL
i	NULL
)	NULL
the	NULL
latter	NULL
is	NULL
reported	NULL
to	NULL
be	NULL
a	NULL
B	NULL
cell-specific	NULL
factor	NULL
(	NULL
46	NULL
,	NULL
=	NULL
_	NULL
PUN133	NULL
N70	NULL
382/	NULL
Pest	NULL
-	NULL
PU.1	NULL
-	NULL
A832	NULL
.	NULL

APest	NULL
-	NULL
N133	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
FIG	NULL
6	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PU.1	NULL
interacts	NULL
via	NULL
its	NULL
amino	NULL
terminus	NULL
with	NULL
another	NULL
protein	NULL
to	NULL
form	NULL
complex	NULL
PU-SF	NULL
.	NULL

The	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
oligonucleotide	NULL
spanning	NULL
positions	NULL
-53	NULL
to	NULL
-37	NULL
was	NULL
incubated	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
5	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
lanes	NULL
7	NULL
through	NULL
12	NULL
)	NULL
of	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
REX	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
following	NULL
in	NULL
vitro-translated	NULL
proteins	NULL
:	NULL
full-length	NULL
PU.1	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
8	NULL
)	NULL
,	NULL
N133	NULL
PU.1	NULL
(	NULL
133	NULL
amino	NULL
acids	NULL
deleted	NULL
from	NULL
the	NULL
amino	NULL
terminus	NULL
)	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
9	NULL
)	NULL
,	NULL
N70	NULL
PU.1	NULL
(	NULL
70	NULL
amino	NULL
acids	NULL
deleted	NULL
from	NULL
the	NULL
amino	NULL
terminus	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
10	NULL
)	NULL
,	NULL
A8/32	NULL
PU.1	NULL
(	NULL
amino	NULL
acids	NULL
8	NULL
to	NULL
32	NULL
deleted	NULL
)	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
11	NULL
)	NULL
,	NULL
and	NULL
APest	NULL
PU.1	NULL
(	NULL
amino	NULL
acids	NULL
119	NULL
to	NULL
160	NULL
deleted	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
12	NULL
)	NULL
.	NULL

For	NULL
comparison	NULL
,	NULL
the	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
13	NULL
to	NULL
15	NULL
,	NULL
the	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
jg	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
MEL	NULL
cells	NULL
(	NULL
MEL	NULL
is	NULL
an	NULL
erytholeukemia	NULL
line	NULL
which	NULL
overexpresses	NULL
PU.1	NULL
because	NULL
of	NULL
viral	NULL
insertional	NULL
activation	NULL
[	NULL
33	NULL
,	NULL
55	NULL
]	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
excess	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
:	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
(	NULL
self	NULL
)	NULL
(	NULL
lane	NULL
14	NULL
)	NULL
and	NULL
mutated	NULL
PU.1	NULL
site	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
(	NULL
GM1	NULL
)	NULL
(	NULL
lane	NULL
15	NULL
)	NULL
.	NULL

All	NULL
abbreviations	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
on	NULL
the	NULL
left	NULL
are	NULL
indicated	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
by	NULL
in	NULL
vitro-translated	NULL
proteins	NULL
A8/32	NULL
and	NULL
APest	NULL
PU.1	NULL
,	NULL
which	NULL
migrate	NULL
just	NULL
ahead	NULL
of	NULL
PU.1	NULL
;	NULL
N70	NULL
,	NULL
which	NULL
migrates	NULL
in	NULL
a	NULL
position	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
a	NULL
nonspecific	NULL
band	NULL
(	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
14	NULL
)	NULL
;	NULL
and	NULL
N133	NULL
PU.1	NULL
.	NULL

The	NULL
autoradiograph	NULL
was	NULL
heavily	NULL
exposed	NULL
to	NULL
show	NULL
the	NULL
PU-SF	NULL
complex	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
absence	NULL
of	NULL
such	NULL
a	NULL
complex	NULL
in	NULL
MEL	NULL
cells	NULL
(	NULL
lane	NULL
13	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Addition	NULL
of	NULL
PU.1	NULL
to	NULL
nuclear	NULL
extracts	NULL
results	NULL
in	NULL
formation	NULL
of	NULL
PU-SF	NULL
.	NULL

The	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
oligonucleotide	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
the	NULL
erythroid	NULL
cell	NULL
line	NULL
CBS	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
the	NULL
glial	NULL
cell	NULL
line	NULL
U87	NULL
(	NULL
lanes	NULL
3	NULL
through	NULL
6	NULL
)	NULL
,	NULL
the	NULL
hepatoma	NULL
cell	NULL
line	NULL
HepG2	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
,	NULL
and	NULL
the	NULL
kidney	NULL
cell	NULL
line	NULL
Cos	NULL
?	NULL

(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
of	NULL
1	NULL
wl	NULL
of	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
.	NULL

In	NULL
lane	NULL
6	NULL
,	NULL
1.5	NULL
pul	NULL
of	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
RB	NULL
protein	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
;	NULL
in	NULL
lane	NULL
5	NULL
,	NULL
1.5	NULL
pil	NULL
of	NULL
preimmune	NULL
serum	NULL
(	NULL
Pre	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
.	NULL

All	NULL
other	NULL
abbreviations	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

The	NULL
autoradiograph	NULL
was	NULL
heavily	NULL
exposed	NULL
to	NULL
show	NULL
the	NULL
PU-SF	NULL
complex	NULL
in	NULL
U87	NULL
cells	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
such	NULL
a	NULL
complex	NULL
in	NULL
CBS	NULL
cells	NULL
.	NULL

47	NULL
)	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
PU-SF	NULL
,	NULL
which	NULL
was	NULL
formed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
many	NULL
cell	NULL
types	NULL
(	NULL
other	NULL
than	NULL
erythroid	NULL
cells	NULL
)	NULL
if	NULL
PU.1	NULL
was	NULL
present	NULL
or	NULL
added	NULL
to	NULL
the	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
and	NULL
6	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
deletion	NULL
of	NULL
the	NULL
PEST	NULL
domain	NULL
(	NULL
amino	NULL
acids	NULL
119	NULL
to	NULL
160	NULL
)	NULL
,	NULL
which	NULL
includes	NULL
the	NULL
site	NULL
interacting	NULL
with	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5837	NULL
TABLE	NULL
1	NULL
.	NULL

Formation	NULL
of	NULL
the	NULL
PU-SF	NULL
complex	NULL
``	NULL
Derivation	NULL
of	NULL
probe	NULL
(	NULL
reference	NULL
)	NULL
Probe	NULL
no	NULL
.	NULL

Sequence	NULL
PU-SF	NULL
formation	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
1	NULL
gtggatccGAAATGAGGIAAGCAGGG	NULL
Yes	NULL
CTTTACTCCITTCGTCCCccatggtq	NULL
2	NULL
TGAAATIGAGGIAAGCAGGG	NULL
No	NULL
CTTTACTCCITTCGTCCCC	NULL
3	NULL
gtggatccGAAATIGAGGIAAGCAGGG	NULL
Yes	NULL
CTTTACTCCITTCGTCCCC	NULL
4	NULL
TGAAATGAGGIAAGCAGGG	NULL
Yes	NULL
CTTTACTCCITTCGTCCCccatggtq	NULL
5	NULL
gtggatccGAAATIGCAGGIAAGCAGGGqqgtacca	NULL
No	NULL
acctaggCTTTACTCCIITCGTCCCccatgqgtq	NULL
6	NULL
AATCCTATGAAATGAGGIAAGCAGGGGAGGGAG	NULL
No	NULL
TAGGATACTTTACTCCIITCGTCCCCTCCCTCC	NULL
7	NULL
TGAAATGAGGIAAGCAGGG	NULL
Yes	NULL
CTTTACTCCITTCGTCCCCTCCCTCC	NULL
8	NULL
AATCCTATGAAATGAGGIAAGCAGGG	NULL
Yes	NULL
CTTTACTCCITTCGTCCCC	NULL
9	NULL
AATEtTATGAAATIGAGGIAAGCAGGG	NULL
Yes	NULL
CTTTACTCCITTCGTCCCC	NULL
10	NULL
No	NULL
cTTttaktcclrtcercecce	NULL
11	NULL
gagagagaGAAATJGAGGIAAGCAGGG	NULL
No	NULL
cTTTactcclrtcercecc	NULL
12	NULL
No	NULL
cCTTTACTCCITTCGTCCCCcaget	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
70	NULL
)	NULL
13	NULL
tcgaCCTAGCTAAAAGGGCGJAACAAGAGGATCAGC	NULL
No	NULL
GGATCGATTTTCCCCITTCTTCTCCTAGTCGagct	NULL
14	NULL
Yes	NULL
ATTTTCCCCITTCTTCTCecatggtyg	NULL
CD11b	NULL
promoter	NULL
(	NULL
41	NULL
)	NULL
15	NULL
Yes	NULL
CTTTTCCTCITTCATCCTecatqgtqy	NULL
16	NULL
GGCAGAAAAGGAGIAAGTAGGAGGCA	NULL
No	NULL
CGTCTTITECCTCITTCATCCTCCGTC	NULL
17	NULL
gctCAAAAGAAGGGCAGAAAAGCGAGIAAGTAG	NULL
Yes	NULL
CGTCTTITECCTCITTCATCCTCCGTC	NULL
18	NULL
gctCAAAAGAAGGGCAGAAAAGCGAGIAAGTAG	NULL
No	NULL
GTTTTCTTCCCGTCTTITTICCTCITTCATCCga	NULL
G-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
62	NULL
)	NULL
19	NULL
cgggatccGGTTTCAGGAAICTTCTCTTG	NULL
Yes	NULL
CCAAAGTCCTTICAAGAGAACccatqgggc	NULL
*	NULL
Oligonucleotide	NULL
probes	NULL
with	NULL
PU.1	NULL
binding	NULL
sites	NULL
were	NULL
end	NULL
labeled	NULL
and	NULL
assayed	NULL
by	NULL
EMSA	NULL
to	NULL
determine	NULL
the	NULL
DNA	NULL
sequences	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
PU-SF	NULL
complex	NULL
.	NULL

Each	NULL
probe	NULL
was	NULL
compared	NULL
with	NULL
the	NULL
one	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
(	NULL
probe	NULL
1	NULL
in	NULL
this	NULL
table	NULL
)	NULL
,	NULL
which	NULL
was	NULL
included	NULL
on	NULL
each	NULL
gel	NULL
as	NULL
a	NULL
standard	NULL
,	NULL
and	NULL
each	NULL
was	NULL
subjected	NULL
to	NULL
competition	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
self	NULL
competitor	NULL
to	NULL
demonstrate	NULL
specificity	NULL
.	NULL

(	NULL
See	NULL
Fig	NULL
.	NULL

7	NULL
as	NULL
an	NULL
example	NULL
.	NULL
)	NULL

Probes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
9	NULL
,	NULL
11	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
were	NULL
also	NULL
tested	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
non-self	NULL
competitor	NULL
(	NULL
E18	NULL
ets	NULL
consensus	NULL
site	NULL
,	NULL
5-GATCGAGACCGGAAGTGGGG-3	NULL
'	NULL
)	NULL
,	NULL
which	NULL
did	NULL
not	NULL
compete	NULL
for	NULL
PU.1	NULL
or	NULL
PU-SF	NULL
complex	NULL
formation	NULL
.	NULL

Uppercase	NULL
letters	NULL
represent	NULL
promoter	NULL
(	NULL
genomic	NULL
)	NULL
sequences	NULL
,	NULL
while	NULL
lowercase	NULL
letters	NULL
represent	NULL
nonpromoter	NULL
sequences	NULL
.	NULL

The	NULL
sequences	NULL
are	NULL
aligned	NULL
relative	NULL
to	NULL
the	NULL
core	NULL
PU.1	NULL
binding	NULL
sites	NULL
,	NULL
as	NULL
defined	NULL
by	NULL
methylation	NULL
interference	NULL
studies	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
string	NULL
of	NULL
three	NULL
or	NULL
four	NULL
adenosine	NULL
residues	NULL
which	NULL
are	NULL
just	NULL
5	NULL
'	NULL
of	NULL
the	NULL
GA	NULL
core	NULL
.	NULL

5838	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

probe	NULL
10	NULL
10014	NULL
14	NULL
15	NULL
15	NULL
1	NULL
1	NULL
5	NULL
6	NULL
6	NULL
1°	NULL
1	NULL
8	NULL
80	NULL
7°	NULL
7	NULL
competitor	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
#	NULL
54	NULL
we	NULL
«	NULL
aie	NULL
.	NULL

Z	NULL
,	NULL
«	NULL
e	NULL
_	NULL
|	NULL
ig	NULL
.	NULL

tis	NULL
-T	NULL
seee	NULL
ge	NULL
is	NULL
-	NULL
ae	NULL
-	NULL
mo	NULL
wa	NULL
-	NULL
--	NULL
-	NULL
dik	NULL
‘	NULL
b	NULL
-	NULL
PU.1	NULL
Sie	NULL
s	NULL
mn	NULL
atc	NULL
.	NULL

c..	NULL
mas	NULL
-	NULL
Whores	NULL
L	NULL
-F	NULL
1°	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

DNA	NULL
sequence	NULL
requirements	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
PU-SF	NULL
.	NULL

Various	NULL
oligonucleotide	NULL
probes	NULL
were	NULL
analyzed	NULL
for	NULL
their	NULL
abilities	NULL
to	NULL
bind	NULL
PU-SF	NULL
by	NULL
EMSA	NULL
.	NULL

The	NULL
probe	NULL
number	NULL
indicated	NULL
at	NULL
the	NULL
top	NULL
corresponds	NULL
to	NULL
the	NULL
probe	NULL
number	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
where	NULL
the	NULL
sequences	NULL
are	NULL
listed	NULL
.	NULL

All	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
both	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
Rex	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
in	NULL
the	NULL
even-numbered	NULL
lanes	NULL
they	NULL
were	NULL
inhibited	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
.	NULL

Lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
13	NULL
,	NULL
and	NULL
14	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
probe	NULL
,	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
,	NULL
with	NULL
single-stranded	NULL
flanking	NULL
BamHI	NULL
and	NULL
KpnI	NULL
sites	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
1	NULL
)	NULL
.	NULL

Competition	NULL
with	NULL
the	NULL
same	NULL
oligonucleotide	NULL
,	NULL
unlabeled	NULL
,	NULL
is	NULL
shown	NULL
in	NULL
lanes	NULL
2	NULL
,	NULL
8	NULL
,	NULL
and	NULL
14	NULL
.	NULL

Lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
M-CSF	NULL
receptor	NULL
probe	NULL
,	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
,	NULL
with	NULL
single-stranded	NULL
flanking	NULL
BamHI	NULL
and	NULL
KpnI	NULL
sites	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
14	NULL
)	NULL
.	NULL

Lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
CD11b	NULL
probe	NULL
,	NULL
bp	NULL
-27	NULL
to	NULL
-11	NULL
,	NULL
with	NULL
single-stranded	NULL
flanking	NULL
BamHI	NULL
and	NULL
KpnI	NULL
sites	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
15	NULL
)	NULL
.	NULL

Lanes	NULL
9	NULL
and	NULL
10	NULL
;	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
,	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
,	NULL
with	NULL
double-stranded	NULL
flanking	NULL
BamHI	NULL
and	NULL
KpnI	NULL
sites	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
5	NULL
)	NULL
.	NULL

Lanes	NULL
11	NULL
and	NULL
12	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
,	NULL
bp	NULL
-61	NULL
to	NULL
-30	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
6	NULL
)	NULL
.	NULL

Lanes	NULL
15	NULL
and	NULL
16	NULL
:	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
,	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
,	NULL
with	NULL
an	NULL
8-base	NULL
single-stranded	NULL
5	NULL
'	NULL
overhang	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
8	NULL
)	NULL
.	NULL

Lanes	NULL
17	NULL
and	NULL
18	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
,	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
,	NULL
with	NULL
an	NULL
8-base	NULL
single-stranded	NULL
5	NULL
'	NULL
overhang	NULL
on	NULL
the	NULL
noncoding	NULL
strand	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
7	NULL
)	NULL
.	NULL

Abbreviations	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

NF-EMS	NULL
(	NULL
47	NULL
)	NULL
,	NULL
did	NULL
not	NULL
abolish	NULL
the	NULL
ability	NULL
of	NULL
PU.1	NULL
to	NULL
form	NULL
PU-SF	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
PU-SF	NULL
complex	NULL
migrated	NULL
with	NULL
a	NULL
mobility	NULL
distinctly	NULL
slower	NULL
than	NULL
that	NULL
formed	NULL
by	NULL
a	NULL
double-stranded	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
PU.1/NF-EMS	NULL
site	NULL
from	NULL
the	NULL
x	NULL
3	NULL
'	NULL
enhancer	NULL
(	NULL
46	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
further	NULL
asked	NULL
whether	NULL
this	NULL
interaction	NULL
is	NULL
specific	NULL
for	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
PU.1	NULL
site	NULL
or	NULL
whether	NULL
other	NULL
functional	NULL
PU.1	NULL
sites	NULL
in	NULL
myeloid	NULL
cells	NULL
can	NULL
form	NULL
this	NULL
complex	NULL
.	NULL

In	NULL
experiments	NULL
performed	NULL
simultaneously	NULL
and	NULL
run	NULL
on	NULL
the	NULL
same	NULL
gel	NULL
,	NULL
certain	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
PU.1	NULL
site	NULL
from	NULL
the	NULL
M-CSF	NULL
receptor	NULL
(	NULL
70	NULL
)	NULL
or	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
41	NULL
)	NULL
failed	NULL
to	NULL
form	NULL
PU-SF	NULL
when	NULL
incubated	NULL
with	NULL
U937	NULL
nuclear	NULL
extracts	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probes	NULL
13	NULL
,	NULL
16	NULL
,	NULL
and	NULL
18	NULL
)	NULL
.	NULL

Formation	NULL
of	NULL
PU-SF	NULL
requires	NULL
a	NULL
single-stranded	NULL
pyrimidine	NULL
region	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
certain	NULL
M-CSF	NULL
receptor	NULL
or	NULL
CD11b	NULL
PU.1	NULL
site	NULL
oligonucleotides	NULL
to	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
PU-SF	NULL
prompted	NULL
us	NULL
to	NULL
investigate	NULL
whether	NULL
specific	NULL
DNA	NULL
sequences	NULL
were	NULL
required	NULL
for	NULL
such	NULL
an	NULL
interaction	NULL
.	NULL

Methylation	NULL
interference	NULL
assays	NULL
did	NULL
not	NULL
indicate	NULL
any	NULL
significant	NULL
difference	NULL
between	NULL
the	NULL
PU.1-and	NULL
PU-SF-bound	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
then	NULL
designed	NULL
a	NULL
series	NULL
of	NULL
oligonucleotide	NULL
probes	NULL
which	NULL
we	NULL
tested	NULL
by	NULL
EMSA	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
REX	NULL
cell	NULL
line	NULL
,	NULL
a	NULL
combination	NULL
which	NULL
produced	NULL
a	NULL
large	NULL
quantity	NULL
of	NULL
PU-SF-DNA	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
PU-SF	NULL
formation	NULL
was	NULL
lost	NULL
when	NULL
both	NULL
single-stranded	NULL
flanking	NULL
BamHI	NULL
(	NULL
coding	NULL
strand	NULL
)	NULL
and	NULL
KpnI	NULL
(	NULL
noncod-ing	NULL
strand	NULL
)	NULL
sites	NULL
were	NULL
eliminated	NULL
from	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
probe	NULL
,	NULL
but	NULL
it	NULL
was	NULL
regained	NULL
when	NULL
either	NULL
site	NULL
was	NULL
added	NULL
back	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
or	NULL
when	NULL
those	NULL
sequences	NULL
were	NULL
added	NULL
to	NULL
the	NULL
M-CSF	NULL
receptor	NULL
and	NULL
CD11b	NULL
PU.1	NULL
binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
6	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
could	NULL
not	NULL
detect	NULL
PU-SF	NULL
when	NULL
using	NULL
a	NULL
probe	NULL
with	NULL
double-stranded	NULL
flanking	NULL
BamHI	NULL
and	NULL
KpnI	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
or	NULL
when	NULL
using	NULL
a	NULL
double-stranded	NULL
probe	NULL
which	NULL
extended	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
sequence	NULL
to	NULL
an	NULL
equiv-	NULL
alent	NULL
length	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

However	NULL
,	NULL
8-base	NULL
single-stranded	NULL
5	NULL
'	NULL
overhangs	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
sequence	NULL
on	NULL
either	NULL
the	NULL
coding	NULL
or	NULL
noncoding	NULL
strand	NULL
were	NULL
sufficient	NULL
to	NULL
allow	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
15	NULL
to	NULL
18	NULL
)	NULL
.	NULL

We	NULL
then	NULL
asked	NULL
whether	NULL
the	NULL
requirement	NULL
of	NULL
PU-SF	NULL
for	NULL
single-stranded	NULL
DNA	NULL
was	NULL
sequence	NULL
specific	NULL
.	NULL

Changing	NULL
the	NULL
cytosine	NULL
residues	NULL
at	NULL
bp	NULL
-57	NULL
and	NULL
-58	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
5	NULL
'	NULL
overhang	NULL
to	NULL
thymidines	NULL
did	NULL
not	NULL
prevent	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
complex	NULL
.	NULL

However	NULL
,	NULL
PU-SF	NULL
could	NULL
not	NULL
be	NULL
detected	NULL
when	NULL
the	NULL
single-stranded	NULL
5	NULL
'	NULL
overhangs	NULL
were	NULL
constructed	NULL
entirely	NULL
of	NULL
pu-rines	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probes	NULL
9	NULL
to	NULL
11	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
has	NULL
some	NULL
requirement	NULL
for	NULL
pyrimidines	NULL
as	NULL
well	NULL
as	NULL
for	NULL
single-stranded	NULL
DNA	NULL
.	NULL

Single-stranded	NULL
oligonucleotides	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probes	NULL
1	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
could	NULL
not	NULL
inhibit	NULL
either	NULL
the	NULL
PU.1	NULL
or	NULL
the	NULL
PU-SF	NULL
complexes	NULL
,	NULL
nor	NULL
could	NULL
an	NULL
oligonucleotide	NULL
(	NULL
GM1	NULL
[	NULL
see	NULL
Fig	NULL
.	NULL

9	NULL
]	NULL
)	NULL
mutated	NULL
only	NULL
at	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
an	NULL
oligonucleotide	NULL
which	NULL
,	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
could	NULL
bind	NULL
PU.1	NULL
but	NULL
not	NULL
PU-SF	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
probe	NULL
12	NULL
)	NULL
did	NULL
inhibit	NULL
both	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
are	NULL
consistant	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
PU-SF	NULL
requires	NULL
PU.1	NULL
to	NULL
bind	NULL
DNA	NULL
.	NULL

The	NULL
single-stranded	NULL
or	NULL
mutated	NULL
competitor	NULL
is	NULL
unable	NULL
to	NULL
bind	NULL
PU.1	NULL
and	NULL
therefore	NULL
unable	NULL
to	NULL
bind	NULL
PU-SF	NULL
,	NULL
and	NULL
a	NULL
competitor	NULL
that	NULL
binds	NULL
PU.1	NULL
but	NULL
not	NULL
PU-SF	NULL
will	NULL
block	NULL
PU.1	NULL
from	NULL
the	NULL
probe	NULL
and	NULL
therefore	NULL
prevent	NULL
binding	NULL
to	NULL
PU-SF	NULL
indirectly	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
abolishes	NULL
binding	NULL
of	NULL
PU.1	NULL
and	NULL
decreases	NULL
promoter	NULL
activity	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
.	NULL

To	NULL
define	NULL
the	NULL
residues	NULL
in	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
contacted	NULL
by	NULL
the	NULL
PU.1	NULL
protein	NULL
,	NULL
methylation	NULL
interference	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
DNA	NULL
fragment	NULL
including	NULL
the	NULL
region	NULL
between	NULL
positions	NULL
-70	NULL
and	NULL
+49	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
the	NULL
PU.1	NULL
protein	NULL
directly	NULL
contacts	NULL
the	NULL
three	NULL
G	NULL
residues	NULL
at	NULL
positions	NULL
-48	NULL
,	NULL
-46	NULL
,	NULL
and	NULL
-45	NULL
.	NULL

No	NULL
other	NULL
strong	NULL
contacts	NULL
could	NULL
be	NULL
observed	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
site	NULL
is	NULL
the	NULL
only	NULL
PU.1	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
proximal	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
F	NULL
B	NULL
G/A	NULL
w	NULL
-	NULL
+49	NULL
«	NULL
tte	NULL
@	NULL
»	NULL
--	NULL
+30	NULL
--	NULL
+16	NULL
«	NULL
oute	NULL
--	NULL
+1	NULL
--	NULL
-9	NULL
``	NULL
am	NULL
--	NULL
-19	NULL
#	NULL
e	NULL
=	NULL
f	NULL
we	NULL
.	NULL

--	NULL
-26	NULL
#	NULL
``	NULL
&	NULL
#	NULL
>	NULL
<	NULL
G	NULL
-	NULL
-42	NULL
[	NULL
1363	NULL
/A	NULL
e	NULL
A	NULL
,	NULL
a*	NULL
/	NULL
fred	NULL
-~—\G*	NULL
cme	NULL
:	NULL
T	NULL
A	NULL
A	NULL
-53	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Methylation	NULL
interference	NULL
analysis	NULL
of	NULL
DNA	NULL
contact	NULL
points	NULL
of	NULL
PU.1	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
.	NULL

The	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
fragment	NULL
from	NULL
bp	NULL
-70	NULL
to	NULL
+49	NULL
was	NULL
end	NULL
labeled	NULL
on	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
noncoding	NULL
strand	NULL
and	NULL
methylated	NULL
by	NULL
treatment	NULL
with	NULL
limiting	NULL
quantities	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
.	NULL

Free	NULL
DNA	NULL
(	NULL
lane	NULL
F	NULL
)	NULL
and	NULL
DNA	NULL
from	NULL
the	NULL
complex	NULL
formed	NULL
by	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
with	NULL
the	NULL
bp	NULL
-70	NULL
to	NULL
+49	NULL
fragment	NULL
(	NULL
lane	NULL
(	NULL
B	NULL
)	NULL
was	NULL
subjected	NULL
to	NULL
piperidine-mediated	NULL
cleavage	NULL
of	NULL
methylated	NULL
guanosine	NULL
residues	NULL
.	NULL

Lane	NULL
G/A	NULL
,	NULL
adenosine-guanosine	NULL
sequence	NULL
standards	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
unmethylated	NULL
probe	NULL
by	NULL
a	NULL
chemical	NULL
cleavage	NULL
protocol	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
region	NULL
between	NULL
bp	NULL
-53	NULL
and	NULL
-42	NULL
is	NULL
shown	NULL
on	NULL
the	NULL
right	NULL
.	NULL

The	NULL
asterisks	NULL
indicate	NULL
the	NULL
direct	NULL
contacts	NULL
between	NULL
the	NULL
DNA	NULL
and	NULL
PU.1	NULL
at	NULL
residues	NULL
-45	NULL
,	NULL
-46	NULL
,	NULL
and	NULL
-48.	NULL
promoter	NULL
,	NULL
since	NULL
PU.1	NULL
also	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
oligonucleotides	NULL
extending	NULL
upstream	NULL
to	NULL
position	NULL
-80	NULL
and	NULL
downstream	NULL
to	NULL
+7	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
the	NULL
importance	NULL
of	NULL
PU.1	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
,	NULL
the	NULL
three	NULL
guanosine	NULL
residues	NULL
identified	NULL
by	NULL
methylation	NULL
interference	NULL
to	NULL
be	NULL
contacted	NULL
by	NULL
PU.1	NULL
were	NULL
mutated	NULL
into	NULL
cytosine	NULL
residues	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

An	NULL
oligonucleotide	NULL
with	NULL
the	NULL
mutated	NULL
PU.1	NULL
site	NULL
could	NULL
not	NULL
compete	NULL
for	NULL
PU.1	NULL
binding	NULL
to	NULL
the	NULL
wild-type	NULL
region	NULL
from	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
;	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
same	NULL
PU.1	NULL
mutant	NULL
site	NULL
oligonucleotide	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
PU.1	NULL
either	NULL
as	NULL
in	NULL
vitro-translated	NULL
protein	NULL
or	NULL
U937	NULL
nuclear	NULL
extracts	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
oligonucleotide	NULL
also	NULL
was	NULL
not	NULL
able	NULL
to	NULL
form	NULL
PU-SF	NULL
observed	NULL
with	NULL
nuclear	NULL
extracts	NULL
,	NULL
supporting	NULL
the	NULL
idea	NULL
that	NULL
DNA	NULL
binding	NULL
of	NULL
PU.1	NULL
is	NULL
critically	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
no	NULL
specific	NULL
protein	NULL
binding	NULL
site	NULL
was	NULL
created	NULL
by	NULL
the	NULL
mutation	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

In	NULL
nuclear	NULL
extracts	NULL
from	NULL
U937	NULL
cells	NULL
,	NULL
we	NULL
observed	NULL
only	NULL
a	NULL
nonspecific	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
which	NULL
comigrated	NULL
with	NULL
a	NULL
similar	NULL
nonspecific	NULL
band	NULL
seen	NULL
with	NULL
the	NULL
wild-type	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lane	NULL
15	NULL
)	NULL
at	NULL
a	NULL
position	NULL
slightly	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lanes	NULL
11	NULL
,	NULL
13	NULL
,	NULL
and	NULL
14	NULL
)	NULL
.	NULL

This	NULL
same	NULL
mutation	NULL
was	NULL
then	NULL
introduced	NULL
into	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter-luciferase	NULL
construct	NULL
.	NULL

We	NULL
introduced	NULL
the	NULL
mutation	NULL
both	NULL
into	NULL
-70GM-CSFr-luc	NULL
,	NULL
which	NULL
retains	NULL
full	NULL
promoter	NULL
activity	NULL
compared	NULL
with	NULL
-393GM-CSFr-luc	NULL
,	NULL
and	NULL
into	NULL
-53GM-CSFr-luc	NULL
,	NULL
PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5839	NULL
which	NULL
has	NULL
increased	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Comparative	NULL
analysis	NULL
of	NULL
transient	NULL
transfections	NULL
in	NULL
U937	NULL
cells	NULL
revealed	NULL
that	NULL
the	NULL
promoter	NULL
activities	NULL
of	NULL
both	NULL
mutants	NULL
were	NULL
significantly	NULL
decreased	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

-53GM-CS-Fr	NULL
(	NULL
GM-1	NULL
)	NULL
-luc	NULL
,	NULL
containing	NULL
mutations	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
at	NULL
the	NULL
three	NULL
base	NULL
pairs	NULL
which	NULL
contact	NULL
PU.1	NULL
,	NULL
demonstrated	NULL
31	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
-70GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-lue	NULL
construct	NULL
was	NULL
reduced	NULL
to	NULL
13	NULL
%	NULL
of	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

In	NULL
nonmyeloid	NULL
Jurkat	NULL
cells	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
-70GM-CSFr-lue	NULL
was	NULL
only	NULL
8	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
,	NULL
and	NULL
mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
(	NULL
-70GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-lue	NULL
did	NULL
not	NULL
result	NULL
in	NULL
a	NULL
significant	NULL
change	NULL
of	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
the	NULL
myeloid	NULL
specificity	NULL
and	NULL
functional	NULL
importance	NULL
of	NULL
PU.1	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
.	NULL

C/EBPa	NULL
binds	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
.	NULL

Deletion	NULL
analysis	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
identified	NULL
a	NULL
fragment	NULL
between	NULL
residues	NULL
-70	NULL
and	NULL
-54	NULL
whose	NULL
deletion	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

We	NULL
asked	NULL
whether	NULL
proteins	NULL
involved	NULL
in	NULL
negative	NULL
regulation	NULL
or	NULL
involved	NULL
in	NULL
a	NULL
competition	NULL
between	NULL
a	NULL
positive	NULL
and	NULL
a	NULL
negative	NULL
factor	NULL
could	NULL
bind	NULL
to	NULL
this	NULL
region	NULL
.	NULL

A	NULL
CCAAT	NULL
site	NULL
around	NULL
bp	NULL
-60	NULL
represents	NULL
a	NULL
potential	NULL
protein	NULL
binding	NULL
site	NULL
in	NULL
this	NULL
fragment	NULL
.	NULL

CCAAT	NULL
sites	NULL
are	NULL
target	NULL
sequences	NULL
for	NULL
a	NULL
variety	NULL
of	NULL
both	NULL
general	NULL
and	NULL
cell-type-specific	NULL
transcription	NULL
factors	NULL
(	NULL
20	NULL
)	NULL
.	NULL

C/EBPs	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell-type-specific	NULL
differentiation	NULL
and	NULL
proliferation	NULL
,	NULL
and	NULL
the	NULL
«	NULL
,	NULL
B	NULL
,	NULL
and	NULL
8	NULL
forms	NULL
are	NULL
expressed	NULL
specifically	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
36	NULL
,	NULL
57	NULL
)	NULL
.	NULL

Theses	NULL
factors	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
myeloid	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
through	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
growth	NULL
factor	NULL
receptors	NULL
,	NULL
like	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
,	NULL
that	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
this	NULL
process	NULL
.	NULL

We	NULL
therefore	NULL
analyzed	NULL
whether	NULL
this	NULL
region	NULL
can	NULL
bind	NULL
C/EBP	NULL
.	NULL

An	NULL
EMSA	NULL
with	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
U937	NULL
cells	NULL
and	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
from	NULL
position	NULL
-80	NULL
to	NULL
-49	NULL
showed	NULL
binding	NULL
of	NULL
a	NULL
specific	NULL
complex	NULL
(	NULL
complex	NULL
C/EBPa	NULL
;	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
which	NULL
could	NULL
be	NULL
blocked	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
self	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
by	NULL
a	NULL
shorter	NULL
oligonucleotide	NULL
spanning	NULL
positions	NULL
-70	NULL
to	NULL
-54	NULL
and	NULL
retaining	NULL
the	NULL
CCAAT	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
by	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
C/EBP	NULL
site	NULL
from	NULL
the	NULL
M-CSF	NULL
receptor	NULL
(	NULL
¢-fms	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
(	NULL
69	NULL
,	NULL
71	NULL
)	NULL
.	NULL

However	NULL
,	NULL
an	NULL
ets	NULL
consensus	NULL
binding	NULL
oligonucleotide	NULL
which	NULL
binds	NULL
multiple	NULL
ets	NULL
factors	NULL
(	NULL
23	NULL
,	NULL
66	NULL
)	NULL
could	NULL
not	NULL
inhibit	NULL
the	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
complex	NULL
could	NULL
be	NULL
diminished	NULL
by	NULL
a	NULL
rabbit	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
carboxyl-terminal	NULL
four-fifths	NULL
of	NULL
C/EBPa	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
but	NULL
not	NULL
by	NULL
normal	NULL
rabbit	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
or	NULL
antisera	NULL
against	NULL
other	NULL
C/EBP	NULL
family	NULL
members	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Besides	NULL
the	NULL
C/EBPa	NULL
complex	NULL
,	NULL
we	NULL
could	NULL
identify	NULL
faster-migrating	NULL
specific	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
complexes	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

These	NULL
complexes	NULL
could	NULL
be	NULL
observed	NULL
as	NULL
well	NULL
in	NULL
Cos	NULL
?	NULL

cells	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
)	NULL
and	NULL
may	NULL
therefore	NULL
represent	NULL
non-cell-type-specific	NULL
activities	NULL
.	NULL

Competition	NULL
studies	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
either	NULL
unlabeled	NULL
strand	NULL
of	NULL
the	NULL
probe	NULL
indicated	NULL
that	NULL
complexes	NULL
B	NULL
and	NULL
C	NULL
bind	NULL
single-stranded	NULL
DNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Single-strand	NULL
competitors	NULL
containing	NULL
sequences	NULL
from	NULL
bp	NULL
-70	NULL
to	NULL
-49	NULL
did	NULL
not	NULL
inhibit	NULL
complexes	NULL
B	NULL
and	NULL
C	NULL
,	NULL
while	NULL
a	NULL
single	NULL
strand	NULL
containing	NULL
the	NULL
sequence	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-70	NULL
did	NULL
,	NULL
indicating	NULL
that	NULL
B	NULL
and	NULL
C	NULL
bind	NULL
the	NULL
region	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-70	NULL
of	NULL
the	NULL
probe	NULL
when	NULL
it	NULL
is	NULL
in	NULL
a	NULL
single-stranded	NULL
form	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
obtain	NULL
further	NULL
evidence	NULL
that	NULL
the	NULL
complex	NULL
is	NULL
C/EBPa	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
gel	NULL
shift	NULL
with	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
Cos	NULL
?	NULL

cells	NULL
which	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
C/EBPa	NULL
expression	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
)	NULL
.	NULL

C/EBPa	NULL
formed	NULL
a	NULL
specific	NULL
complex	NULL
with	NULL
the	NULL
oligonucleotide	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-49	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
in	NULL
the	NULL
U937	NULL
cell	NULL
nuclear	NULL
extract	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
which	NULL
could	NULL
also	NULL
be	NULL
inhibited	NULL
by	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
5840	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

-53	NULL
we	NULL
e	NULL
ik	NULL
-37	NULL
Probe	NULL
:	NULL
gtggatccGAAA	NULL
CCAAGCAGGG	NULL
CTTTAGTGGTTCGTCCCeccatgqgtyg	NULL
Probe	NULL
:	NULL
-	NULL
53/-37	NULL
GM-1	NULL
-53/-37	NULL
wt	NULL
Protein	NULL
:	NULL
-C	NULL
PU.1	NULL
U937	NULL
PU.1	NULL
U937	NULL
Competitor	NULL
:	NULL
-	NULL
>	NULL
>	NULL
cm	NULL
wi	NULL
-	NULL
cmm	NULL
wi	NULL
t/	NULL
-	NULL
wie	NULL
cm	NULL
-	NULL
wm	NULL
T	NULL
--	NULL
NS	NULL
--	NULL
PU-SF	NULL
«	NULL
ms	NULL
-	NULL
PUA	NULL
-	NULL
3	NULL
%	NULL
F	NULL
1	NULL
Lane	NULL
:	NULL
20	NULL
30	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
abolishes	NULL
PU.1	NULL
binding	NULL
in	NULL
EMSA	NULL
.	NULL

The	NULL
probe	NULL
used	NULL
in	NULL
lanes	NULL
1	NULL
to	NULL
10	NULL
was	NULL
a	NULL
double-stranded	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
from	NULL
position	NULL
-53	NULL
to	NULL
-37	NULL
with	NULL
point	NULL
mutations	NULL
of	NULL
the	NULL
guanosine	NULL
residues	NULL
(	NULL
bp	NULL
-48	NULL
,	NULL
-46	NULL
,	NULL
and	NULL
-45	NULL
)	NULL
identified	NULL
by	NULL
methylation	NULL
interference	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
PU.1	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
(	NULL
GM1	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
11	NULL
to	NULL
15	NULL
,	NULL
the	NULL
probe	NULL
was	NULL
the	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
oligonucleotide	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Probes	NULL
were	NULL
end	NULL
labeled	NULL
and	NULL
incubated	NULL
with	NULL
either	NULL
1	NULL
pl	NULL
of	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
6	NULL
and	NULL
11	NULL
to	NULL
13	NULL
)	NULL
or	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
)	NULL
.	NULL

A	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
:	NULL
mutated	NULL
PU.1	NULL
site	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
(	NULL
GM1	NULL
)	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
13	NULL
)	NULL
,	NULL
wild-type	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-53	NULL
to	NULL
-37	NULL
(	NULL
Wt	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
9	NULL
,	NULL
12	NULL
,	NULL
and	NULL
15	NULL
)	NULL
,	NULL
and	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-41	NULL
to	NULL
-25	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
10	NULL
)	NULL
.	NULL

All	NULL
other	NULL
abbreviations	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
and	NULL
6	NULL
.	NULL

A	NULL
nonspecific	NULL
complex	NULL
,	NULL
which	NULL
does	NULL
not	NULL
compete	NULL
with	NULL
excess	NULL
cold	NULL
self	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
migrates	NULL
just	NULL
ahead	NULL
of	NULL
PU.1	NULL
and	NULL
is	NULL
seen	NULL
in	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
(	NULL
also	NULL
observed	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
to	NULL
6	NULL
)	NULL
.	NULL

positions	NULL
-70	NULL
to	NULL
-54	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
but	NULL
not	NULL
by	NULL
an	NULL
oligonucleotide	NULL
in	NULL
which	NULL
the	NULL
adenosine	NULL
residues	NULL
of	NULL
the	NULL
CCAAT	NULL
site	NULL
were	NULL
mutated	NULL
into	NULL
guanosine	NULL
residues	NULL
(	NULL
GM2	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
complex	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
a	NULL
high-affinity	NULL
C/EBP	NULL
binding	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
(	NULL
5	NULL
,	NULL
60	NULL
)	NULL
but	NULL
not	NULL
by	NULL
a	NULL
mutated	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

C/EBPa	NULL
binding	NULL
was	NULL
abolished	NULL
by	NULL
the	NULL
specific	NULL
«	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
while	NULL
antisera	NULL
against	NULL
C/EBPB	NULL
and	NULL
C/EBP38	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Gel	NULL
shift	NULL
assays	NULL
with	NULL
Cos7	NULL
cell	NULL
extracts	NULL
transfected	NULL
with	NULL
C/EBPB	NULL
and	NULL
-8	NULL
resulted	NULL
also	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
specific	NULL
complexes	NULL
with	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-49	NULL
which	NULL
appeared	NULL
similar	NULL
to	NULL
complexes	NULL
formed	NULL
by	NULL
these	NULL
extracts	NULL
with	NULL
the	NULL
high-affinity	NULL
consensus	NULL
C/EBP	NULL
site	NULL
(	NULL
5	NULL
,	NULL
60	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
C/EBPB	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
CCAAT	NULL
site	NULL
was	NULL
much	NULL
weaker	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
the	NULL
consensus	NULL
high-affinity	NULL
C/EBP	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
supershift	NULL
experiments	NULL
with	NULL
antisera	NULL
raised	NULL
against	NULL
C/EBPB	NULL
and	NULL
-8	NULL
and	NULL
the	NULL
oligonucleotide	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-49	NULL
did	NULL
not	NULL
result	NULL
in	NULL
supershifts	NULL
in	NULL
U937	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
faint	NULL
complex	NULL
(	NULL
NS	NULL
)	NULL
suggesting	NULL
a	NULL
supershift	NULL
can	NULL
also	NULL
be	NULL
observed	NULL
in	NULL
Cos	NULL
?	NULL

extracts	NULL
transfected	NULL
with	NULL
C/EBPa	NULL
(	NULL
seen	NULL
in	NULL
the	NULL
longer	NULL
exposures	NULL
of	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
but	NULL
not	NULL
in	NULL
untransfected	NULL
Cos	NULL
?	NULL

cells	NULL
,	NULL
and	NULL
it	NULL
therefore	NULL
most	NULL
likely	NULL
represents	NULL
a	NULL
cross-reaction	NULL
of	NULL
these	NULL
C/EBP	NULL
antibodies	NULL
with	NULL
C/EBPa	NULL
.	NULL

However	NULL
,	NULL
in	NULL
U937	NULL
cells	NULL
,	NULL
we	NULL
observed	NULL
significant	NULL
levels	NULL
of	NULL
C/EBPa	NULL
and	NULL
not	NULL
C/EBPB	NULL
or	NULL
C/EBP38	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
(	NULL
71	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
taken	NULL
together	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
homodimers	NULL
of	NULL
C/EBPa	NULL
are	NULL
the	NULL
major	NULL
C/EBP	NULL
form	NULL
in	NULL
U937	NULL
cells	NULL
binding	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
CCAAT	NULL
site	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
CCAAT	NULL
site	NULL
abolishes	NULL
binding	NULL
of	NULL
C/EBPa	NULL
and	NULL
diminishes	NULL
promoter	NULL
activity	NULL
.	NULL

To	NULL
address	NULL
the	NULL
question	NULL
whether	NULL
this	NULL
CCAAT	NULL
site	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
negative	NULL
regulatory	NULL
effect	NULL
of	NULL
this	NULL
area	NULL
,	NULL
we	NULL
mutated	NULL
this	NULL
site	NULL
by	NULL
point	NULL
mutations	NULL
changing	NULL
two	NULL
adenosine	NULL
residues	NULL
at	NULL
positions	NULL
-60	NULL
and	NULL
-61	NULL
into	NULL
guanosines	NULL
,	NULL
which	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
C/EBP	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

We	NULL
introduced	NULL
this	NULL
mutation	NULL
to	NULL
form	NULL
the	NULL
mutant	NULL
construct	NULL
-70GM-CSFr	NULL
(	NULL
GM-2	NULL
)	NULL
-lue	NULL
.	NULL

Comparative	NULL
analysis	NULL
of	NULL
this	NULL
construct	NULL
in	NULL
transient	NULL
transfections	NULL
in	NULL
U937	NULL
cells	NULL
revealed	NULL
that	NULL
this	NULL
site	NULL
is	NULL
a	NULL
positive	NULL
regulatory	NULL
site	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
CCAAT	NULL
site	NULL
diminished	NULL
the	NULL
activity	NULL
to	NULL
30	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
nonmyeloid	NULL
Jurkat	NULL
cells	NULL
the	NULL
activity	NULL
of	NULL
-70GM-CSFr	NULL
(	NULL
GM-2	NULL
)	NULL
-lue	NULL
was	NULL
slightly	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
construct	NULL
,	NULL
indicating	NULL
the	NULL
myeloid	NULL
specificity	NULL
of	NULL
the	NULL
positive	NULL
function	NULL
of	NULL
the	NULL
CCAAT	NULL
site	NULL
.	NULL

These	NULL
data	NULL
point	NULL
to	NULL
a	NULL
positive-negative	NULL
role	NULL
of	NULL
the	NULL
region	NULL
from	NULL
bp	NULL
-70	NULL
to	NULL
-54	NULL
in	NULL
which	NULL
C/EBPa	NULL
acts	NULL
as	NULL
a	NULL
positive	NULL
regulator	NULL
.	NULL

Mutation	NULL
of	NULL
both	NULL
the	NULL
PU.1	NULL
and	NULL
CCAAT	NULL
sites	NULL
had	NULL
no	NULL
additional	NULL
effect	NULL
above	NULL
that	NULL
of	NULL
a	NULL
single	NULL
mutation	NULL
of	NULL
each	NULL
site	NULL
,	NULL
pointing	NULL
to	NULL
an	NULL
independent	NULL
function	NULL
of	NULL
each	NULL
site	NULL
(	NULL
results	NULL
of	NULL
two	NULL
experi-ments	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PU.1	NULL
and	NULL
C/EBPa	NULL
activate	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
in	NULL
nonmyeloid	NULL
cells	NULL
.	NULL

To	NULL
further	NULL
establish	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
PU.1	NULL
and	NULL
C/EBPa	NULL
,	NULL
we	NULL
performed	NULL
transactivation	NULL
experiments	NULL
with	NULL
the	NULL
nonmyeloid	NULL
cell	NULL
line	NULL
HepG2	NULL
,	NULL
which	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
A	NULL
PU.1	NULL
53	NULL
--	NULL
--	NULL
--	NULL
[	NULL
Luc	NULL
|	NULL
-41	NULL
--	NULL
--	NULL
[	NULL
Lue	NULL
]	NULL
CEBP	NULL
PU.1	NULL
70	NULL
70	NULL
|	NULL
-70	NULL
-	NULL
@	NULL
»	NULL
--	NULL
<	NULL
O	NULL
--	NULL
--	NULL
-	NULL
[	NULL
_	NULL
Lue	NULL
]	NULL
PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5841	NULL
I	NULL
I	NULL
&	NULL
I	NULL
&	NULL
&	NULL
f	NULL
4a	NULL
in	NULL
750	NULL
1000	NULL
Promoter	NULL
activity	NULL
(	NULL
Fold	NULL
above	NULL
pXP2	NULL
)	NULL
I	NULL
I	NULL
I	NULL
1	NULL
U	NULL
&	NULL
&	NULL
f-3	NULL
-	NULL
f-	NULL
&	NULL
&	NULL
)	NULL
t	NULL
2	NULL
2	NULL
e	NULL
e	NULL
Promoter	NULL
activity	NULL
(	NULL
Fold	NULL
above	NULL
pXP2	NULL
)	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

Point	NULL
mutations	NULL
of	NULL
the	NULL
PU.1	NULL
and	NULL
CCAAT	NULL
sites	NULL
diminish	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
activity	NULL
in	NULL
a	NULL
cell-type-specific	NULL
way	NULL
.	NULL

(	NULL
A	NULL
)	NULL
-53GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-lue	NULL
(	NULL
bottom	NULL
bar	NULL
graph	NULL
,	NULL
shaded	NULL
oval	NULL
)	NULL
,	NULL
extending	NULL
from	NULL
bp	NULL
-53	NULL
to	NULL
+49	NULL
and	NULL
containing	NULL
the	NULL
mutated	NULL
PU.1	NULL
site	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
U937	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
luciferase	NULL
activity	NULL
was	NULL
compared	NULL
with	NULL
the	NULL
activities	NULL
of	NULL
the	NULL
wild-type	NULL
-53GM-CSFr-luc	NULL
(	NULL
top	NULL
bar	NULL
,	NULL
white	NULL
oval	NULL
)	NULL
and	NULL
the	NULL
PU.1	NULL
site	NULL
deletion	NULL
-41GM-CSFr-luc	NULL
(	NULL
middle	NULL
bar	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
5	NULL
'	NULL
end	NULL
points	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Wild-type	NULL
-70GM-CSFr-luc	NULL
(	NULL
top	NULL
bar	NULL
graph	NULL
,	NULL
white	NULL
ovals	NULL
)	NULL
,	NULL
mutated	NULL
PU.1	NULL
site	NULL
-70GM-CSFr	NULL
(	NULL
GM-1	NULL
)	NULL
-lue	NULL
(	NULL
middle	NULL
bar	NULL
,	NULL
shaded	NULL
oval	NULL
representing	NULL
the	NULL
GM1	NULL
PU.1	NULL
site	NULL
mutation	NULL
and	NULL
white	NULL
oval	NULL
indicating	NULL
a	NULL
wild-type	NULL
CCAAT	NULL
site	NULL
)	NULL
,	NULL
and	NULL
mutated	NULL
CCAAT	NULL
site	NULL
-70GM-CSFr	NULL
(	NULL
GM-2	NULL
)	NULL
-luc	NULL
(	NULL
bottom	NULL
bar	NULL
,	NULL
shaded	NULL
oval	NULL
representing	NULL
the	NULL
GM2	NULL
CCAAT	NULL
site	NULL
mutation	NULL
and	NULL
white	NULL
oval	NULL
indicating	NULL
a	NULL
wild-type	NULL
PU.1	NULL
site	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
myelomonocytic	NULL
U937	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
the	NULL
average	NULL
fold	NULL
luciferase	NULL
activity	NULL
over	NULL
that	NULL
with	NULL
promoterless	NULL
pXP2	NULL
and	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
mean	NULL
were	NULL
calculated	NULL
.	NULL

lacks	NULL
endogenous	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
and	NULL
expresses	NULL
C/EBPa	NULL
only	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
(	NULL
14	NULL
)	NULL
.	NULL

-70GM-CSFr-lue	NULL
was	NULL
transfected	NULL
into	NULL
HepG2	NULL
cells	NULL
along	NULL
with	NULL
either	NULL
the	NULL
full-length	NULL
PU.1	NULL
expression	NULL
plasmid	NULL
(	NULL
PU.1-pECE	NULL
)	NULL
,	NULL
the	NULL
expression	NULL
plasmids	NULL
for	NULL
the	NULL
amino-terminally	NULL
truncated	NULL
form	NULL
of	NULL
PU.1	NULL
(	NULL
N133	NULL
PU.1	NULL
and	NULL
N70	NULL
PU.1	NULL
)	NULL
,	NULL
or	NULL
the	NULL
C/EBPa	NULL
expression	NULL
plasmid	NULL
(	NULL
MSV-C/EBPa	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
pro	NULL
moter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cotransfected	NULL
full-length	NULL
PU.1	NULL
was	NULL
increased	NULL
to	NULL
twice	NULL
that	NULL
of	NULL
the	NULL
control	NULL
,	NULL
while	NULL
the	NULL
presence	NULL
of	NULL
C/EBPa	NULL
increased	NULL
the	NULL
promoter	NULL
activity	NULL
to	NULL
180	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

13A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cotransfection	NULL
with	NULL
the	NULL
amino-terminally	NULL
truncated	NULL
forms	NULL
of	NULL
PU.1	NULL
resulted	NULL
in	NULL
either	NULL
a	NULL
slight	NULL
decrease	NULL
(	NULL
N133	NULL
PU.1	NULL
)	NULL
or	NULL
no	NULL
change	NULL
(	NULL
N70	NULL
PU.1	NULL
)	NULL
in	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
PU.1	NULL
to	NULL
C/EBP	NULL
«	NULL
did	NULL
not	NULL
potentiate	NULL
transactivation	NULL
of	NULL
either	NULL
5842	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

-80	NULL
-49	NULL
Probe	NULL
-80/-49	NULL
:	NULL
$	NULL
AGCMTTACAGG	NULL
’	NULL
I	NULL
‘	NULL
TTC	NULL
CTATGAM'IJ	NULL
robe	NULL
-50/-47	NULL
:	NULL
CTCOTTAATGTCCAAA	NULL
TACTTTA	NULL
-70	NULL
4.114	NULL
270/-54	NULL
:	NULL
gtggatccAGGTTTC	NULL
CTA	NULL
70/-54	NULL
:	NULL
TC	NULL
Tacctaggtg	NULL
Protein	NULL
:	NULL
=	NULL
U937	NULL
J	NULL
1	NULL
Antibody	NULL
:	NULL
=	NULL
>	NULL
=	NULL
=	NULL
>	NULL
=	NULL
=-	NULL
=	NULL
NRS	NULL
g	NULL
B	NULL
5	NULL
Competitor	NULL
:	NULL
<	NULL
-	NULL
jg	NULL
]	NULL
22	NULL
,	NULL
ets	NULL
fms	NULL
e	NULL
0	NULL
+	NULL
0	NULL
-	NULL
oT	NULL
_	NULL
m	NULL
wim	NULL
=	NULL
.	NULL

wae	NULL
CaP	NULL
-~	NULL
NS	NULL
--	NULL
C/EBP	NULL
q	NULL
A	NULL
B	NULL
-_	NULL
C	NULL
1°	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
FIG	NULL
.	NULL

11	NULL
.	NULL

Identification	NULL
of	NULL
C/EBPa	NULL
binding	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

A	NULL
double-stranded	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
position	NULL
-80	NULL
to	NULL
-49	NULL
was	NULL
end	NULL
labeled	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
10	NULL
)	NULL
of	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
U937	NULL
cells	NULL
.	NULL

A	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
:	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
position	NULL
-80	NULL
to	NULL
-49	NULL
(	NULL
self	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
-70	NULL
to	NULL
-54	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
E18	NULL
ets	NULL
consensus	NULL
site	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
(	NULL
nonself	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
(	NULL
23	NULL
,	NULL
66	NULL
)	NULL
,	NULL
and	NULL
M-CSF	NULL
receptor	NULL
(	NULL
¢-fms	NULL
)	NULL
promoter	NULL
C/EBP	NULL
site	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
,	NULL
1.5	NULL
pl	NULL
of	NULL
antisera	NULL
against	NULL
C/EBPa	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
C/EBPB	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
and	NULL
C/EBP	NULL
8	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
or	NULL
normal	NULL
rabbit	NULL
serum	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
.	NULL

Abbreviations	NULL
:	NULL
T	NULL
,	NULL
top	NULL
of	NULL
gel	NULL
;	NULL
NS	NULL
,	NULL
a	NULL
nonspecific	NULL
band	NULL
which	NULL
is	NULL
observed	NULL
in	NULL
nonmyeloid	NULL
cell	NULL
extracts	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
C/EBPs	NULL
and	NULL
likely	NULL
enhanced	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
B	NULL
or	NULL
8	NULL
serum	NULL
in	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
;	NULL
C/EBP	NULL
,	NULL
gel	NULL
shifted	NULL
complex	NULL
formed	NULL
by	NULL
C/EBP	NULL
;	NULL
A	NULL
,	NULL
nonspecific	NULL
complex	NULL
;	NULL
B	NULL
and	NULL
C	NULL
,	NULL
specific	NULL
single-stranded-DNA-binding	NULL
complexes	NULL
(	NULL
shorter	NULL
exposure	NULL
of	NULL
the	NULL
autoradiograph	NULL
reveals	NULL
two	NULL
bands	NULL
;	NULL
the	NULL
autoradiograph	NULL
was	NULL
heavily	NULL
exposed	NULL
to	NULL
show	NULL
the	NULL
C/EBPa	NULL
complex	NULL
)	NULL
.	NULL

All	NULL
other	NULL
abbreviations	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

6.	NULL
factor	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
PU.1	NULL
was	NULL
able	NULL
to	NULL
enhance	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
construct	NULL
which	NULL
contained	NULL
a	NULL
single	NULL
PU.1	NULL
binding	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
TK	NULL
promoter	NULL
an	NULL
average	NULL
of	NULL
sixfold	NULL
(	NULL
Fig	NULL
.	NULL

13B	NULL
)	NULL
.	NULL

A	NULL
plasmid	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
did	NULL
not	NULL
show	NULL
transactivation	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
the	NULL
minimal	NULL
TK	NULL
promoter	NULL
.	NULL

These	NULL
results	NULL
support	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
C/EBPa	NULL
and	NULL
PU.1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
expression	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
delineates	NULL
a	NULL
role	NULL
for	NULL
the	NULL
amino-terminal	NULL
domain	NULL
of	NULL
PU.1	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
.	NULL

DISCUSSION	NULL
The	NULL
expression	NULL
of	NULL
specific	NULL
growth	NULL
factor	NULL
receptors	NULL
is	NULL
critically	NULL
important	NULL
for	NULL
the	NULL
development	NULL
of	NULL
hematopoietic	NULL
cells	NULL
,	NULL
and	NULL
therefore	NULL
the	NULL
factors	NULL
regulating	NULL
their	NULL
expression	NULL
could	NULL
be	NULL
key	NULL
regulators	NULL
of	NULL
hematopoiesis	NULL
.	NULL

Recently	NULL
PU.1	NULL
emerged	NULL
as	NULL
a	NULL
candidate	NULL
key	NULL
regulator	NULL
as	NULL
suggested	NULL
by	NULL
gene	NULL
inactivation	NULL
and	NULL
targeting	NULL
studies	NULL
(	NULL
56	NULL
,	NULL
66	NULL
)	NULL
.	NULL

Most	NULL
myeloid	NULL
cell-specific	NULL
gene	NULL
promoters	NULL
,	NULL
including	NULL
the	NULL
M-CSF	NULL
receptor	NULL
(	NULL
70	NULL
)	NULL
,	NULL
contain	NULL
functional	NULL
PU.1	NULL
sites	NULL
.	NULL

The	NULL
role	NULL
of	NULL
members	NULL
of	NULL
the	NULL
C/EBP	NULL
family	NULL
of	NULL
tran	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

scription	NULL
factors	NULL
for	NULL
hematopoiesis	NULL
is	NULL
less	NULL
well	NULL
studied	NULL
;	NULL
only	NULL
a	NULL
few	NULL
mammalian	NULL
myeloid	NULL
target	NULL
genes	NULL
have	NULL
been	NULL
definitely	NULL
identified	NULL
so	NULL
far	NULL
(	NULL
3	NULL
,	NULL
4	NULL
,	NULL
36	NULL
,	NULL
37	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
gene	NULL
,	NULL
which	NULL
demonstrates	NULL
cell-type-specific	NULL
activity	NULL
in	NULL
myeloid	NULL
cells	NULL
,	NULL
contains	NULL
functionally	NULL
important	NULL
PU.1	NULL
and	NULL
C/EBPa	NULL
sites	NULL
.	NULL

While	NULL
PU.1	NULL
and	NULL
C/EBPa	NULL
«	NULL
are	NULL
also	NULL
expressed	NULL
outside	NULL
the	NULL
myeloid	NULL
lineage	NULL
,	NULL
myeloid	NULL
specificity	NULL
could	NULL
be	NULL
obtained	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
both	NULL
factors	NULL
.	NULL

PU.1	NULL
,	NULL
expressed	NULL
in	NULL
myeloid	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
24	NULL
)	NULL
,	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
myeloid	NULL
activity	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
,	NULL
as	NULL
is	NULL
C/EBP	NULL
,	NULL
which	NULL
within	NULL
the	NULL
hematopoietic	NULL
system	NULL
is	NULL
expressed	NULL
specifically	NULL
in	NULL
myeloid	NULL
cells	NULL
and	NULL
not	NULL
in	NULL
other	NULL
lineages	NULL
,	NULL
such	NULL
as	NULL
B	NULL
cells	NULL
(	NULL
57	NULL
,	NULL
64	NULL
)	NULL
.	NULL

In	NULL
the	NULL
region	NULL
extending	NULL
from	NULL
position	NULL
-80	NULL
to	NULL
-49	NULL
,	NULL
we	NULL
could	NULL
detect	NULL
specific	NULL
DNA	NULL
binding	NULL
in	NULL
U937	NULL
myeloid	NULL
cells	NULL
by	NULL
C/EBPa	NULL
but	NULL
not	NULL
by	NULL
other	NULL
C/EBP	NULL
proteins	NULL
.	NULL

The	NULL
mutation	NULL
of	NULL
two	NULL
bases	NULL
within	NULL
this	NULL
region	NULL
(	NULL
mutant	NULL
GM2	NULL
,	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
CCAAT	NULL
site	NULL
at	NULL
bp	NULL
-60	NULL
and	NULL
=61	NULL
)	NULL
,	NULL
which	NULL
abolished	NULL
C/EBPa	NULL
binding	NULL
,	NULL
decreased	NULL
promoter	NULL
activity	NULL
by	NULL
70	NULL
%	NULL
,	NULL
indicating	NULL
that	NULL
C/EBPa	NULL
acts	NULL
as	NULL
a	NULL
significant	NULL
positive	NULL
regulator	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
.	NULL

However	NULL
,	NULL
two	NULL
other	NULL
complexes	NULL
,	NULL
found	NULL
in	NULL
both	NULL
myeloid	NULL
and	NULL
nonmyeloid	NULL
cells	NULL
,	NULL
bind	NULL
to	NULL
this	NULL
region	NULL
(	NULL
complexes	NULL
B	NULL
and	NULL
C	NULL
;	NULL
Fig	NULL
.	NULL

11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

These	NULL
complexes	NULL
do	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
C/EBP	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
as	NULL
defined	NULL
by	NULL
the	NULL
GM2	NULL
-80	NULL
-49	NULL
AGCAATTACAGGTTTCCCAA	NULL
CTATGAAA	NULL
'	NULL
J	NULL
‘	NULL
Probe	NULL
:	NULL
CTCGTTAATGTCCAAAGGGTTAGGATACTTTA	NULL
Protein	NULL
:	NULL
-	NULL
Cos	NULL
Cos-C/EBP	NULL
a	NULL
Antibody	NULL
:	NULL
|	NULL
=	NULL
ot	NULL
oto	NULL
00	NULL
>	NULL
o=	NULL
ot	NULL
-	NULL
Oct	NULL
a	NULL
3	NULL
Competitor	NULL
:	NULL
=~	NULL
-	NULL
=	NULL
S	NULL
GM2	NULL
ets	NULL
C	NULL
Me	NULL
-	NULL
*	NULL
0	NULL
=	NULL
=	NULL
T	NULL
-	NULL
--	NULL
*~	NULL
JC	NULL
@	NULL
a	NULL
4	NULL
%	NULL
*	NULL
%	NULL
C/EBP	NULL
a	NULL
-	NULL
®	NULL
«	NULL
an	NULL
A—	NULL
B	NULL
_	NULL
C	NULL
-	NULL
#	NULL
Lane	NULL
:	NULL
10	NULL
20	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
FIG	NULL
.	NULL

12	NULL
.	NULL

Characterization	NULL
of	NULL
C/EBPa	NULL
binding	NULL
to	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
in	NULL
EMSA	NULL
.	NULL

The	NULL
end-labeled	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-49	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
mock-transfected	NULL
Cos	NULL
?	NULL

cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
from	NULL
Cos	NULL
?	NULL

cells	NULL
transfected	NULL
with	NULL
a	NULL
C/EBPa	NULL
«	NULL
expression	NULL
vector	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
11	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
:	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-80	NULL
to	NULL
-49	NULL
(	NULL
self	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
mutated	NULL
CCAAT	NULL
site	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
bp	NULL
-73	NULL
to	NULL
-54	NULL
(	NULL
GM2	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
E18	NULL
ets	NULL
consensus	NULL
site	NULL
(	NULL
for	NULL
sequence	NULL
,	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
(	NULL
23	NULL
,	NULL
66	NULL
)	NULL
;	NULL
high-affinity	NULL
C/EBP	NULL
binding	NULL
site	NULL
C	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
(	NULL
60	NULL
)	NULL
,	NULL
and	NULL
mutated	NULL
C/EBP	NULL
binding	NULL
site	NULL
Mc	NULL
(	NULL
5	NULL
``	NULL
-TGCAGAGACTAGTCTCTGCA-3	NULL
'	NULL
)	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
(	NULL
60	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
8	NULL
to	NULL
11	NULL
,	NULL
antisera	NULL
against	NULL
Oct-1	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
C/EBPa	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
C/EBPB	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
and	NULL
C/EBP3	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
.	NULL

Abbreviations	NULL
are	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

11	NULL
.	NULL

Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
3	NULL
>	NULL
2.5	NULL
2.0	NULL
1.0	NULL
7	NULL
1.0	NULL
7	NULL
0.5	NULL
Transactivation	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
-70	NULL
bp	NULL
promoter	NULL
(	NULL
fold	NULL
induction	NULL
)	NULL
0.0	NULL
=	NULL
+PU.1	NULL
+N133	NULL
+N70	NULL
+C/EBPa	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Fold	NULL
incduction	NULL
upon	NULL
addition	NULL
of	NULL
PUpECE	NULL
pT8l-lue	NULL
7	NULL
mutPU.1-T81-lue	NULL
7	NULL
PU.1-T81-lue	NULL
FIG	NULL
.	NULL

13	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
PU.1	NULL
site	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
nonmyeloid	NULL
cells	NULL
.	NULL

The	NULL
hepatoma	NULL
cell	NULL
line	NULL
HepG2	NULL
was	NULL
transfected	NULL
by	NULL
the	NULL
Ca	NULL
,	NULL
(	NULL
PO	NULL
,	NULL
)	NULL
,	NULL
precipitation	NULL
method	NULL
with	NULL
10	NULL
g	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
promoter	NULL
construct	NULL
-70GM-CSFr-luc	NULL
and	NULL
with	NULL
one	NULL
of	NULL
the	NULL
following	NULL
expression	NULL
constructs	NULL
:	NULL
none	NULL
(	NULL
bar	NULL
1	NULL
)	NULL
,	NULL
the	NULL
PU.1	NULL
expression	NULL
construct	NULL
PUpECE	NULL
(	NULL
+PU.1	NULL
)	NULL
(	NULL
bar	NULL
2	NULL
)	NULL
,	NULL
an	NULL
expression	NULL
construct	NULL
with	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
133	NULL
of	NULL
PU.1	NULL
deleted	NULL
(	NULL
+N133	NULL
)	NULL
(	NULL
bar	NULL
3	NULL
)	NULL
,	NULL
an	NULL
expression	NULL
construct	NULL
with	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
70	NULL
of	NULL
PU.1	NULL
deleted	NULL
(	NULL
+N70	NULL
)	NULL
(	NULL
bar	NULL
4	NULL
)	NULL
,	NULL
and	NULL
the	NULL
C/EBPa	NULL
expression	NULL
construct	NULL
MSV-C/EBPa	NULL
(	NULL
+C/EBPa	NULL
)	NULL
(	NULL
bar	NULL
5	NULL
)	NULL
.	NULL

Luciferase	NULL
was	NULL
measured	NULL
40	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
plasmid	NULL
CMV-hGH	NULL
.	NULL

The	NULL
data	NULL
are	NULL
the	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transactivation	NULL
of	NULL
a	NULL
minimal	NULL
TK	NULL
promoter	NULL
containing	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
PU.1	NULL
site	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
the	NULL
parental	NULL
TK-luciferase	NULL
vector	NULL
(	NULL
pT81-luc	NULL
)	NULL
,	NULL
pT81-luc	NULL
containing	NULL
a	NULL
single	NULL
PU.1	NULL
site	NULL
with	NULL
the	NULL
GM1	NULL
mutation	NULL
(	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
(	NULL
mutPU.1-T81-luc	NULL
)	NULL
,	NULL
or	NULL
pT81-lue	NULL
containing	NULL
a	NULL
single	NULL
wild-type	NULL
PU.1	NULL
binding	NULL
site	NULL
,	NULL
bp	NULL
-53	NULL
to	NULL
-36	NULL
(	NULL
PU.1-T81-luc	NULL
)	NULL
,	NULL
with	NULL
and	NULL
without	NULL
1	NULL
ag	NULL
of	NULL
PUpECE	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
activity	NULL
upon	NULL
addition	NULL
of	NULL
PUpECE	NULL
.	NULL

The	NULL
error	NULL
bars	NULL
represent	NULL
the	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
of	NULL
at	NULL
least	NULL
four	NULL
experiments	NULL
.	NULL

PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
5843	NULL
mutation	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
but	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
either	NULL
unlabeled	NULL
strand	NULL
containing	NULL
sequences	NULL
from	NULL
bp	NULL
-80	NULL
to	NULL
-70	NULL
,	NULL
suggesting	NULL
that	NULL
they	NULL
are	NULL
formed	NULL
by	NULL
single-strand-binding	NULL
proteins	NULL
which	NULL
do	NULL
not	NULL
exhibit	NULL
strand	NULL
specificity	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
region	NULL
from	NULL
bp	NULL
-70	NULL
to	NULL
-53	NULL
led	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
region	NULL
mediates	NULL
negative	NULL
as	NULL
well	NULL
as	NULL
positive	NULL
regulatory	NULL
effects	NULL
.	NULL

Competition	NULL
by	NULL
overlapping	NULL
binding	NULL
sites	NULL
of	NULL
a	NULL
non-cell-type-specific	NULL
factor	NULL
with	NULL
C/EBP	NULL
could	NULL
contribute	NULL
to	NULL
cell	NULL
type	NULL
specificity	NULL
.	NULL

An	NULL
example	NULL
for	NULL
the	NULL
model	NULL
of	NULL
competition	NULL
by	NULL
use	NULL
of	NULL
overlapping	NULL
DNA	NULL
binding	NULL
sites	NULL
between	NULL
negative	NULL
and	NULL
positive	NULL
factors	NULL
has	NULL
been	NULL
described	NULL
for	NULL
the	NULL
myeloid	NULL
cell-specific	NULL
gp91-phox	NULL
promoter	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
ubiquitously	NULL
expressed	NULL
CCAAT	NULL
displacement	NULL
protein	NULL
results	NULL
in	NULL
repression	NULL
of	NULL
the	NULL
gp91-phox	NULL
gene	NULL
in	NULL
nonmyeloid	NULL
and	NULL
early	NULL
myeloid	NULL
cells	NULL
(	NULL
61	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
studies	NULL
with	NULL
the	NULL
CCAAT	NULL
region	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
showed	NULL
that	NULL
CCAAT	NULL
displacement	NULL
protein	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
this	NULL
region	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Another	NULL
example	NULL
for	NULL
negative	NULL
regulation	NULL
is	NULL
the	NULL
conversion	NULL
of	NULL
a	NULL
transcriptional	NULL
activator	NULL
into	NULL
a	NULL
repressor	NULL
.	NULL

The	NULL
beta	NULL
interferon	NULL
gene	NULL
,	NULL
which	NULL
is	NULL
upregulated	NULL
by	NULL
viral	NULL
induction	NULL
,	NULL
is	NULL
switched	NULL
off	NULL
in	NULL
uninduced	NULL
cells	NULL
by	NULL
a	NULL
repressor	NULL
that	NULL
first	NULL
was	NULL
believed	NULL
to	NULL
block	NULL
the	NULL
binding	NULL
to	NULL
an	NULL
adjacent	NULL
NF-B	NULL
site	NULL
(	NULL
17	NULL
)	NULL
.	NULL

This	NULL
protein	NULL
has	NULL
been	NULL
recently	NULL
cloned	NULL
in	NULL
Drosophila	NULL
melanogaster	NULL
as	NULL
the	NULL
high-mobility-group	NULL
(	NULL
HMG	NULL
)	NULL
-like	NULL
protein	NULL
DSP1	NULL
,	NULL
which	NULL
can	NULL
switch	NULL
NF-kB	NULL
from	NULL
a	NULL
transcriptional	NULL
activator	NULL
to	NULL
a	NULL
repressor	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
,	NULL
further	NULL
studies	NULL
are	NULL
needed	NULL
to	NULL
identify	NULL
the	NULL
putative	NULL
negative	NULL
regulatory	NULL
factor	NULL
or	NULL
factors	NULL
,	NULL
their	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
and	NULL
their	NULL
roles	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
receptor	NULL
.	NULL

We	NULL
identified	NULL
C/EBPa	NULL
«	NULL
to	NULL
be	NULL
the	NULL
major	NULL
C/EBP	NULL
form	NULL
in	NULL
myeloid	NULL
extracts	NULL
of	NULL
U937	NULL
cells	NULL
binding	NULL
to	NULL
the	NULL
CCAAT	NULL
site	NULL
at	NULL
position	NULL
-61	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
protein	NULL
expression	NULL
data	NULL
obtained	NULL
by	NULL
immunoblots	NULL
(	NULL
57	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
expression	NULL
of	NULL
C/EBP	NULL
proteins	NULL
is	NULL
temporally	NULL
regulated	NULL
during	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
(	NULL
36	NULL
,	NULL
57	NULL
)	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
speculate	NULL
that	NULL
changes	NULL
in	NULL
the	NULL
C/EBP	NULL
expression	NULL
pattern	NULL
could	NULL
influence	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
is	NULL
upregulated	NULL
early	NULL
during	NULL
IL-3-plus-GM-CSF-induced	NULL
differentiation	NULL
of	NULL
CD34*	NULL
progenitor	NULL
cells	NULL
and	NULL
decreases	NULL
later	NULL
when	NULL
the	NULL
cells	NULL
have	NULL
undergone	NULL
further	NULL
maturation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
has	NULL
been	NULL
observed	NULL
for	NULL
protein	NULL
expression	NULL
of	NULL
C/EBPa	NULL
during	NULL
differentiation	NULL
of	NULL
the	NULL
murine	NULL
myeloid	NULL
progenitor	NULL
cell	NULL
line	NULL
32Dc13	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Other	NULL
C/EBPa	NULL
target	NULL
genes	NULL
in	NULL
myeloid	NULL
cells	NULL
include	NULL
the	NULL
receptor	NULL
for	NULL
M-CSF	NULL
(	NULL
69	NULL
,	NULL
71	NULL
)	NULL
and	NULL
G-CSF	NULL
(	NULL
62	NULL
)	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
also	NULL
regulated	NULL
by	NULL
PU.1	NULL
(	NULL
62	NULL
,	NULL
70	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
postulate	NULL
a	NULL
major	NULL
role	NULL
for	NULL
C/EBPs	NULL
in	NULL
the	NULL
specific	NULL
expression	NULL
of	NULL
myeloid	NULL
CSF	NULL
receptor	NULL
genes	NULL
.	NULL

It	NULL
will	NULL
be	NULL
the	NULL
focus	NULL
of	NULL
future	NULL
research	NULL
to	NULL
elucidate	NULL
the	NULL
role	NULL
of	NULL
the	NULL
C/EBPs	NULL
in	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
.	NULL

GM-CSF	NULL
receptor	NULL
«	NULL
is	NULL
predicted	NULL
by	NULL
these	NULL
studies	NULL
to	NULL
be	NULL
a	NULL
critical	NULL
target	NULL
for	NULL
these	NULL
transcription	NULL
factors	NULL
.	NULL

In	NULL
gel	NULL
shifts	NULL
with	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
PU.1	NULL
site	NULL
,	NULL
we	NULL
observed	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
more	NULL
slowly	NULL
migrating	NULL
complex	NULL
(	NULL
PU-SF	NULL
)	NULL
with	NULL
nuclear	NULL
extracts	NULL
of	NULL
myeloid	NULL
and	NULL
B	NULL
cells	NULL
.	NULL

This	NULL
complex	NULL
could	NULL
be	NULL
formed	NULL
by	NULL
addition	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
(	NULL
but	NULL
not	NULL
from	NULL
erythroid	NULL
cells	NULL
)	NULL
to	NULL
either	NULL
PU.1	NULL
or	NULL
the	NULL
closely	NULL
related	NULL
ets	NULL
family	NULL
member	NULL
Spi-B	NULL
(	NULL
51	NULL
)	NULL
.	NULL

We	NULL
have	NULL
not	NULL
observed	NULL
formation	NULL
of	NULL
the	NULL
PU-SF	NULL
complex	NULL
when	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
is	NULL
replaced	NULL
by	NULL
a	NULL
C/EBP	NULL
binding	NULL
site	NULL
,	NULL
even	NULL
when	NULL
the	NULL
oligonucleotide	NULL
contains	NULL
single-stranded	NULL
ends	NULL
(	NULL
62a	NULL
)	NULL
.	NULL

Comparative	NULL
analysis	NULL
with	NULL
studies	NULL
of	NULL
other	NULL
myeloid	NULL
PU.1	NULL
sites	NULL
indicates	NULL
that	NULL
this	NULL
complex	NULL
is	NULL
not	NULL
unique	NULL
for	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
PU.1	NULL
site	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
PU-SF	NULL
complex	NULL
is	NULL
novel	NULL
and	NULL
does	NULL
not	NULL
involve	NULL
proteins	NULL
which	NULL
have	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
PU.1	NULL
:	NULL
TBP	NULL
(	NULL
19	NULL
)	NULL
,	NULL
RB	NULL
protein	NULL
(	NULL
19	NULL
)	NULL
,	NULL
5844	NULL
HOHAUS	NULL
ET	NULL
AL	NULL
.	NULL

or	NULL
NF-EMS	NULL
(	NULL
11	NULL
,	NULL
46	NULL
,	NULL
47	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
promoter	NULL
was	NULL
supported	NULL
by	NULL
transactivation	NULL
of	NULL
the	NULL
promoter	NULL
by	NULL
full-length	NULL
PU.1	NULL
but	NULL
not	NULL
by	NULL
amino-terminally	NULL
truncated	NULL
forms	NULL
of	NULL
the	NULL
PU.1	NULL
protein	NULL
which	NULL
fail	NULL
to	NULL
form	NULL
PU-SF	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
,	NULL
the	NULL
magnitude	NULL
of	NULL
transactivation	NULL
of	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
by	NULL
PU.1	NULL
was	NULL
only	NULL
twofold	NULL
.	NULL

However	NULL
,	NULL
the	NULL
extent	NULL
of	NULL
transactivation	NULL
does	NULL
not	NULL
necessarily	NULL
reflect	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
,	NULL
particularly	NULL
when	NULL
the	NULL
transactivation	NULL
studies	NULL
are	NULL
performed	NULL
with	NULL
the	NULL
native	NULL
promoter	NULL
.	NULL

Another	NULL
promoter	NULL
with	NULL
a	NULL
functionally	NULL
critical	NULL
PU.1	NULL
site	NULL
which	NULL
is	NULL
only	NULL
moderately	NULL
transactivated	NULL
(	NULL
two-	NULL
to	NULL
threefold	NULL
)	NULL
by	NULL
PU.1	NULL
is	NULL
CD11b	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Experiments	NULL
performed	NULL
with	NULL
the	NULL
PU.1	NULL
site	NULL
placed	NULL
upstream	NULL
of	NULL
a	NULL
heterologous	NULL
promoter	NULL
show	NULL
that	NULL
the	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
PU.1	NULL
site	NULL
could	NULL
be	NULL
transactivated	NULL
an	NULL
average	NULL
of	NULL
sixfold	NULL
.	NULL

EMSA	NULL
studies	NULL
indicate	NULL
that	NULL
DNA	NULL
interaction	NULL
with	NULL
PU-SF	NULL
requires	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
PU.1	NULL
,	NULL
a	NULL
single-stranded	NULL
region	NULL
of	NULL
DNA	NULL
containing	NULL
pyrimidines	NULL
proximal	NULL
to	NULL
a	NULL
PU.1	NULL
binding	NULL
site	NULL
.	NULL

Although	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
amino-truncated	NULL
forms	NULL
of	NULL
PU.1	NULL
protein	NULL
to	NULL
transactivate	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
PU-SF	NULL
has	NULL
a	NULL
functional	NULL
role	NULL
in	NULL
this	NULL
promoter	NULL
,	NULL
we	NULL
can	NULL
not	NULL
yet	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
those	NULL
regions	NULL
of	NULL
the	NULL
PU.1	NULL
protein	NULL
are	NULL
critical	NULL
for	NULL
an	NULL
unrelated	NULL
activating	NULL
function	NULL
.	NULL

Additional	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
establish	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
.	NULL

There	NULL
is	NULL
substantial	NULL
evidence	NULL
for	NULL
the	NULL
role	NULL
of	NULL
single-stranded	NULL
binding	NULL
factors	NULL
in	NULL
other	NULL
promoters	NULL
,	NULL
both	NULL
as	NULL
activators	NULL
and	NULL
repressors	NULL
(	NULL
31	NULL
,	NULL
65	NULL
,	NULL
67	NULL
)	NULL
.	NULL

In	NULL
the	NULL
simplest	NULL
scenario	NULL
,	NULL
two	NULL
factors	NULL
which	NULL
bind	NULL
to	NULL
opposite	NULL
strands	NULL
of	NULL
the	NULL
same	NULL
site	NULL
,	NULL
VACssBF1	NULL
and	NULL
VACssBF2	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
repression	NULL
of	NULL
the	NULL
vascular	NULL
smooth	NULL
muscle	NULL
«	NULL
-actin	NULL
gene	NULL
promoter	NULL
,	NULL
perhaps	NULL
by	NULL
stabilizing	NULL
single-stranded	NULL
structure	NULL
and	NULL
preventing	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
positive	NULL
regulatory	NULL
factor	NULL
which	NULL
requires	NULL
double-stranded	NULL
DNA	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Other	NULL
theories	NULL
include	NULL
stabilization	NULL
of	NULL
single-stranded	NULL
regions	NULL
that	NULL
serve	NULL
to	NULL
relieve	NULL
torsional	NULL
stress	NULL
induced	NULL
by	NULL
transcription	NULL
or	NULL
provide	NULL
a	NULL
flexible	NULL
joint	NULL
to	NULL
facilitate	NULL
DNA-bound	NULL
protein-protein	NULL
interactions	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Wang	NULL
et	NULL
al	NULL
.	NULL

postulate	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
serum	NULL
response	NULL
factor	NULL
to	NULL
the	NULL
serum	NULL
response	NULL
element	NULL
of	NULL
the	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
A-chain	NULL
promoter	NULL
induces	NULL
DNA	NULL
bending	NULL
and	NULL
strain	NULL
which	NULL
can	NULL
be	NULL
released	NULL
by	NULL
strand	NULL
separation	NULL
and	NULL
that	NULL
this	NULL
altered	NULL
conformation	NULL
is	NULL
stabilized	NULL
by	NULL
a	NULL
second	NULL
,	NULL
single-stranded	NULL
binding	NULL
factor	NULL
,	NULL
SSBF	NULL
(	NULL
67	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
interaction	NULL
between	NULL
PU.1	NULL
and	NULL
PU-SF	NULL
provides	NULL
a	NULL
similar	NULL
function	NULL
.	NULL

For	NULL
example	NULL
,	NULL
PU.1	NULL
might	NULL
recruit	NULL
PU-SF	NULL
to	NULL
stabilize	NULL
an	NULL
alternative	NULL
DNA	NULL
conformation	NULL
.	NULL

The	NULL
domain	NULL
of	NULL
the	NULL
PU.1	NULL
protein	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
is	NULL
located	NULL
in	NULL
the	NULL
amino	NULL
terminus	NULL
between	NULL
amino	NULL
acids	NULL
32	NULL
and	NULL
70	NULL
.	NULL

Other	NULL
PU.1	NULL
targets	NULL
in	NULL
which	NULL
the	NULL
amino-terminal	NULL
region	NULL
of	NULL
the	NULL
protein	NULL
is	NULL
essential	NULL
include	NULL
the	NULL
J	NULL
chain	NULL
gene	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
59	NULL
)	NULL
and	NULL
the	NULL
IL-18	NULL
promoter	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Further	NULL
localization	NULL
of	NULL
the	NULL
domain	NULL
in	NULL
the	NULL
PU.1	NULL
protein	NULL
responsible	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
PU-SF	NULL
and	NULL
identification	NULL
of	NULL
the	NULL
factor	NULL
involved	NULL
in	NULL
PU-SF	NULL
formation	NULL
will	NULL
help	NULL
to	NULL
define	NULL
the	NULL
specific	NULL
role	NULL
of	NULL
PU-SF	NULL
in	NULL
GM-CSF	NULL
receptor	NULL
«	NULL
expression	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Richard	NULL
Maki	NULL
,	NULL
David	NULL
Kabat	NULL
,	NULL
Philip	NULL
Auron	NULL
,	NULL
Myung	NULL
Shin	NULL
,	NULL
and	NULL
Marian	NULL
Koshland	NULL
for	NULL
PU.1	NULL
antisera	NULL
and	NULL
PU.1	NULL
expression	NULL
vectors	NULL
;	NULL
Wen-Chen	NULL
Yeh	NULL
,	NULL
Steven	NULL
McKnight	NULL
,	NULL
and	NULL
Alan	NULL
Friedman	NULL
for	NULL
C/EBP	NULL
antisera	NULL
and	NULL
C/EBP	NULL
expression	NULL
vectors	NULL
;	NULL
Deborah	NULL
Galson	NULL
for	NULL
nuclear	NULL
extracts	NULL
from	NULL
MEL	NULL
and	NULL
CBS	NULL
cells	NULL
;	NULL
Stefanie	NULL
Timmerman	NULL
and	NULL
Bill	NULL
Kae-lin	NULL
for	NULL
RB	NULL
antisera	NULL
and	NULL
U87	NULL
nuclear	NULL
extracts	NULL
;	NULL
Tony	NULL
Imbalzanl	NULL
and	NULL
Robert	NULL
Kingston	NULL
for	NULL
HeLa	NULL
cell	NULL
extracts	NULL
;	NULL
Nouria	NULL
Hernandez	NULL
for	NULL
TBP	NULL
antisera	NULL
;	NULL
Arnold	NULL
Berk	NULL
for	NULL
TBP	NULL
expression	NULL
vectors	NULL
;	NULL
Nadia	NULL
Carlesso	NULL
and	NULL
James	NULL
Griffin	NULL
for	NULL
GM-CSF	NULL
receptor	NULL
a	NULL
cDNA	NULL
;	NULL
Chris	NULL
Hetherington	NULL
for	NULL
Cos	NULL
cell	NULL
nuclear	NULL
extracts	NULL
;	NULL
David	NULL
Gonzalez	NULL
for	NULL
synthesis	NULL
of	NULL
oligonucle-	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

otides	NULL
;	NULL
and	NULL
Dong-Er	NULL
Zhang	NULL
,	NULL
Hui-Min	NULL
Chen	NULL
,	NULL
Hanna	NULL
Radomska	NULL
,	NULL
Laura	NULL
Smith	NULL
,	NULL
and	NULL
Phil	NULL
Auron	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
suggestions	NULL
.	NULL

S.H	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Mildred-Scheel-Stiftung	NULL
,	NULL
Deutsche	NULL
Krebshilfe	NULL
.	NULL

D.G.T	NULL
.	NULL

is	NULL
a	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

Z.S	NULL
.	NULL

is	NULL
an	NULL
Edward	NULL
Livingston	NULL
Trudeau	NULL
Scholar	NULL
of	NULL
the	NULL
American	NULL
Lung	NULL
Association	NULL
and	NULL
also	NULL
acknowledges	NULL
the	NULL
generous	NULL
support	NULL
of	NULL
Steven	NULL
J.	NULL
Ackerman	NULL
during	NULL
the	NULL
course	NULL
of	NULL
these	NULL
studies	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grants	NULL
CA41456	NULL
and	NULL
DK48660	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ahne	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
W.	NULL
H.	NULL
Stratling	NULL
.	NULL

1994	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
myeloid-specific	NULL
enhancer	NULL
of	NULL
the	NULL
chicken	NULL
lysozyme	NULL
gene-major	NULL
role	NULL
for	NULL
an	NULL
Ets	NULL
transcription	NULL
factor-binding	NULL
site	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:17794-17801	NULL
.	NULL

2	NULL
.	NULL

Arcari	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
Martinelli	NULL
,	NULL
and	NULL
F.	NULL
Salvatore	NULL
.	NULL

1984	NULL
.	NULL

The	NULL
complete	NULL
sequence	NULL
of	NULL
a	NULL
full	NULL
length	NULL
cDNA	NULL
for	NULL
human	NULL
liver	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
:	NULL
evidence	NULL
for	NULL
multiple	NULL
mRNA	NULL
species	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

12:9179-9189	NULL
.	NULL

3	NULL
.	NULL

Bretz	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
S.	NULL
C.	NULL
Williams	NULL
,	NULL
M.	NULL
Baer	NULL
,	NULL
P.	NULL
F.	NULL
Johnson	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Schwartz	NULL
.	NULL

1994	NULL
.	NULL

C/EBP-related	NULL
protein	NULL
2	NULL
confers	NULL
lipopolysaccharide-inducible	NULL
expression	NULL
of	NULL
interleukin	NULL
6	NULL
and	NULL
monocyte	NULL
chemoattractant	NULL
protein	NULL
1	NULL
to	NULL
a	NULL
lymphoblastic	NULL
cell	NULL
line	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:7306-7310	NULL
.	NULL

4	NULL
.	NULL

Burk	NULL
,	NULL
O.	NULL
,	NULL
S.	NULL
Mink	NULL
,	NULL
M.	NULL
Ringwald	NULL
,	NULL
and	NULL
K.	NULL
H.	NULL
Klempnauner	NULL
.	NULL

1993	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
the	NULL
chicken	NULL
mim-1	NULL
gene	NULL
by	NULL
v-myb	NULL
and	NULL
C/EBP	NULL
transcription	NULL
factors	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:2027-2038	NULL
.	NULL

5	NULL
.	NULL

Cao	NULL
,	NULL
Z.	NULL
,	NULL
R.	NULL
M.	NULL
Umek	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1991	NULL
.	NULL

Regulated	NULL
expression	NULL
of	NULL
three	NULL
C/EBP	NULL
isoforms	NULL
during	NULL
adipose	NULL
conversion	NULL
of	NULL
3T3-L1	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

51538-1552	NULL
.	NULL

6	NULL
.	NULL

Chen	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
P.	NULL
Zhang	NULL
,	NULL
M.	NULL
T.	NULL
Voso	NULL
,	NULL
S.	NULL
Hohaus	NULL
,	NULL
D.	NULL
A.	NULL
Gonzalez	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
D.	NULL
E.	NULL
Zhang	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1995	NULL
.	NULL

Neutrophils	NULL
and	NULL
monocytes	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
PU.1	NULL
(	NULL
Spi-1	NULL
)	NULL
but	NULL
not	NULL
Spi-B	NULL
.	NULL

Blood	NULL
85:2918-2928	NULL
.	NULL

7	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

8	NULL
.	NULL

DiPersio	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
Billing	NULL
,	NULL
S.	NULL
Kaufman	NULL
,	NULL
P.	NULL
Eghtesady	NULL
,	NULL
R.	NULL
E.	NULL
Williams	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Gasson	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:1834-1841	NULL
.	NULL

9	NULL
.	NULL

Duncan	NULL
,	NULL
R.	NULL
,	NULL
L.	NULL
Bazar	NULL
,	NULL
G.	NULL
Michelotti	NULL
,	NULL
T.	NULL
Tomonaga	NULL
,	NULL
H.	NULL
Krutzsch	NULL
,	NULL
M.	NULL
Avigan	NULL
,	NULL
and	NULL
D.	NULL
Levens	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
sequence-specific	NULL
,	NULL
single-strand	NULL
binding	NULL
protein	NULL
activates	NULL
the	NULL
far	NULL
upstream	NULL
element	NULL
of	NULL
c-myc	NULL
and	NULL
defines	NULL
a	NULL
new	NULL
DNA-binding	NULL
motif	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:465-480	NULL
.	NULL

10	NULL
.	NULL

Eichbaum	NULL
,	NULL
Q.	NULL
G.	NULL
,	NULL
R.	NULL
Iyer	NULL
,	NULL
D.	NULL
P.	NULL
Raveh	NULL
,	NULL
C.	NULL
Mathieu	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Ezekowitz	NULL
.	NULL

1994	NULL
.	NULL

Restriction	NULL
of	NULL
interferon	NULL
gamma	NULL
responsiveness	NULL
and	NULL
basal	NULL
expression	NULL
of	NULL
the	NULL
myeloid	NULL
human	NULL
FegammaR1b	NULL
gene	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
functional	NULL
PU.1	NULL
site	NULL
and	NULL
a	NULL
transcription	NULL
initiator	NULL
consensus	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1985-1996	NULL
.	NULL

11	NULL
.	NULL

Eisenbeis	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
and	NULL
U.	NULL
Storb	NULL
.	NULL

1993	NULL
.	NULL

PU.1	NULL
is	NULL
a	NULL
component	NULL
of	NULL
a	NULL
multiprotein	NULL
complex	NULL
which	NULL
binds	NULL
an	NULL
essential	NULL
site	NULL
in	NULL
the	NULL
murine	NULL
immunoglobulin	NULL
lambda-2-4	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:6452-6461	NULL
.	NULL

12	NULL
.	NULL

Emanuel	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
L.	NULL
J.	NULL
Baes	NULL
,	NULL
S.	NULL
W.	NULL
Zhu	NULL
,	NULL
R.	NULL
P.	NULL
Castleberry	NULL
,	NULL
R.	NULL
J.	NULL
Gualtieri	NULL
,	NULL
and	NULL
K.	NULL
S.	NULL
Zuckerman	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
monocyte-derived	NULL
hemopoietic	NULL
growth	NULL
factors	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
myeloproliferation	NULL
in	NULL
juvenile	NULL
chronic	NULL
myeloge-nous	NULL
leukemia	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

19:1017-1024	NULL
.	NULL

13	NULL
.	NULL

Feinman	NULL
,	NULL
R.	NULL
,	NULL
W.	NULL
Q.	NULL
Qiu	NULL
,	NULL
R.	NULL
N.	NULL
Pearse	NULL
,	NULL
B.	NULL
S.	NULL
Nikolajezyk	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
M.	NULL
Sheffery	NULL
,	NULL
and	NULL
J.	NULL
V.	NULL
Ravetch	NULL
.	NULL

1994	NULL
.	NULL

PU.1	NULL
and	NULL
an	NULL
HLH	NULL
family	NULL
member	NULL
contribute	NULL
to	NULL
the	NULL
myeloid-specific	NULL
transcription	NULL
of	NULL
the	NULL
Fe-gammaRIIIA	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:3852-3860	NULL
.	NULL

14	NULL
.	NULL

Friedman	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
W.	NULL
H.	NULL
Landschulz	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1989	NULL
.	NULL

CCAAT/	NULL
enhancer	NULL
binding	NULL
protein	NULL
activates	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
serum	NULL
albumin	NULL
gene	NULL
in	NULL
cultured	NULL
hepatoma	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1314-1322	NULL
.	NULL

15	NULL
.	NULL

Gearing	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

King	NULL
,	NULL
N.	NULL
M.	NULL
Gough	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Nicola	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
cloning	NULL
of	NULL
a	NULL
receptor	NULL
for	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:3667-3676	NULL
.	NULL

16	NULL
.	NULL

Goebl	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
F.	NULL
Moreau-Gachelin	NULL
,	NULL
D.	NULL
Ray	NULL
,	NULL
P.	NULL
Tambourin	NULL
,	NULL
A.	NULL
Tavitian	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
PU.1	NULL
transcription	NULL
factor	NULL
is	NULL
the	NULL
product	NULL
of	NULL
the	NULL
putative	NULL
oncogene	NULL
Spi-1	NULL
.	NULL

Cell	NULL
61:1165-1166	NULL
.	NULL

17	NULL
.	NULL

Goodbourn	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1988	NULL
.	NULL

Overlapping	NULL
positive	NULL
and	NULL
negative	NULL
regulatory	NULL
domains	NULL
of	NULL
the	NULL
human	NULL
beta-interferon	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:1447-1451	NULL
.	NULL

18	NULL
.	NULL

Haas	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
M.	NULL
Strobel	NULL
,	NULL
A.	NULL
Leutz	NULL
,	NULL
P.	NULL
Wendelgass	NULL
,	NULL
C.	NULL
Muller	NULL
,	NULL
E.	NULL
Sterneck	NULL
,	NULL
G.	NULL
Ricthmuller	NULL
,	NULL
and	NULL
H.	NULL
W.	NULL
Ziegler-Heitbrock	NULL
.	NULL

1992	NULL
.	NULL

Constitutive	NULL
monocyte-restricted	NULL
activity	NULL
of	NULL
NF-M	NULL
,	NULL
a	NULL
nuclear	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
C/EBP	NULL
motif	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:237-243	NULL
.	NULL

19	NULL
.	NULL

Hagemeier	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
J.	NULL
Bannister	NULL
,	NULL
A.	NULL
Cook	NULL
,	NULL
and	NULL
T.	NULL
Kouzarides	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
activation	NULL
domain	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
protein	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
TFIID	NULL
in	NULL
vitro	NULL
:	NULL
RB	NULL
shows	NULL
sequence	NULL
similarity	NULL
to	NULL
TFIID	NULL
and	NULL
TFIIB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:1580-1584	NULL
.	NULL

20	NULL
.	NULL

Johnson	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1989	NULL
.	NULL

Eukaryotic	NULL
transcriptional	NULL
regulatory	NULL
proteins	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

58:799-839	NULL
.	NULL

21	NULL
.	NULL

Jubinsky	NULL
,	NULL
P.	NULL
T.	NULL
,	NULL
A.	NULL
S.	NULL
Laurie	NULL
,	NULL
D.	NULL
G.	NULL
Nathan	NULL
,	NULL
J.	NULL
Yetzaldepe	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Sieff	NULL
.	NULL

1994	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
the	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
alpha	NULL
subunit	NULL
.	NULL

Blood	NULL
84:4174-4185	NULL
.	NULL

22	NULL
.	NULL

Katz	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Kowenzleutz	NULL
,	NULL
C.	NULL
Muller	NULL
,	NULL
K.	NULL
Meese	NULL
,	NULL
S.	NULL
A.	NULL
Ness	NULL
,	NULL
and	NULL
A.	NULL
Leutz	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NF-M	NULL
transcription	NULL
factor	NULL
is	NULL
related	NULL
to	NULL
C/EBP-beta	NULL
and	NULL
plays	NULL
a	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47.	NULL
role	NULL
in	NULL
signal	NULL
transduction	NULL
,	NULL
differentiation	NULL
and	NULL
leukemogenesis	NULL
of	NULL
avian	NULL
my-clomonocytic	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:1321-1332	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
T.	NULL
Papayannopoulou	NULL
,	NULL
J.	NULL
Moore	NULL
,	NULL
and	NULL
R.	NULL
Hromas	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
ets	NULL
oncogene	NULL
family	NULL
member	NULL
,	NULL
fli-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:5769-5773	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

Kominato	NULL
,	NULL
Y.	NULL
,	NULL
D.	NULL
L.	NULL
Galson	NULL
,	NULL
W.	NULL
R.	NULL
Waterman	NULL
,	NULL
A.	NULL
C.	NULL
Webb	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Auron	NULL
.	NULL

1995	NULL
.	NULL

Monocyte-specific	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
prointerleukin	NULL
16	NULL
gene	NULL
(	NULL
IL1B	NULL
)	NULL
is	NULL
dependent	NULL
upon	NULL
promoter	NULL
sequences	NULL
which	NULL
bind	NULL
the	NULL
hematopoietic	NULL
transcription	NULL
factor	NULL
Spi-1/PU.1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:58-68	NULL
.	NULL

Kuipers	NULL
,	NULL
O.	NULL
P.	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

Boot	NULL
,	NULL
and	NULL
W.	NULL
M.	NULL
de	NULL
Vos	NULL
.	NULL

1991	NULL
.	NULL

Improved	NULL
site-directed	NULL
mutagenesis	NULL
method	NULL
using	NULL
PCR	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:4558	NULL
.	NULL

Lehming	NULL
,	NULL
N.	NULL
,	NULL
D.	NULL
Thanos	NULL
,	NULL
J.	NULL
M.	NULL
Brickman	NULL
,	NULL
J.	NULL
Ma	NULL
,	NULL
T.	NULL
Maniatis	NULL
,	NULL
and	NULL
M.	NULL
Ptashne	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
HMG-like	NULL
protein	NULL
that	NULL
can	NULL
switch	NULL
a	NULL
transcriptional	NULL
activator	NULL
to	NULL
a	NULL
repressor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
371:175-179	NULL
.	NULL

Lin	NULL
,	NULL
F.	NULL
T.	NULL
,	NULL
and	NULL
M.	NULL
D.	NULL
Lane	NULL
.	NULL

1994	NULL
.	NULL

CCAAT/enhancer	NULL
binding	NULL
protein	NULL
«	NULL
is	NULL
sufficient	NULL
to	NULL
initiate	NULL
the	NULL
3T3-L1	NULL
adipocyte	NULL
differentiation	NULL
program	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:8757-8761	NULL
.	NULL

Maury	NULL
,	NULL
W.	NULL
1994	NULL
.	NULL

Monocyte	NULL
maturation	NULL
controls	NULL
expression	NULL
of	NULL
equine	NULL
infectious	NULL
anemia	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:6270-6279	NULL
.	NULL

Maxam	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1977	NULL
.	NULL

A	NULL
new	NULL
method	NULL
for	NULL
sequencing	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
74:560-564	NULL
.	NULL

Michelotti	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
T.	NULL
Tomonaga	NULL
,	NULL
H.	NULL
Krutzsch	NULL
,	NULL
and	NULL
D.	NULL
Levens	NULL
.	NULL

1995	NULL
.	NULL

Cellular	NULL
nucleic	NULL
acid	NULL
binding	NULL
protein	NULL
regulates	NULL
the	NULL
CT	NULL
element	NULL
of	NULL
the	NULL
human	NULL
c-myc	NULL
protooncogene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:9494-9499	NULL
.	NULL

Miyajima	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
L.	NULL
F.	NULL
Mui	NULL
,	NULL
T.	NULL
Ogorochi	NULL
,	NULL
and	NULL
K.	NULL
Sakamaki	NULL
.	NULL

1993	NULL
.	NULL

Receptors	NULL
for	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
interleukin-3	NULL
,	NULL
and	NULL
in-terleukin-5	NULL
.	NULL

Blood	NULL
82:1960-1974	NULL
.	NULL

Moreau-Gachelin	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
Tavitian	NULL
,	NULL
and	NULL
P.	NULL
Tambourin	NULL
.	NULL

1988	NULL
.	NULL

Spi-1	NULL
is	NULL
a	NULL
putative	NULL
oncogene	NULL
in	NULL
virally	NULL
induced	NULL
murine	NULL
erythroleukaemias	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
331:277-280	NULL
.	NULL

Moulton	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
K.	NULL
Semple	NULL
,	NULL
H.	NULL
Wu	NULL
,	NULL
and	NULL
C.	NULL
K.	NULL
Glass	NULL
.	NULL

1994	NULL
.	NULL

Cell-specific	NULL
expression	NULL
of	NULL
the	NULL
macrophage	NULL
scavenger	NULL
receptor	NULL
gene	NULL
is	NULL
dependent	NULL
on	NULL
PU.1	NULL
and	NULL
a	NULL
composite	NULL
AP-1/ets	NULL
motif	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:4408-4418	NULL
.	NULL

Nakagawa	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Kosugi	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
K.	NULL
Arai	NULL
,	NULL
and	NULL
T.	NULL
Yokota	NULL
.	NULL

1994	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
alpha	NULL
subunit	NULL
of	NULL
the	NULL
human	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
receptor-implications	NULL
for	NULL
the	NULL
evolution	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:10905-10912	NULL
.	NULL

Natsuka	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Akira	NULL
,	NULL
Y.	NULL
Nishio	NULL
,	NULL
S.	NULL
Hashimoto	NULL
,	NULL
T.	NULL
Sugita	NULL
,	NULL
H.	NULL
Isshiki	NULL
,	NULL
and	NULL
T.	NULL
Kishimoto	NULL
.	NULL

1992	NULL
.	NULL

Macrophage	NULL
differentiation-specific	NULL
expression	NULL
of	NULL
NF-IL6	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
for	NULL
interleukin-6	NULL
.	NULL

Blood	NULL
79:460-466	NULL
.	NULL

Ness	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
E.	NULL
Kowenzleutz	NULL
,	NULL
T.	NULL
Casini	NULL
,	NULL
T.	NULL
Graf	NULL
,	NULL
and	NULL
A.	NULL
Leutz	NULL
.	NULL

1993	NULL
.	NULL

Myb	NULL
and	NULL
NF-M-combinatorial	NULL
activators	NULL
of	NULL
myeloid	NULL
genes	NULL
in	NULL
heterologous	NULL
cell	NULL
types	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:749-759	NULL
.	NULL

Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
1988	NULL
.	NULL

Luciferase	NULL
reporter	NULL
gene	NULL
vectors	NULL
for	NULL
analysis	NULL
of	NULL
promoters	NULL
and	NULL
enhancers	NULL
.	NULL

BioTechniques	NULL
6:454-458	NULL
.	NULL

Nuchprayoon	NULL
,	NULL
L	NULL
,	NULL
S.	NULL
Meyers	NULL
,	NULL
L.	NULL
M.	NULL
Scott	NULL
,	NULL
J.	NULL
Suzow	NULL
,	NULL
S.	NULL
Hiebert	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Friedman	NULL
.	NULL

1994	NULL
.	NULL

PEBP2/CBEF	NULL
,	NULL
the	NULL
murine	NULL
homolog	NULL
of	NULL
the	NULL
human	NULL
myeloid	NULL
AML1	NULL
and	NULL
PEBP28/CBFB	NULL
proto-oncoproteins	NULL
,	NULL
regulates	NULL
the	NULL
murine	NULL
myelo-peroxidase	NULL
and	NULL
neutrophil	NULL
elastase	NULL
genes	NULL
in	NULL
immature	NULL
myeloid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:5558-5568	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
T.	NULL
C.	NULL
Burn	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1991	NULL
.	NULL

Optimization	NULL
of	NULL
transient	NULL
transfection	NULL
into	NULL
human	NULL
myeloid	NULL
cell	NULL
lines	NULL
using	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

19:1038-1041	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
R.	NULL
J.	NULL
Scheibe	NULL
,	NULL
D.	NULL
E.	NULL
Zhang	NULL
,	NULL
H.	NULL
M.	NULL
Chen	NULL
,	NULL
D.	NULL
L.	NULL
Galson	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
proto-oncogene	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:5014-5020	NULL
.	NULL

Park	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
D.	NULL
Friend	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Urdal	NULL
.	NULL

1986	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
cell	NULL
surface	NULL
receptor	NULL
for	NULL
human	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

164:251-262	NULL
.	NULL

Park	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
P.	NULL
E.	NULL
Waldron	NULL
,	NULL
D.	NULL
Friend	NULL
,	NULL
H.	NULL
M.	NULL
Sassenfeld	NULL
,	NULL
V.	NULL
Price	NULL
,	NULL
D.	NULL
Anderson	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
R.	NULL
G.	NULL
Andrews	NULL
,	NULL
I	NULL
D.	NULL
Bernstein	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Urdal	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-3	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
G-CSF	NULL
receptor	NULL
expression	NULL
on	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
leukemia	NULL
cells	NULL
:	NULL
receptor	NULL
heterogeneity	NULL
and	NULL
relationship	NULL
to	NULL
growth	NULL
factor	NULL
responsiveness	NULL
.	NULL

Blood	NULL
74:56-65	NULL
.	NULL

Paul	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Schuetze	NULL
,	NULL
S.	NULL
L.	NULL
Kozak	NULL
,	NULL
C.	NULL
A.	NULL
Kozak	NULL
,	NULL
and	NULL
D.	NULL
Kabat	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
Sfpi-1	NULL
proviral	NULL
integration	NULL
site	NULL
of	NULL
Friend	NULL
erythroleukemia	NULL
encodes	NULL
the	NULL
ets-related	NULL
transcription	NULL
factor	NULL
PU.1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:464-467	NULL
.	NULL

Perez	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Coeffier	NULL
,	NULL
F.	NULL
Moreau-Gachelin	NULL
,	NULL
J.	NULL
Wietzerbin	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Benech	NULL
.	NULL

1994	NULL
.	NULL

Involvement	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
PU.1/Spi-1	NULL
in	NULL
myeloid	NULL
cell-restricted	NULL
expression	NULL
of	NULL
an	NULL
interferon-inducible	NULL
gene	NULL
encoding	NULL
the	NULL
human	NULL
high-affinity	NULL
Fc	NULL
gamma	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:5023-5031	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1992	NULL
.	NULL

PU.1	NULL
recruits	NULL
a	NULL
second	NULL
nuclear	NULL
factor	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
x	NULL
3	NULL
'	NULL
enhancer	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:368-378	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1993	NULL
.	NULL

Effect	NULL
of	NULL
PU.1	NULL
phosphorylation	NULL
on	NULL
interaction	NULL
with	NULL
NF-EMS	NULL
and	NULL
transcriptional	NULL
activation	NULL
.	NULL

Science	NULL
259:1622-1625	NULL
.	NULL

PU.1	NULL
AND	NULL
C/EBPa	NULL
«	NULL
REGULATE	NULL
GM-CSF	NULL
RECEPTOR	NULL
«	NULL
GENE	NULL
48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

5845	NULL
Pope	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
A.	NULL
Leutz	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Ness	NULL
.	NULL

1994	NULL
.	NULL

C/EBP	NULL
beta	NULL
regulation	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
gene	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:1449-1455	NULL
.	NULL

Raines	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
L.	NULL
Liu	NULL
,	NULL
S.	NULL
G.	NULL
Quan	NULL
,	NULL
V.	NULL
Joe	NULL
,	NULL
J.	NULL
F.	NULL
DiPersio	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Golde	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
and	NULL
molecular	NULL
cloning	NULL
of	NULL
a	NULL
soluble	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:8203-8207	NULL
.	NULL

Rapoport	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
C.	NULL
N.	NULL
Abboud	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
DiPersio	NULL
.	NULL

1992	NULL
.	NULL

Granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
:	NULL
receptor	NULL
biology	NULL
,	NULL
signal	NULL
transduction	NULL
,	NULL
and	NULL
neutrophil	NULL
activation	NULL
.	NULL

Blood	NULL
Rev	NULL
.	NULL

6:43-57	NULL
.	NULL

Ray	NULL
,	NULL
D.	NULL
,	NULL
R.	NULL
Bosselut	NULL
,	NULL
J.	NULL
Ghysdael	NULL
,	NULL
M.	NULL
G.	NULL
Mattei	NULL
,	NULL
A.	NULL
Tavitian	NULL
,	NULL
and	NULL
F.	NULL
Moreau-Gachelin	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
Spi-B	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
related	NULL
to	NULL
the	NULL
putative	NULL
oncoprotein	NULL
Spi-1/PU.1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4297-4304	NULL
.	NULL

Rosmarin	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
D.	NULL
Caprio	NULL
,	NULL
R.	NULL
Levy	NULL
,	NULL
and	NULL
C.	NULL
Simkevich	NULL
.	NULL

1995	NULL
.	NULL

CD18	NULL
(	NULL
B	NULL
;	NULL
leukocyte	NULL
integrin	NULL
)	NULL
promoter	NULL
requires	NULL
PU.1	NULL
transcription	NULL
factor	NULL
for	NULL
myeloid	NULL
activity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:801-805	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Schuetze	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Paul	NULL
,	NULL
B.	NULL
C.	NULL
Gliniak	NULL
,	NULL
and	NULL
D.	NULL
Kabat	NULL
.	NULL

1992	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
PU.1	NULL
transcription	NULL
factor	NULL
in	NULL
controlling	NULL
differentiation	NULL
of	NULL
Friend	NULL
erythroleukemia	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:2967-2975	NULL
.	NULL

Schuetze	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
E.	NULL
Stenberg	NULL
,	NULL
and	NULL
D.	NULL
Kabat	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Ets-related	NULL
transcription	NULL
factor	NULL
PU.1	NULL
immortalizes	NULL
erythroblasts	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:5670-5678	NULL
.	NULL

Scott	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
M.	NULL
C.	NULL
Simon	NULL
,	NULL
J.	NULL
Anastai	NULL
,	NULL
and	NULL
H.	NULL
Singh	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
multiple	NULL
hematopoietic	NULL
lin-cages	NULL
.	NULL

Science	NULL
265:1573-1577	NULL
.	NULL

Scott	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
C.	NULL
I.	NULL
Civin	NULL
,	NULL
P.	NULL
Rorth	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Friedman	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
temporal	NULL
expression	NULL
pattern	NULL
of	NULL
three	NULL
C/EBP	NULL
family	NULL
members	NULL
in	NULL
differentiating	NULL
myelomonocytic	NULL
cells	NULL
.	NULL

Blood	NULL
80:1725-1735	NULL
.	NULL

Shibuya	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Mak	NULL
.	NULL

1983	NULL
.	NULL

Isolation	NULL
and	NULL
induction	NULL
of	NULL
erythroleuke-mic	NULL
cell	NULL
lines	NULL
with	NULL
properties	NULL
of	NULL
erythroid	NULL
progenitor	NULL
burst-forming	NULL
cell	NULL
(	NULL
BFU-E	NULL
)	NULL
and	NULL
erythroid	NULL
precursor	NULL
cell	NULL
(	NULL
CFU-E	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
80:3721-3725	NULL
.	NULL

Shin	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Koshland	NULL
.	NULL

1993	NULL
.	NULL

Ets-related	NULL
protein	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
immunoglobulin	NULL
J-chain	NULL
gene	NULL
through	NULL
a	NULL
novel	NULL
Ets-binding	NULL
clement	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2006-2015	NULL
.	NULL

Shuman	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
C.	NULL
R.	NULL
Vinson	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1990	NULL
.	NULL

Evidence	NULL
of	NULL
changes	NULL
in	NULL
protease	NULL
sensitivity	NULL
and	NULL
subunit	NULL
exchange	NULL
rate	NULL
on	NULL
DNA	NULL
binding	NULL
by	NULL
C/EBP	NULL
.	NULL

Science	NULL
249:771-774	NULL
.	NULL

Skalnik	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
E.	NULL
C.	NULL
Strauss	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Orkin	NULL
.	NULL

1991	NULL
.	NULL

CCAAT	NULL
displacement	NULL
protein	NULL
as	NULL
a	NULL
repressor	NULL
of	NULL
the	NULL
myelomonocytic-specific	NULL
gp91-phox	NULL
gene	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:16736-16744	NULL
.	NULL

Smith	NULL
,	NULL
L	NULL
T.	NULL
,	NULL
D.	NULL
A.	NULL
Gonzalez	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
myeloid	NULL
specific	NULL
granulocyte	NULL
colony	NULL
stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
receptor	NULL
promoter	NULL
contains	NULL
a	NULL
functional	NULL
site	NULL
for	NULL
the	NULL
myeloid	NULL
transcription	NULL
factor	NULL
PU.1	NULL
(	NULL
Spi-1	NULL
)	NULL
.	NULL

Blood	NULL
84:372a	NULL
.	NULL

62a.Smith	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

Unpublished	NULL
observations	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
lymphoid-specific	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323:640-643	NULL
.	NULL

Sterneck	NULL
,	NULL
E.	NULL
,	NULL
C.	NULL
Muller	NULL
,	NULL
S.	NULL
Katz	NULL
,	NULL
and	NULL
A.	NULL
Leutz	NULL
.	NULL

1992	NULL
.	NULL

Autocrine	NULL
growth	NULL
induced	NULL
by	NULL
kinase	NULL
type	NULL
oncogenes	NULL
in	NULL
myeloid	NULL
cells	NULL
requires	NULL
AP-1	NULL
and	NULL
NF-M	NULL
,	NULL
a	NULL
myeloid	NULL
specific	NULL
,	NULL
C/EBP-like	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:115-126	NULL
.	NULL

Sun	NULL
,	NULL
S.	NULL
Q.	NULL
,	NULL
E.	NULL
S.	NULL
Stoflet	NULL
,	NULL
J.	NULL
G.	NULL
Cogan	NULL
,	NULL
A.	NULL
R.	NULL
Strauch	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Getz	NULL
.	NULL

1995	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
the	NULL
vascular	NULL
smooth	NULL
muscle	NULL
«	NULL
-actin	NULL
gene	NULL
in	NULL
fibroblasts	NULL
and	NULL
myoblasts	NULL
:	NULL
disruption	NULL
of	NULL
enhancer	NULL
function	NULL
by	NULL
sequence-specific	NULL
single-stranded-DNA-binding	NULL
proteins	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2429-2436	NULL
.	NULL

Voso	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
T.	NULL
C.	NULL
Burn	NULL
,	NULL
G.	NULL
Wulf	NULL
,	NULL
B.	NULL
Lim	NULL
,	NULL
G.	NULL
Leone	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

Inhibition	NULL
of	NULL
hematopoiesis	NULL
by	NULL
competitive	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
PU.1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:7932-7936	NULL
.	NULL

Wang	NULL
,	NULL
Z.	NULL
Y.	NULL
,	NULL
X.	NULL
H.	NULL
Lin	NULL
,	NULL
M.	NULL
Nobyuoshi	NULL
,	NULL
Q.	NULL
Q.	NULL
Qui	NULL
,	NULL
and	NULL
T.	NULL
F.	NULL
Deuel	NULL
.	NULL

1992	NULL
.	NULL

Binding	NULL
of	NULL
single-stranded	NULL
oligonucleotides	NULL
to	NULL
a	NULL
non-B-form	NULL
DNA	NULL
structure	NULL
results	NULL
in	NULL
loss	NULL
of	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
A-chain	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:13669-13674	NULL
.	NULL

Wognum	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Y.	NULL
Westerman	NULL
,	NULL
T.	NULL
P.	NULL
Visser	NULL
,	NULL
and	NULL
G.	NULL
Wagemaker	NULL
.	NULL

1994	NULL
.	NULL

Distribution	NULL
of	NULL
receptors	NULL
for	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
on	NULL
immature	NULL
CD34+	NULL
bone	NULL
marrow	NULL
cells	NULL
,	NULL
differentiating	NULL
monomyeloid	NULL
progenitors	NULL
,	NULL
and	NULL
mature	NULL
blood	NULL
cell	NULL
subsets	NULL
.	NULL

Blood	NULL
84:764-774	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
K.	NULL
I.	NULL
Fujioka	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
L.	NULL
H.	NULL
Shapiro	NULL
,	NULL
H.	NULL
M.	NULL
Chen	NULL
,	NULL
A.	NULL
T.	NULL
Look	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
region	NULL
which	NULL
directs	NULL
monocytic	NULL
activity	NULL
of	NULL
the	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
(	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
)	NULL
receptor	NULL
promoter	NULL
and	NULL
binds	NULL
PEBP2/CBF	NULL
(	NULL
AML1	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:8085-8095	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
H.	NULL
M.	NULL
Chen	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
directs	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:373-381	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
S.	NULL
Meyers	NULL
,	NULL
K.	NULL
L.	NULL
Rhoades	NULL
,	NULL
H.	NULL
M.	NULL
Chen	NULL
,	NULL
S.	NULL
W.	NULL
Hiebert	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

CCAAT	NULL
enhancer	NULL
binding	NULL
protein	NULL
(	NULL
C/EBP	NULL
)	NULL
and	NULL
AML1	NULL
(	NULL
CBFa2	NULL
)	NULL
synergistically	NULL
activate	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

